Louisiana State University

LSU Digital Commons
LSU Doctoral Dissertations

Graduate School

6-22-2018

New Platinum(II) and Rhenium(I) Complexes of "Linear" Chelate
Ligands Terminated with Pyridyl or Imidazolyl N-Donor Groups
Himali Kokila Ranasinghe Pilana Vithanage
Louisiana State University and Agricultural and Mechanical College

Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_dissertations
Part of the Inorganic Chemistry Commons, and the Organic Chemistry Commons

Recommended Citation
Pilana Vithanage, Himali Kokila Ranasinghe, "New Platinum(II) and Rhenium(I) Complexes of "Linear"
Chelate Ligands Terminated with Pyridyl or Imidazolyl N-Donor Groups" (2018). LSU Doctoral
Dissertations. 4641.
https://digitalcommons.lsu.edu/gradschool_dissertations/4641

This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It
has been accepted for inclusion in LSU Doctoral Dissertations by an authorized graduate school editor of LSU
Digital Commons. For more information, please contactgradetd@lsu.edu.

NEW PLATINUM(II) AND RHENIUM(I) COMPLEXES OF "LINEAR"
CHELATE LIGANDS TERMINATED WITH PYRIDYL OR IMIDAZOLYL
N-DONOR GROUPS

A Dissertation
Submitted to the Graduate Faculty of the
Louisiana State University and
Agricultural and Mechanical College
in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy
in
The Department of Chemistry

by
Himali Kokila Ranasinghe Pilana Vithanage
B.Sc. University of Sri Jayewardenepura, Sri Lanka, 2012
August 2018

©Copyright 2018
Kokila Ranasinghe
All rights reserved

ii

We must not forget that when radium was discovered no one knew that it would prove useful in
hospitals. The work was one of pure science. And this is a proof that scientific work must not be
considered from the point of view of the direct usefulness of it. It must be done for itself, for the
beauty of science, and then there is always the chance that a scientific discovery may become
like the radium a benefit for humanity.
– Marie Curie
Lecture at Vassar College, Poughkeepsie, New York (14 May 1921)
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ABSTRACT
The overall goal of this dissertation research is to design, synthesize, and study new Pt(II)
and Re(I) complexes relevant to biomedical applications. One of the projects involves the
assessment of the interactions of bulky tridentate carrier ligands with a bound guanine nucleobase
derivative (G) in platinum complexes, with a goal of developing chemistry potentially relevant to
active anti-cancer Pt drugs. In another project, the fac-[ReI(CO)3]+ core is used to prepare novel
Re(I) complexes with the purpose of developing new linking chemistry relevant to 99mTc and 187Re
radiopharmaceuticals. This research explores the use of three different types of linear carrierligands in approaches directed toward achieving the stated goals.
The first type of linear tridentate carrier ligand employed (N(R)1,1′-Me2dma, when R = H,
bis(1-methyl-2-methylimidazolyl)amine) is terminated by imidazolyl rings and has a central Ndonor with an NH or an N−C bond. High in-plane steric bulk in monofunctional Pt(II) complexes
is a feature associated with increased anti-cancer activity. Therefore, understanding carrier-ligand
steric effects is crucial in designing new platinum drugs. For that purpose, the new N(R)1,1′Me2dma ligands were utilized to synthesize [Pt(II)(N(R)1,1′-Me2dma)Cl]Cl complexes. The
chemical behavior of adducts of simple purine derivatives (G) made with these monofunctional
Pt(II) complexes was studied. The ligands and complexes were characterized using NMR
spectroscopy, single-crystal X-ray crystallography and ESI mass spectrometry. Solution NMR
spectroscopy was used as the primary tool to study the Pt(II)(N(R)1,1′-Me2dma)G adducts. During
this work, the 3′-GMP mono adduct of [Pt(N(H)1,1′-Me2dma)Cl]Cl complex was crystallized,
allowing the first crystallographic molecular structure determination for a 3′-GMP platinum(II)
complex.

xiv

The other two types of linear tridentate ligands have the central N donor in a sulfonamide
linkage. New ligands terminated with either two pyridyl rings (second type, N(SO2R)3,3′,5,5′Me4dpa and N(SO2R)6,6′-Me2dpa, derivatives of 2-dipicolylamine) or with two imidazolyl rings
(third type, N(SO2R)1,1′-Me2dma) were prepared. Pt(II) and Re(I) complexes of these new ligands
were synthesized and their chemical properties studied.

xv

CHAPTER 1. INTRODUCTION
Transition metal complexes play an important role in modern medicine.1-2 Anticancer
activity in Pt(II) complexes,3 radio-diagnostic properties of
properties of

99m

Tc complexes,4 radio-therapeutic

187

Re complexes,4 anti-metastatic activity of Ru(III) complexes1 and antiarthritic

properties of Au(I) complexes1 are some common examples illustrating the involvement of metal
compounds in therapeutic and diagnostic pharmaceuticals. In metal-mediated pharmaceuticals, the
metal atom is often chelated by a carrier ligand. In addition to coordinating to the metal atom, a
carrier-ligand can introduce new properties to the pharmaceutical agent. As an example, by linking
a targeting moiety onto the carrier ligand, a drug molecule can be delivered to a specific destination
in the body such as a tumor (Figure 1.1).

Figure 1.1. Schematic representation of a target-specific metal-mediated therapeutic or diagnostic
drug molecule.
Therefore, developing new linking strategies relevant to the chelating ligands is crucial in
designing new metal-mediated pharmaceuticals with specific chemical properties. Furthermore,
steric factors of the carrier ligands can be directly associated with the structure-activity relationship
of certain drug molecules. In such cases, understanding carrier ligand steric effects is important in
designing new drugs; one such example is the anticancer activity in platinum(II) complexes.5-7
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1.1 Carrier-Ligand Bulk and Anticancer Activity in Platinum(II) Complexes
Platinum complexes exclusively bind at the N7 atom in purine bases (preferably guanine)
of DNA. There are two major types of platinum−DNA adducts: intrastrand cross-links and
monofunctional adducts (Figure 1.2).8-10 Predominantly, the 1,2 intrastrand G*G* cross-link lesion
is considered as the active lesion responsible for the anticancer activity of cisplatin.11-17 G*
represents G residues in DNA or oligomers with a Pt(II) bound to N7.

Figure 1.2. Chart showing common Pt−DNA binding modes and the distorted G*G* and Lippard’s
base pair steps in intrastrand cross-link lesions.
Studies of an HMG-bound 16-mer duplex studied by X-ray methods18 and a 9-mer duplex
studied by NMR methods in solution19 reveal that the DNA distortion induced by cisplatin (G*G*
cross-link lesion) extends over two base pair (bp) steps (Figure 1.2), the cross-link bp step
(between the 5′-G*·C bp and the 3′-G*·C bp) and the adjacent bp step (also referred to as the
Lippard bp step,20 between the 5′-G*·C bp and the next bp in the 5′-direction along the duplex).
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Both bp steps are highly distorted. Both solid-state and solution studies have revealed that the
Lippard bp step has a large shift and a large slide.18-19,21 Therefore, the Lippard bp step could
possibly play a more important role in anticancer activity than the G*G* cross-link bp step.19-22
1.2 Monofunctional Platinum Complexes and Pt(Ltri)G Adducts
Monofunctional platinum complexes were considered as inactive in early days.23-24
Because the monofunctional agents studied previously contained small carrier ligands (such as
[Pt(diethylenetriamine)Cl]Cl and [Pt(NH3)3Cl]Cl),18,25-27 the small distortion to the DNA structure
created by these compounds is insufficient to inhibit cancer cell growth. Later, certain
monofunctional platinum complexes containing bulky carrier ligands were found to be anticancer
active (pyriplatin and phenanthriplatin);28 this finding increased interest in developing
monofunctional platinum anticancer agents. A distortion very similar to that found in the Lippard
bp step of DNA having the cisplatin lesion was later also observed in an X-ray structure of an
oligomer

adduct

of

the

bulky

monofunctional

platinum

anticancer

agent,

cis-

[Pt(NH3)2(pyridine)Cl]+ (pyriplatin).29-30 This finding indicates that the monofunctional platinum
agents can be anticancer active, if enough bulk is present at one cis position to induce distortion in
the adjacent bp step in DNA. Therefore, studying carrier-ligand steric effects is key in designing
such new monofunctional platinum drugs and in understanding their mechanism of action.
Studying DNA duplexes bearing Pt drug lesions can be very complicated. Work from this
laboratory19 showed many mistakes were made in such studies and the nature of the distortion
reported in several papers was not correct. Historically, simple models (adducts with small
oligomers, or with single stranded DNA, etc.) are often employed to execute preliminary studies
of new platinum complexes.18-19,31-34 Adducts of platinum complexes with unlinked
guanine/hypoxanthine derivatives (G) are the simplest models;31,35-36 hence, they provide an
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accurate starting point to study the chemical and physical properties of new platinum agents. Also,
such simple models allow one to employ invaluable characterization techniques such as NMR
spectroscopy or X-ray crystallography.5-7,16,37 In the studies presented here, we assess the
interactions of G with newly designed platinum(II) complexes (bifunctional and monofunctional),
specifically the influence of carrier-ligand bulk on the properties of the formed G adducts.
The nucleobase (G) in Pt(Ltri)G type adducts (Ltri = a tridentate, one bidentate and one
monodentate, or three monodentate ligands) orients roughly perpendicular to the coordination
plane defined by Pt and the four ligating atoms N, N′, N′′, and Cl or N7(G). The nucleobase can
rotate around the Pt−N7 single bond and acquire two possible orientations (Figure 1.3, arrow up
and arrow down). When N, N′, and N′′ are symmetric with respect to the coordination plane and
N equals N′′, both orientations lead to one rotamer, if R′ is not chiral. If N is not equal to N′′, the
two orientations represent two rotamers. If N′ is not symmetric with respect to the coordination
plane, two rotamers are possible regardless of whether or not N is equal to N′′.

Figure 1.3. The two possible orientations of G in Pt(Ltri)G type adducts. Note that the nucleobase
is represented by an arrow with the tip at the H8 of the purine.
If the rotation of G around the Pt−N7 bond is too fast relative to the NMR time scale, only
one set of signals for the two rotamers of the Pt(Ltri)G adduct can be observed. However, if the Ltri
carrier ligand is bulky enough to impede the nucleobase rotation, two separate sets of signals for
each rotamer can be observed. NMR spectroscopy can thus be used effectively to assess whether
a Ltri ligand is bulky enough to interact with G (and interfere with its free rotation) in a Pt(Ltri)G

4

type adduct. Such information can provide insight into how that monofunctional platinum complex
would influence the structure of Pt−DNA adducts on the cellular level.
1.3 Rhenium Complexes as Models for Diagnostic and Therapeutic Radiopharmaceuticals
Nuclear medicine is a powerful, non-invasive tool, which can be used for diagnostic and
therapeutic medical processes for many diseases. Technetium-99m (99mTc) is one of the most
widely used radio-imaging agents.4,38-39 The radioactive isotope of rhenium,

187

Re, has also

received much attention owing to its useful therapeutic properties.4,38-39 Rhenium and technetium
are members of the same group in the periodic table and share similar chemical and physical
properties. Therefore, non-radioactive Re(I) complexes (185Re) are commonly used as models in
developing new radiopharmaceuticals of

99m

Tc and

187

Re.38-39 In such developments, fac-

[MI(CO)3]+ core plays a major role because of its many ideal properties relevant to medicinal
applications (such as high in vivo robustness, stable association of the low oxidation numbered
metal atom, water-soluble precursor complex, fac-[MI(CO)3(H2O)3]+, etc.).4,40 Many carrier-ligand
systems coordinated to the fac-[MI(CO)3]+ core have been studied.4,38-39,41 However, developing
new linking strategies with different bioconjugation possibilities is useful in designing new
radiopharmaceuticals.
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CHAPTER 2. A VERY RARE EXAMPLE OF A STRUCTURALLY CHARACTERIZED
3'-GMP METAL COMPLEX. NMR AND SYNTHESTIC ASSESSMENT OF ADDUCTS
FORMED BY GUANINE DERIVATIVES WITH [Pt(Ltri)Cl]Cl COMPLEXES WITH AN
N,N',N" TRIDENTATE LIGAND (Ltri) TERMINATED BY IMIDAZOLE RINGS*
2.1 Introduction
High carrier-ligand bulk leads to decreases in anticancer activity and increases in toxicity
of bifunctional platinum(II) anticancer agents,42-46 whereas for monofunctional platinum(II) agents
we believe5-6,12,47 that high carrier-ligand bulk correlates with increased anticancer
activity.12,25,29,48-50 Bifunctional agents, such as cisplatin, form G*G* intrastrand cross-link lesions
and cause large distortions in DNA structure, manifest in large changes in CD51 and NMR26-27
spectra. (G residues in DNA or oligomers with a Pt(II) center bound to N7 are designated as G*).
In contrast, small monofunctional platinum agents, such as [Pt(dien)Cl]Cl (dien =
diethylenetriamine) and [Pt(NH3)3Cl]Cl, cause minimal changes in the DNA CD14,18 and NMR2627

spectra, indicating that monofunctional agents with small carrier ligands are unable to distort

the DNA structure greatly upon adduct formation.5 Studies of oligomer duplexes having one G*G*
cross-link lesion (an HMG-bound 16-mer duplex studied by X-ray methods18 and a 9-mer duplex
studied by NMR methods in solution19) reveal that the DNA distortion induced by bifunctional
Pt(II) agents extends over two base pair (bp) steps. The cross-link bp step (between the 5′-G*•C
bp and the 3′-G*•C bp) and the adjacent bp step (between the 5′-G*•C bp and the next bp in the
5′-direction along the duplex) are both highly distorted.

*Reproduced with permission from American Chemical Society: Ranasinghe, Kokila.; Marzilli,
Patricia A.; Pakhomova, Svetlana.; Marzilli, Luigi G. “A Very Rare Example of a Structurally
Characterized 3'-GMP Metal Complex. NMR and Synthetic Assessment of Adducts Formed by
Guanine Derivatives with [Pt(Ltri)Cl]Cl Complexes with an N,N',N" Tridentate Ligand (Ltri)
Terminated by Imidazole Rings.” Inorg. Chem. (2017), 56(14), 8462-8477. Copyright 2017
American Chemical Society.
”. Inorg. Chem. (2017), 53(20), 11096-11107. Copyright 2014 American Chemical Society.
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Both solid-state and solution structural studies have revealed that the adjacent bp step has
a large shift and a large slide.18-19,21 Therefore, we considered the possibility that this highly
distorted bp step could play an important role in anticancer activity.19-20A very similar distortion
as found in this adjacent bp step was later observed in an X-ray structure of an oligomer adduct of
a bulky monofunctional platinum anticancer agent.29-30 Such findings indicate that a
monofunctional agent with bulky carrier ligands could manifest anticancer activity by forming
DNA adducts with a highly distorted bp step similar to that found in DNA adducts formed by non
bulky bifunctional agents such as cisplatin. Understanding carrier-ligand steric effects is thus key
in designing new platinum drugs. Adducts formed between the Pt agents and G ligands (bold G =
monodentate N9-substituted guanine or hypoxanthine derivative, Figure 2.1) have been studied by
NMR methods in order to assess carrier-ligand bulk.22,47,52

Figure 2.1. Top: Numbering scheme for [Pt(N(R)1,1′-Me2dma)Cl]+ complexes containing carrier
ligands based on di-(2-methylimidazolyl)amine, N(H)dma (R = H, Z = H). To our knowledge, no
complexes of N(H)dma with Pt are known. Bottom: Numbering scheme for the guanine nucleobase
and for 3′-GMP and 5′-GMP. Ino and 5′-IMP contain hypoxanthine, having a hydrogen instead of
the amino group at position 2 of the purine ring. The atom-numbering schemes depicted here are
employed in the NMR discussion.
9

In order to gain a fundamental understanding of the steric effects within monofunctional
Pt(II) G adducts, this laboratory has used NMR techniques to assess the properties of Pt(Ltri)G
adducts (Ltri = an N,N',N" tridentate carrier ligand) formed by monofunctional platinum agents
with Ltri ligands based on di-(2-picolyl)amine [N(H)dpa] or dien.5-7,53-54 The present study focuses
on the preparation of water-soluble [Pt(II)(Ltri)Cl]Y complexes of tridentate imidazolyl ligands
and on identifying the adducts that these complexes form in solution with various purine
derivatives. We utilize both di-(1-methyl-2-methylimidazolyl)amine [N(H)1,1′-Me2dma (1)] and
a ligand new to the literature, N-(methyl)-di-(1-methyl-2-methylimidazolyl)amine [N(Me)1,1′Me2dma (2)]; we designate these ligands as N(R)1,1′-Me2dma (Figure 2.1, R = H, Me). The
tridentate ligand, N(H)1,1′-Me2dma, and its derivatives (with a substituent on the central N; e.g.,
‒CH2CH2OH) have been used to synthesize complexes of various metals (e.g., Re, Cu, Tc, Fe)
usually intended for biomedical applications.55-62
We describe the synthesis of [Pt(N(H)1,1′-Me2dma)Cl]Y (3) and [Pt(N(Me)1,1′Me2dma)Cl]Y (4) [Y = Cl- (3a and 4a) and BF4- (3b and 4b)] and the structural characterization
of their cations by 1H NMR spectroscopy and single-crystal X-ray diffraction. We then use 1H
NMR spectroscopy to examine Pt(N(R)1,1′-Me2dma)G adducts formed from [Pt(N(R)1,1′Me2dma)Cl]Cl complexes and compare the results to those of other Pt(Ltri)G adducts. In the
present study, the crystallization of one product, [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O
(5), allowed characterization by single-crystal X-ray diffraction.
Structures of metal 3'-GMP complexes are particularly rare. Only two molecular structures
of complexes with 3'-GMP are described in the literature, and both are Cu(II) complexes. One,
[Cu(3'-GMP)(phen)(H2O)]2•7H2O,63 lacks M─N7 bonding, and the other, ([Cu3(3'-GMP)2(3'GMPH)2(H2O)5]•7H2O)n,64 is a polymeric compound exhibiting nucleotide metal coordination
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through both the N7 atoms and the phosphate groups. Thus, to our knowledge 5 is the first
crystallographically characterized complex with any metal in which 3′-GMP is bound through only
an M─N7 bond. Other relevant structures with one Pt─N7 bond do not contain a nucleotide; these
are

[Pt(dien)(guanosine)](ClO4)2,65

[Pt(dien)(inosine)](NO3)2•H2O,66

[Pt(NH3)3(9-

methylhypoxanthine)]Cl(NO3)•1.5H2O,67 [Pt(NH3)3(9-ethylhypoxanthine)]Cl(NO3)•H2O,67 and
cis-[Pt(NH3)2(N2,N2-dimethyl-9-methylguanine)Cl]PF6.68 In contrast, there are many reported
structures of complexes with two cis Pt─N7 bonds to G ligands, quite often 5′-GMP.35,44,69-78
In studies of Pt(N(H)dpa)G adducts, no quality crystals for single-crystal X-ray structures
could be obtained to support the conclusions reached by using NMR methods.5-7,53 The structure
of [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) gives us deeper insights into previous
findings on Pt(N(H)dpa)G adducts, in addition to confirming and supporting our previous analysis
of solution results for Pt(N(H)dpa)G adducts.
2.2 Experimental Section
Starting Materials. Sodium salts of G nucleotides [5'-guanosine monophosphate (5'GMP), 5'-guanosine diphosphate (5′-GDP), 5'-guanosine triphosphate (5'-GTP), 5'-inosine
monophosphate (5'-IMP), and 3'-guanosine monophosphate (3'-GMP)], neutral purine derivatives
[inosine (Ino), 1-methylguanosine (1-MeGuo), and 9-ethylguanine (9-EtG)], K2[PtCl4], 1-methyl2-imidazolecarboxaldehyde, and methylamine hydrochloride (MeNH3Cl) were used as received
from Sigma-Aldrich. cis-Pt(DMSO)2Cl2,79 N(H)1,1′-Me2dma (1),58 and 2-(chloromethyl)-1methylimidazole hydrochloride80 were prepared by known methods. Because the protonation state
and hence the charge of the Pt(N(R)1,1′-Me2dma)G adducts in which G = a nucleotide are not well
defined, we omit charges for the adducts. However, charges are specified for structurally
characterized isolated complexes.
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NMR Measurements. NMR spectra were recorded on an Avance-III Prodigy 500 MHz
Bruker spectrometer. Peak positions are relative to TMSP-d4 in D2O or to solvent residual peak
with TMS as reference. A presaturation pulse to suppress the water peak was employed when
necessary. All NMR data were processed with TopSpin and MestReNova 10.0.0 software. The pH
values of D2O or 65:35 D2O:DMSO-d6 solutions examined by NMR spectroscopy are stated as
measured and not corrected for D2O. The pH (uncorrected) of all solutions, including reaction
mixtures, was adjusted when necessary with DNO3 or NaOD (0.5 M) D2O solutions.
Mass Spectrometric Measurements. High resolution mass spectra were recorded on an
Agilent 6210 ESI TOF LCMS mass spectrometer.
X-ray Data Collection and Structure Determination. Diffraction data were collected on
a Bruker Kappa Apex-II DUO CCD diffractometer with Mo K radiation (λ = 0.71073 Å),
equipped with an Oxford Cryosystems Cryostream. All X-ray structures were determined by direct
methods and difference Fourier techniques and refined by full-matrix least-squares by using
SHELXL201481 with H atoms in idealized positions.
N-(methyl)-di-(1-methyl-2-methylimidazolyl)amine

[N(Me)1,1′-Me2dma,

2].

A

solution of 2-(chloromethyl)-1-methylimidazole hydrochloride (1.00 g, 6 mmol), K2CO3 (1.7 g, 12
mmol), and MeNH3Cl (0.16 g, 2.4 mmol) in acetonitrile (100 mL) was heated at reflux under
nitrogen for 18 h. After the mixture was allowed to cool to room temperature and filtered, the
solvent was removed under reduced pressure. The resulting pale yellow residue was dissolved in
eluent A [acetone:5.0 M NH4OH (80:20)] and purified by chromatography on a silica column with
eluent A. The fractions collected were spotted and analyzed on TLC plates by using eluent A. The
cleanest fractions, as assessed by 1H NMR spectroscopy, were combined and taken to dryness by
rotary evaporation to afford a colorless oil (0.21 g, 40% yield). 1H NMR signals (ppm) in D2O (pH

12

8.3): 7.09 (s, 2H, H5/5'), 6.96 (s, 2H, H4/4'), 3.68 (s, 4H, CH2), 3.56 (s, 6H, CH3), 2.25 (s, 3H,
CH3). 1H NMR signals (ppm) in DMSO-d6: 7.07 (s, 2H, H5/5'), 6.76 (s, 2H, H4/4'), 3.52 (s, 4H,
CH2), 3.48 (s, 6H, CH3), 2.06 (s, 3H, CH3). ESI-MS (m/z): [M + H]+ calcd for C11H17N5, 220.1557;
found, 220.1558.
[Pt(N(H)1,1′-Me2dma)Cl]Y (3a and 3b). A solution of N(H)1,1′-Me2dma (21 mg, 0.1
mmol) in methanol (1 mL) was added to a methanol solution of cis-Pt(DMSO)2Cl2 (42 mg, 0.1
mmol, in 5 mL) and the mixture was heated at 50 °C overnight. The pale yellow [Pt(N(H)1,1′Me2dma)Cl]Cl (3a) solid (24 mg, 55% yield) formed was collected by filtration, washed with cold
methanol, then with ether, and air dried. 1H NMR signals (ppm) in D2O (pH 4): 7.03 (d, J = 1.5
Hz, 2H), 6.85 (d, J = 1.6 Hz, 2H, H4/4'), 4.63 (d, J = 15.4 Hz, 2H, CH2), 3.67 (s, 6H, CH3); one of
the methylene signals is masked by the solvent peak. 1H NMR signals (ppm) in DMSO-d6: 8.31
(bs, 1H, NH), 7.38 (s, 2H, H5/5'), 6.93 (s, 2H, H4/4'), 4.56 (d, J = 15.3 Hz, 2H, CH2), 4.53 (d, J =
15.0 Hz, 2H, CH2), 3.73 (s, 6H, CH3). ESI-MS (m/z): [M + H]+ calcd for C10H15ClN5Pt, 436.0737;
found, 436.0639. An aqueous solution of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) (80 mg, 2 mL) was
treated with an excess of NaBF4 (30 mg) to yield a yellow solid. A solution of this solid in acetone
(50 mg, 2 mL) was allowed to stand at room temperature, and slow evaporation produced pale
yellow, X-ray quality crystals of [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b) formed after 4 d. 1H NMR
signals (ppm) in DMSO-d6: 8.12 (bs, 1H, NH), 7.38 (2H, H5/5'), 6.93 (2H, H4/4'), 4.55 (d, J =
15.3 Hz, 2H, CH2), 4.53 (d, J = 15.3 Hz, 2H, CH2), 3.73 (s, 6H, CH3).
[Pt(N(Me)1,1′-Me2dma)Cl]Y (4a and 4b). A solution of N(Me)1,1′-Me2dma (22 mg, 0.1
mmol) in methanol (1 mL) was added to a methanol solution of cis-Pt(DMSO)2Cl2 (42 mg, 0.1
mmol, in 5 mL), and the mixture was heated at 50 °C overnight. The pale yellow solid (29 mg,
61% yield) that formed was collected by filtration, washed with cold methanol, then with ether,
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and air dried. X-ray quality crystals of [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a) were obtained by mixing
equal volumes (1 mL) of acetonitrile solutions of cis-Pt(DMSO)2Cl2 (10 mg, 12.5 mM) and the
ligand (5 mg, 12.5 mM) and allowing the resulting solution to stand at room temperature. Pale
yellow, needle-like crystals that separated overnight were characterized by single-crystal X-ray
crystallography. 1H NMR signals (ppm) in D2O (pH 4, uncorrected for D2O): 7.15 (d, J = 1.5 Hz,
2H, H5/5'), 7.01 (d, J = 1.6 Hz, 2H, H4/4'), 4.97 (d, J = 15.4 Hz, 2H, CH2), 4.64 (d, J = 15.4 Hz,
2H, CH2), 3.73 (s, 6H, CH3), 3.12 (s, 3H, CH3). 1H NMR signals (ppm) in DMSO-d6: 7.43 (d, J =
1.6 Hz, 2H, H5/5'), 6.97 (d, J = 1.6 Hz, 2H, H4/4'), 4.87 (d, J = 15.1 Hz, 2H, CH2), 4.72 (d, J =
15.4 Hz, 2H, CH2), 3.77 (s, 6H, CH3), 2.99 (s, 3H, CH3). An aqueous solution of 4a (87 mg, 2 mL)
was treated with an excess of NaBF4 (30 mg) to yield a yellow solid. When a solution of this solid
in acetone (50 mg, 2 mL) was allowed to stand at room temperature, slow evaporation afforded Xray quality, pale yellow crystals of [Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b) after 2 d. 1H NMR signals
(ppm) in DMSO-d6: 7.43 (d, J = 1.7 Hz, 2H, H5/5'), 6.96 (d, J = 1.7 Hz, 2H, H4/4'), 4.86 (d, J =
15.3 Hz, 2H, CH2), 4.71 (d, J = 15.3 Hz, 2H, CH2), 3.77 (s, 6H, CH3), 2.99 (s, 3H, CH3).
G Adduct Formation with [Pt(N(R)1,1′-Me2dma)Cl]Cl. A 10 mM solution of
[Pt(N(R)1,1′-Me2dma)Cl]Cl (R = H or Me) in D2O at pH 4 (uncorrected) was treated with 2.5
molar equiv of G (G = 5'-GMP, 5'-GTP, 3'-GMP, 5'-IMP and Ino for R = H or Me, and with G =
5'-GDP, 1-MeGuo and 9-EtG for R = H). The solution was maintained at 25 °C and at pH 4 and
monitored by 1H NMR spectroscopy until the [Pt(N(R)1,1′-Me2dma)Cl]Cl signals completely
disappeared. The signals of the reactants are shifted by stacking interactions between free G and
the [Pt(N(R)1,1′-Me2dma)Cl]+ cation. As the adduct formed (decreasing the concentrations of the
reactants), the resulting decrease in the extent of stacking interactions between the reactants caused
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the slight shift changes. Similar results were found in studies of Pt(N(H)dpa)G adducts, and a more
complete explanation can be found in the published report.5
In order to compare properties for the [Pt(N(H)1,1′-Me2dma)Cl]+ cation and Pt(N(H)1,1′Me2dma)G adducts with those reported in a D2O:DMSO-d6 (65:35) solvent mixture for the
[Pt(N(H)dpa))Cl]+ cation and Pt(N(H)dpa)G adducts,5 the formation of selected Pt(N(H)1,1′Me2dma)G adducts (G = 5'-GMP and 5'-GTP) from [Pt(N(H)1,1′-Me2dma)Cl]+ was studied in this
solvent mixture at pH 4 (uncorrected) (Supporting Information, Table A.2).
Crystallization of [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5). In order to obtain
X-ray quality crystals of the Pt(N(H)1,1′-Me2dma)(3'-GMP) adduct, 12.2 mg of 3'-GMP (2.5
molar equiv) was added to a 20 mM solution (5.2 mg/600 µL) of [Pt(N(H)1,1′-Me2dma)Cl]Cl in
D2O, and the pH was adjusted to 4. The solution was allowed to stand at room temperature. Pale
yellow, needle-like crystals were collected after two weeks.
2.3 Results and Discussion
Synthesis of N(R)1,1′-Me2dma and [Pt(N(R)1,1′-Me2dma)Cl]Y (Y = Cl or BF4).
N(H)1,1′-Me2dma

(1)

was

synthesized

by

hydrogenation

of

the

1-methyl-2-

imidazolecarboxaldehyde oxime as reported in the literature.58 Several procedures are known57,59,82
for

coupling

the

appropriate

amine

derivative

with

two

equiv

of

1-methyl-2-

imidazolecarboxaldehyde in the presence of sodium triacetoxyborohydride in order to synthesize
tridentate imidazolyl ligands having different substituents at the central nitrogen. However, the
attempt to synthesize the N(Me)1,1′-Me2dma (2) ligand by this method was unsuccessful.
Therefore, we employed a coupling method known to produce tridentate pyridyl derivatives, which
involves coupling the appropriate amine with 2-(chloromethyl)pyridine.83 Correspondingly, the
coupling of methylamine with two equiv of 2-(chloromethyl)-1-methylimidazole under basic
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conditions produced N(Me)1,1′-Me2dma (2) in acceptable yield. Several platinum precursors, such
as cis-Pt(DMSO)2Cl2, K2[PtCl4] and Pt(1,5-cyclooctadiene)Cl2, have been used in synthesizing
platinum complexes of pyridyl or imidazolyl ligands.84-88 The procedures with the latter two
precursors use water as the solvent. Because our complexes are highly soluble in water, we
employed cis-Pt(DMSO)2Cl2 in methanol and obtained [Pt(N(R)1,1′-Me2dma)Cl]Cl (3a and 4a) in
55−61% yields.
Structural Results. Crystal data and details of the structural refinement for [Pt(N(H)1,1′Me2dma)Cl]BF4 (3b), [Pt(N(Me)1,1′-Me2dma)Cl]Cl•H2O (4a), [Pt(N(Me)1,1′-Me2dma)Cl]BF4
(4b), and [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) are summarized in Table 2.1. Selected
bond lengths and angles are reported in Table 2.2, along with data for [Pt(N(H)dpa)Cl]Cl89 and
[Pt(N(Me)dpa)Cl]Cl90 for comparison. The ORTEP plots for cations of [Pt(N(H)1,1′Me2dma)Cl]BF4 (3b), [Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b), and

[Pt(N(H)1,1′-Me2dma)(3′-

GMPH)]NO3•5H2O (5) (Figure 2.2; the 4a structure is similar to 4b and not shown here) show the
numbering system used to describe the solid-state data. Crystals of 3b contain two independent
complexes in the asymmetric unit, only one (A) of which is shown in Figure 2.2 and used in the
discussion. The N2 atom of the cation [Pt(N(H)1,1′-Me2dma)Cl]+ is disordered over two almost
equivalent positions with occupancies of 0.51:0.49 (1A:2A). Compound 4b is a non-merohedral
twin. Compound 5 was losing solvent rapidly during crystal harvesting. The resulting crystal
structure has a disordered nitrate anion and water molecules. Hydrogen atoms of water molecules
and the phosphate moiety were not located in the difference Fourier map. In the discussions related
to the 3′-GMPH group in complex 5, the standard numbering system for guanine derivatives
(Figure 2.1) is employed to allow comparisons with known structures.
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Table 2.1. Crystal Data and Structure Refinement for [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b),
[Pt(N(Me)1,1′-Me2dma)Cl]Cl•H2O (4a), [Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b), and [Pt(N(H)1,1′Me2dma)(3′-GMPH)]NO3•5H2O (5)
3b

4a

4b

5

C10H15ClN5Pt·

C11H17Cl2N5Pt·

C11H17ClN5Pt

C20H27N10O8PPt·

BF4

OH2

·BF4

NO3·5(H2O)

fw

522.62

503.30

536.65

913.66

crystal system

triclinic

monoclinic

monoclinic

orthorhombic

Pī

P21/c

C2/c

P212121

a (Å)

7.4468(4)

10.7948(6)

22.684(3)

9.0409(6)

b (Å)

12.5154(7)

11.5052(6)

12.5272(17)

16.7570(12)

c (Å)

17.0151(11)

12.2870(7)

11.2101(15)

20.8873(15)

α (deg)

110.894(2)

90

90

90

 (deg)

92.093(3)

97.773(3)

95.074(6)

90

γ (deg)

97.991(3)

90

90

90

V (Å3)

1460.77(15)

1537.19(15)

3173.1(7)

3164.4(4)

T (K)

106

90

90

90

4

4

8

4

calc (mg/m3)

2.376

2.175

2.247

1.918

abs coeff (mm-1)

9.83

9.48

9.06

4.58

2max ()

52.8

61.0

71.8

51.4

R[F2 > 2σ(F2)]a

0.035

0.030

0.030

0.037

Rwb

0.071

0.089

0.089

0.084

res. dens. (e Å-3)

1.46, -0.90

4.90, -2.56

2.39, -1.60

1.68, -0.94

data/parameters

5955/430

4689/190

7527/212

5877/457

space group

Z

a

R = (||F| - |Fc||)/|F|. bRw = [[w(F2 - Fc2)2]/[w(F2)2]]1/2, in which w = 1/[2(F2) + (dP)2
+ (eP)] and P = (F2 + 2Fc2).
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Table 2.2. Selected Bond Distances (Å) and Angles (deg) for [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b), [Pt(N(Me)1,1′-Me2dma)Cl]Cl•H2O
(4a), [Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b), [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5), [Pt(N(H)dpa)Cl]Cla, and
[Pt(N(Me)dpa)Cl]Clb
3b

4a

4b

5

[Pt(N(H)dpa)Cl]Cl

[Pt(N(Me)dpa)Cl]Cl

bond distances
Pt–N1

1.992(6)

1.992(3)

1.978(4)

2.004(8)

2.008(6)

2.006(3)

Pt–N2

2.035(13), 2.069(13)

2.042(3)

2.041(3)

2.031(9)

2.009(12)

2.017(3)

Pt–N3

1.98(2)

1.998(3)

2.002(4)

1.995(9)

2.011(5)

2.007(3)

Pt–Cl or N6

2.317(6)

2.3065(7)

2.2793(10)

2.007(8)

2.301(2)

2.3048(10)

bond angles
N1–Pt–N3

164.6(2)

164.27(14)

165.32(14)

164.5(4)

166.0(2)

166.0(2)

N1–Pt–Cl or N6

97.08(18)

96.21(9)

96.85(11)

96.4(4)

97.2(2)

96.62(9)

N2–Pt–Cl or N6

167.6(6), 169.9(5)

176.63(8)

176.53(9)

178.0(6)

168.7(6)

179.52(9)

N3–Pt–Cl or N6

98.27(17)

98.63(9)

97.12(12)

98.7(4)

97.8(2)

96.82(9)

N2–Pt–N1

83.1(4), 81.5(4)

82.67(12)

83.60(15)

81.6(3)

83.3(3)

83.35(12)

N2–Pt–N3

81.8(4), 83.5(4)

82.80(11)

82.73(15)

83.3(3)

83.3(3)

83.4(2)

Pt–N3–C6c

113.1(5)

111.9(2)

111.6(3)

110.6(7)

112.7(4)d

114.1(5)d

Pt–N3–C8c

139.4(5)

141.0(3)

139.5(3)

140.9(8)

127.2(5)d

128.7(5)d

C6–N3–C8c

107.1(6)

106.8(3)

108.8(4)

108.3(10)

120.1(6)d

117.0(6)d

a

Data from ref.89 bData from ref.90 cThe angles for the other ring are similar to the values reported here. dFor [Pt(N(H)dpa)Cl]Cl and
[Pt(N(Me)dpa)Cl]Cl the C6 and C8 numbering in the table represents the C2 and C6 atoms, respectively, in NMR discussions.
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[Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b) and [Pt(N(Me)1,1′-Me2dma)Cl]Y (4a, Y = Cl, and
4b, Y = BF4). Cations of 3b, 4a and 4b have a pseudo square planar geometry. The four
coordination sites are occupied by the N1, N2 and N3 atoms of the tridentate ligands and by a Cl
atom (trans to N2). The Pt─Cl and Pt─N bond distances and N1─Pt─N3 bite angles in 3b, 4a and
4b are not significantly different from the values reported for their [Pt(N(H)dpa)Cl]+89 and
[Pt(N(Me)dpa)Cl]+90 analogs (Table 2.2). In these complexes, all of the Pt─N bond distances lie
within the ranges expected for Pt─N(sp2) bond distances (1.99─2.08 Å)7,84,91 or Pt─N(sp3) bond
distances (2.01─2.12 Å).7,54,92-93

Figure 2.2. ORTEP plots showing the cations of [Pt(N(H)1,1′-Me2dma)Cl]BF4 (3b, top left),
[Pt(N(Me)1,1′-Me2dma)Cl]BF4
(4b,
bottom
left),
and
[Pt(N(H)1,1′-Me2dma)(3′GMPH)]NO3•5H2O (5, right). Thermal ellipsoids are drawn with 50% probability.
For the cations in 3b, 4a and 4b, the sp3 geometry of the central N atom places the two
methylene groups on the side of the coordination plane opposite to the NH or N(Me) groups
(Figure 2.3 and Figure A.1 in Supporting Information). As a result, the plane of the imidazolyl
19

rings (defined by the 3 C and 2 N atoms in the ring) is tilted with respect to the coordination plane
(defined by Pt and the four ligating atoms N1, N3, N2 and Cl/(G)N7). The average tilt angles for
rings

in

[Pt(N(H)1,1′-Me2dma)Cl]BF4

(3b),

[Pt(N(H)dpa)Cl]Cl,89

and

[Pt(N(H)6,6′-

Me2dpa)Cl]Cl7 structures are 7.1°, 5.4° and 5.2°, respectively. Addition of a methyl group on the
central nitrogen appears to force the CH2 groups to be farther below the coordination plane
(Figures A1 and A2 in Supporting Information); consequently, the average tilt angles
approximately double to 12.4°, 12.9° and 12.3° in [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a),
[Pt(N(Me)1,1′-Me2dma)Cl]BF4 (4b), and [Pt(N(Me)dpa)Cl]Cl,90 respectively. The tilting of all the
imidazolyl rings with respect to the coordination plane results in the H4/4' protons projecting
toward the same side of the coordination plane as the NH or N(Me) groups (Figure 2.3).

Figure 2.3. Orientation of the H4/4′ protons, methylene groups, and the imidazolyl rings in the
[Pt(N(R)1,1′-Me2dma)Cl]BF4 cations [top: 3b (R = H), middle and bottom: 4b (R = Me)] viewed
along the coordination plane. Also shown are designations of the endo-CH and the exo-CH
protons. For clarity, the N-Me groups of the imidazolyl rings are hidden.
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[Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5). The Pt─N1, Pt─N2, and Pt─N3 (Table
2.2) bond distances of this pseudo square planar Pt(II) complex do not differ significantly from the
values for 3b. Also, the N1─Pt─N3 bite angle of 5 (164.5(4)°) is comparable to the value for
[Pt(N(H)1,1′-Me2dma)Cl]+ in 3b (164.6(2)°, Table 2.2). Compared to the tilting observed for 3b
(7.1°), the imidazolyl rings in 5 have a greater degree of tilting. One of the imidazolyl rings is
tilted by 19.1° and the other ring by 10.0°. The Pt─N7(G) bond of 2.007(8) Å in 5 falls within the
typical Pt─N7(G) bond distance ranges reported for mono adducts65-68 (1.99─2.07 Å) and for bis
adducts35,44,69-78 (2.02─2.08 Å). The metric parameters and conformational features of the 3′GMPH ligand are normal and are described in the Supporting Information.
The difference, Pt–N7–C5 bond angle minus the Pt–N7–C8 bond angle, in structures of
Pt(II) complexes of G (G = any derivative of guanine) is defined as the 'rocking angle'. 94 The
typical range of the rocking angle, identified some years ago as being about -2° to +11°,94 indicates
that the Pt–N7–C8 angle is normally smaller than the Pt–N7–C5 angle. Rocking angles in more
recent structures also almost always fall in this range.67,69,71-72,74-76 Mono adducts tend to be at the
lower end of this range. Small rocking angles usually are observed when the structure has no clear
intramolecular interactions, as in [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]+ (5), which has a positive
rocking angle of 1.4°. Rare examples of highly negative values for the rocking angle occur only
when the carrier ligand has high bulk, such as for Pt(N,N,N′,N′-tetramethylethylenediamine)G2
complexes, with values of -3.2° (G = 5′-GMP)70 and -6.8° (G = 9-MeG).44
An analysis by Yao et al. of crystallographic data for cis-[PtL2G2] type structures available
at the time demonstrated a linear correlation (R = 0.897) between the rocking angle and the Pt–O6
non bonded distance.94 The linear correlation also accounts for the Pt–O6 distance in 5 (3.40 Å)
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and in all relevant structures published after the report by Yao et al.94 and discussed here.67,69-72,7476

Canting is another parameter used to compare structural features of Pt(II) complexes of
coordinated purines. If the dihedral angle between the plane of a base and the coordination plane
is close to 90°, the base is not canted. The smaller the dihedral angle, the greater the canting. This
dihedral angle in 5 is 66.5°, indicating moderate canting. As previously reported,78,95 6-oxopurine
Cu(II) complexes exhibit an interesting relationship between the dihedral angle and intramolecular
hydrogen bonding interactions of the 6-oxo group with protons in cis-carrier ligands. If the proton
can project out of the coordination plane, such as a proton on a ligating sp 3 N cis to the purine, a
hydrogen bond is then possible. When a hydrogen bond is present, the dihedral angle falls in a
highly canted 40−60° range. In the absence of such an interaction, the angle is usually greater than
65° and in the moderately canted range. Except for a few Pt(II) complexes exhibiting strong
intramolecular base-base stacking between two adjacent cis purines,69,72-73,77 all published Pt(II) 6oxopurine complexes also seem to follow this relationship.44,65-68,70-71,74-76,78 Accordingly, the small
canting value exhibited by 5 (characteristic of the absence of intramolecular hydrogen bond
interactions) is consistent with the closest proton in the carrier ligand being a partially positive CH
atom lying essentially in the coordination plane.
NMR Spectroscopy. 1H NMR spectroscopy was used to characterize the N(Me)1,1′Me2dma ligand (in D2O and DMSO-d6), the [Pt(N(R)1,1′-Me2dma)Cl]+ complexes (in D2O and
DMSO-d6), and the Pt(N(R)1,1′-Me2dma)G adducts (in D2O) reported here. NMR signals were
assigned by analyzing their chemical shifts, splitting pattern, integration, and data from 2D NMR
experiments. Selected 1D 1H and
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C NMR data and assignments in D2O for [Pt(N(H)1,1′-

Me2dma)Cl]Cl, [Pt(N(Me)1,1′-Me2dma)Cl]Cl, and their G adducts are collected in Tables 2.3, 2.4
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and 2.5. The atom-numbering scheme in Figure 2.1 is employed in the NMR discussion. 1H NMR
results in D2O/DMSO-d6 (65:35) for Pt(N(H)1,1′-Me2dma)G adducts (G = 5′-GMP and 5′-GTP)
appear in the Supporting Information.
Table 2.3. 1H NMR Data (ppm) for the N(R)1,1′-Me2dma Carrier Ligands in Pt(N(R)1,1′Me2dma)G and in [Pt(N(R)1,1′-Me2dma)Cl]Cl (D2O, pH 4.0, 25 °C)
R

Cl or G

t
(days)
a

H4/4'

H5/5'

syn

1/1′-Me

N-Me

7.03

3.67

-

anti

H

Clb

H

5'-GMPc

6

6.53, 6.52

6.57, 6.55

7.07d

3.75

-

H

5'-GTPc

6

6.52, 6.51

6.56, 6.54

7.07d

3.74

-

H

3'-GMPc

10

6.56, 6.53

6.58, 6.57

7.09d

3.75

-

H

5'-IMPc

6

6.50, 6.47

6.53, 6.52

7.08d

3.76

-

H

5'-GDPc

4

6.52, 6.51

6.57, 6.55

7.07d

3.74

-

H

Inoc

10

6.51, 6.49

6.54, 6.52

7.09d

3.77

-

H

1-MeGuoc

10

6.52, 6.51

6.55

7.09d

3.77

-

H

9-EtGc

10

6.52

6.54

7.10d

3.77

-

Me

Cle

7.15

3.73

3.12

Me

5'-GMPc

10

6.58, 6.57

6.65, 6.63

7.12d

3.79

3.18

Me

5'-GTPc

10

6.58, 6.56

6.66, 6.65

7.13d

3.79

3.18

Me

3'-GMPc

10

6.61, 6.58

6.66, 6.64

7.14d

3.80

3.20

Me

5'-IMPc

10

6.54, 6.51

6.59, 6.58

7.12d

3.79

3.20

Me

Inoc

10

6.55, 6.53

6.59, 6.57

7.13d

3.79

3.22

6.85

7.01

a

t = reaction completion time. bendo-H6/6′ signal is masked by the solvent peak and exo-H6/6′
signal is 4.63 ppm (15.4 Hz). cexo- and endo-H6/6′ signals are masked by the solvent peak. dsyn
and anti signals are overlapped. eendo- and exo-H6/6′ are 4.97 and 4.64 ppm, respectively.
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Table 2.4. Selected 1H NMR Data (ppm) for the G Ligand in Pt(N(R)1,1′-Me2dma)G Adducts
(D2O, pH 4.0, 25 °C)
H8
R

H8

H8

H1'

H1'

H1'

syn:anti
Δδa

G
free

syn

anti

free

syn

anti

ratio

H

5'-GMP

8.10

8.69

9.00

5.91

6.05

6.10

0.31

1.07:1

H

5'-GTP

8.19

8.74

9.05

5.92

6.05

6.09

0.31

1.01:1

H

3'-GMP

8.01

8.65

8.95

5.93

6.05

6.09

0.30

1.18:1

H

5'-IMPb

8.44

9.08

9.40

6.12

6.28

6.31

0.32

1.05:1

H

5'-GDP

8.12

8.71

9.01

5.91

6.04

6.09

0.30

1.02:1

H

Inoc

8.34

9.04

9.35

6.09

6.23

6.27

0.31

1.22:1

H

1-MeGuo

7.96

8.63

8.92

5.88

6.02

6.07

0.29

1.25:1

H

9-EtGd

7.91

8.43

8.74

-

-

-

0.31

1.30:1

Me

5'-GMP

8.11

8.66

8.98

5.91

6.05

6.09

0.32

1.60:1

Me

5'-GTP

8.14

8.69

9.01

5.93

6.05

6.09

0.32

1.63:1

Me

3'-GMP

8.01

8.61

8.97

5.94

6.04

6.10

0.36

1.57:1

Me

5'-IMPe

8.44

9.04

9.36

6.14

6.27

6.31

0.32

1.65:1

Me

Inof

8.33

8.97

9.33

6.08

6.26

6.20

0.36

1.26:1

a

Shift difference between the H8 signals of the syn and anti rotamers (cf. text). bH2: 8.21 (free),
8.40 (syn), and 8.34 ppm (anti). cH2: 8.21 (free), 8.40 (syn), and 8.34 ppm (anti). dCH2: 4.08 (free),
4.26 (syn), 4.21 ppm (anti); CH3: 1.41 (free), 1.48 (syn), 1.54 ppm (anti). eH2: 8.21 (free), 8.40
(syn) and 8.32 ppm (anti). fH2: 8.21 (free), 8.40 (syn), and 8.33 ppm (anti).
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Table 2.5. 1D 13C NMR Data (ppm) for [Pt(N(R)1,1′-Me2dma)Cl]Cl [3a (R = H) and 4a (R =
Me)] and for Their 5'-GMP Adducts (D2O, pH 4.0, 25 °C)
carbonsa

3a

5'-GMP C8
5'-GMP C1'

C5/5'

122.32

adduct

4a

syn

anti

syn

anti

139.96

140.03

139.96

140.04

87.97

88.03

87.94

87.95

122.48

122.36

122.40
C4/4'

123.42

adduct

122.78
122.70

124.40

124.33

124.73

124.29

124.70

124.20

124.59
124.52

a

C2/2'

153.92

153.80

152.87

152.46

C6/6'

51.02

51.50

61.95

61.94

51.44

61.90

51.39

61.88

C1/1'

34.58

34.62

34.72

34.74

N(Me)

-

-

52.72

52.24

Free 5′-GMP: C8, 137.48 ppm; C1', 86.85 ppm.
[Pt(N(R)1,1′-Me2dma)Cl]Cl Assignments. Complexes 3 (R = H) and 4 (R = Me) both

have two downfield 1H NMR signals (Figure 2.4), as expected for the H4/4' and H5/5' aromatic
protons. However, the small coupling constant of ∼1.5 Hz, combined with the effect of the nearby
quadrupolar nitrogen atoms, causes the signals to appear as singlets in some spectra. In a ROESY
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spectrum (Supporting Information) in D2O for [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a), a strong NOE
cross-peak from the 1/1′-Me signal at 3.67 ppm to the most downfield signal (7.03 ppm) allows
the signal to be assigned to H5/5'. The other aromatic peak (6.85 ppm) can thus be assigned to
H4/4', an assignment supported by the absence of any NOE cross-peak from the H4/4' signal to
any other peak except to the H5/5' signal.

Figure 2.4. 1H NMR spectra (25 °C, D2O, pH 4) of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) (top) and
[Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a) (bottom) complexes (shifts in ppm).
The two protons in each methylene group in the [Pt(N(R)1,1′-Me2dma)Cl]+ cations are not
magnetically equivalent; these are designated as endo-CH and exo-CH (Figure 2.3). The two 1H
NMR methylene signals are doublets. Analysis of NOE cross-peaks led us to assign the upfield
and downfield [Pt(N(R)1,1′-Me2dma)Cl]Cl doublets to the exo-CH and endo-CH signals,
respectively. A similar relationship was found for [Pt(N(H)dpa)Cl]Cl.5 The 13C NMR shifts were
determined from 1D NMR spectra (Table 2.5). The

13

C NMR signals for the C4/4', C5/5', and

C1/1' carbons of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) were assigned (Table 2.5) with the aid of crosspeaks (in ppm) involving the H4/4' (6.85−123.4), H5/5' (7.03−122.3), and 1/1'-Me (3.67−34.6)
signals, respectively, in an HSQC experiment (Supporting Information). Cross-peaks from the
endo-CH and exo-CH signals assign the

13

C NMR signal at 51.5 ppm to C6/6'. The only signal

with no HSQC cross-peak (153.92 ppm) is assigned to C2/2'. As described in Supporting
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Information, this approach for assigning the signals of 3a was also used to assign the 1H and 13C
NMR signals (Tables 2.3 and 2.5) for [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a).
Although the 3a and 4a structures are similar except for the different substituent on the
central N atom, the methylene signals (in DMSO-d6) are separated by only 0.03 ppm for 3a (an AB
pattern, endo-CH at 4.56 and exo-CH at 4.53 ppm), whereas the separation between the two
doublets of 4a is 0.15 ppm (in DMSO-d6, endo-CH at 4.87 and exo-CH at 4.72 ppm). These
separations of methylene signals in [Pt(N(R)1,1′-Me2dma)Cl]Cl are significantly less than the
values reported for their [Pt(N(R)dpa)Cl]Cl analogs (in DMSO-d6, 0.325 and 0.6490 ppm for R =
H and Me, respectively). However, the coupling constants for all four platinum complexes are ∼15
Hz regardless of the carrier ligand or the substituent at the central N.
The robustness of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) in D2O (pH 7), in DMSO-d6, and in
strongly acidic (0.2 M HCl) conditions was monitored by using 1H NMR spectroscopy. The spectra
revealed no change even 10 days after addition of HCl (Supporting Information).
Pt(N(R)1,1′-Me2dma)G Adducts. NMR Background for Determining Rotamer
Conformation in Adducts. In simple Pt(Ltri)G adducts, the inductive effect of the Pt(II) center
causes the H8, H2 (in hypoxanthine derivatives, cf. Figure 2.1), and ribose H1′ peaks of bound G
to be shifted downfield compared to these signals for free G.96-97 Two G base orientations and
hence two rotamers are possible for Pt(Ltri)G adducts having Ltri ligands that are unsymmetrical
with respect to the coordination plane but symmetrical about a plane perpendicular to the
coordination plane (Figure 2.5). By convention,96 the rotamer of Pt(Ltri)G adducts having the R
group and the guanine O6 on the same side of the coordination plane is named syn, and the rotamer
having these groups on opposite sides of this plane is named anti (Figure 2.5). The syn and anti
rotamers interconvert by rotation about the Pt−N7 bond.19,43,97-99 Furthermore, neither rotamer has
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a plane of symmetry in an adduct formed by G derivatives having a chiral ribose, such as 5'-GMP.
Therefore, in each rotamer the corresponding protons in the two halves of the carrier ligand are
not magnetically equivalent. When NMR evdience is found that Pt(Ltri)G rotamers exist, only two
signals are found for each type of G proton but as many as four signals can be observed for each
proton type of carrier-ligand proton. Such a situation in fact applies to the new Pt(N(R)1,1′Me2dma)G adducts studied here (Figure 2.6).

Figure 2.5. The two possible purine orientations for Pt(Ltri)G adducts when the tridentate carrier
ligand (Ltri) is unsymmetrical with respect to the coordination plane but symmetrical about a plane
perpendicular to the coordination plane. Note that the nucleobase is represented by an arrow with
the tip at the H8 of the purine. R can be any substituent such as H or Me.
For separate sets of NMR signals of the syn and anti rotamers to be observed, the carrier
ligand must be bulky enough to slow the rotation rate of the nucleobase on the NMR time scale.3637,96-102

For

example,

Pt(Me5dien)G

adducts

(Me5dien

=

N,N,N′,N′′,N′′′-

pentamethyldiethylenetriamine) exhibit two sharp H8 NMR signals, one for each rotamer,
indicating that the presence of terminal dimethylamino groups provides enough bulk to hinder
nucleobase rotation about the Pt–N7 bond.96 In contrast, because of the relatively low bulk of dien,
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the H8 proton of the Pt(dien)G adducts shows only one sharp G H8 NMR peak, indicating fast
rotation of the guanine base about the Pt―N7 bond.5 Recently, the N(H)dpa ligand was found to
possess enough bulk to impede the rotation of the guanine nucleobase in Pt(N(H)dpa)G adducts.56

Similarly, all new Pt(N(R)1,1′-Me2dma)G adducts examined in the present study have spectra

with two sharp downfield H8 NMR signals (Figure 2.7 and Supporting Information), a finding
consistent with hindered rotation of the purine base.

Figure 2.6. Models of the two possible rotamers for Pt(Ltri)G complexes with tridentate ligands
(Ltri) unsymmetrical with respect to the coordination plane but symmetrical about a plane
perpendicular to the coordination plane, illustrated for Ltri = N(H)1,1′-Me2dma and G = 9-EtG.
Rotation of the ethyl group around the N9–CH2 bond creates a time-averaged mirror plane,
preserving the symmetry of the Pt(N(H)1,1′-Me2dma) moiety. However, if a chiral N-9 substituent
is created by replacing one methylene proton (circled), then the two halves of the Pt(N(H)1,1′Me2dma) moiety become magnetically inequivalent.
The main factor influencing the downfield shift of 1H NMR signals on complex formation
is the Pt(II) inductive effect, and this effect is expected to fall off as the number of bonds between
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the proton and the Pt(II) increases. However, the inductive effect is not expected to be different
for the two rotamers. Indeed, the shift difference (Δδ) between the H8 signals of the syn and anti
rotamers is only ∼0.04 ppm for the Pt(Me5dien)(5'-GMP) adduct and Δδ = 0 for H2 in almost all
closely related 5'-IMP adducts.96 In contrast, the aromatic rings terminating both ends of the
tridentate ligand lead to large Δδ values for H8 of ∼0.36 ppm for the Pt(N(H)dpa)G adducts.5 The
syn H8 signal is upfield to the anti H8 signal. These observations for Pt(N(H)dpa)G adducts were
explained by invoking models with a relatively uncanted guanine nucleobase in both rotamers. In
such a model, H8 is closer to the shielding region of tilted anisotropic pyridyl groups of the carrier
ligand in the syn rotamer than in the anti rotamer, accounting for the syn rotamer having the more
upfield H8 signal.5 As we discuss below, this explanation can be evaluated with the help of the
structure of 5 because the H8 signals of Pt(N(R)1,1′-Me2dma)G adducts exhibit NMR features
similar to those of Pt(N(H)dpa)G adducts.
Pt(N(H)1,1′-Me2dma)(5'-GMP) Adduct. Spectra of the reaction mixture of [Pt(N(H)1,1′Me2dma)Cl]Cl (3a) and 2.5 molar equiv of 5'-GMP in D2O (pH 4) showed new 1H NMR signals
clearly detectable about 1 h after mixing. The signals for 3a disappeared in ∼6 days (Figure 2.7),
indicating that the reaction was complete. Compared to the H8 signal for free 5'-GMP at 8.10 ppm,
two sharp downfield H8 singlets characteristic of Pt(II)-bound 5'-GMP were observed. As
discussed above, two H8 singlets (Figure 2.7) provide evidence for impeded rotation of the guanine
nucleobase in two rotamers of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct; for reasons given above,
the H8 signals at 9.00 and 8.69 ppm are assigned to the anti and syn rotamers, respectively.
Furthermore, strong EXSY cross-peaks between the syn and anti H8 signals in the ROESY
spectrum of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (Figure 2.8) add further strong evidence
that the two H8 signals arise from slow exchange between two rotamers. In contrast, ROESY
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spectra of Pt(N(H)dpa)G adducts show no EXSY cross-peaks,5 indicating that the exchange
between Pt(N(H)dpa)G rotamers occurs relatively more slowly than exchange between
Pt(N(H)1,1′-Me2dma)G rotamers.

Figure 2.7. Aromatic and H1' region of the 1H NMR spectra (25 °C, D2O, pH 4) of [Pt(N(H)1,1′Me2dma)Cl]+(10 mM, bottom) and of the reaction mixture forming Pt(N(H)1,1′-Me2dma)(5'GMP) recorded 15 min, 14 h, 24 h, 76 h, and 147 h after adding 2.5 molar equiv of 5'-GMP (shifts
in ppm).
The two rotamers of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct each have an H1' doublet
shifted downfield similarly (∼0.2 ppm) by metal coordination. The NOE cross-peak between the
downfield anti H8 signal and the downfield H1' doublet (6.10 ppm) in the ROESY spectrum
(Figure 2.8) assigns this H1' doublet to the anti rotamer. The NOE cross-peak from the syn H8
signal to the doublet at 6.05 ppm confirms its assignment as syn H1'. Because both the H1′ and H8
protons are associated with the five-membered ring of the guanine base, the H1′ and H8 signals
are shielded more by the tilted imidazolyl rings in the syn rotamer than in the anti rotamer. A
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similar relationship was found to be caused by the tilted pyridyl rings in the Pt(N(H)dpa)G class
of adducts.5

Figure 2.8. 1H–1H ROESY spectrum of Pt(N(H)1,1′-Me2dma)(5′-GMP), showing syn H8-anti H8
EXSY cross-peaks and H8–H4/4′ and H8–H1′ NOE cross-peaks (D2O, pH 4.0, 25 °C, shifts in
ppm).
The above rotamer assignments rely on shifts of the bound 5'-GMP signals as described
previously.5 The NMR features of Pt(N(R)1,1′-Me2dma)G adducts and the molecular structure of
5 allow the use of NOE cross-peaks between the bound G H8 and the carrier-ligand signals to
remove any doubt about previous assignments. From its characteristic shift and the integration, the
singlet at 3.75 ppm is unambiguously assigned to the 1/1'-Me signal of the Pt(N(H)1,1′Me2dma)(5'-GMP) adduct. The 1/1'-Me signal shows a strong cross-peak to an apparent singlet at
7.07 ppm in the ROESY spectrum (Supporting Information), allowing the assignment of the 7.07
ppm signal to H5/5'. This H5/5' singlet has a strong, broad cross-peak to four closely bunched
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singlets near 6.57–6.52 ppm (Figure 2.8). The four singlets together integrate as having the same
intensity as the H5/5' singlet, and thus all can be assigned to the H4/4' protons. These signals
exhibit no cross-peaks with the 1/1'-Me signal, confirming the H4/4' assignment. As mentioned
above, the two halves of the carrier ligand are not magnetically equivalent when the N9-substituent
is chiral (Figure 2.6).
In the ROESY spectra of both Pt(N(H)1,1′-Me2dma)(5'-GMP) (Figure 2.8) and
Pt(N(Me)1,1′-Me2dma)(5'-GMP) (Supporting Information), the H8-H4/4' NOE cross-peaks are
stronger for the anti rotamer than for the syn rotamer. To understand this difference in NOE crosspeaks, we used the GaussView 5.0.8 software program to construct a model of the anti rotamer
(Figure A.3 in Supporting Information) from the molecular structure of the syn rotamer in
[Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5). The 3'-GMP ligand of the syn rotamer in 5 was
rotated by 180° about the Pt−N7 bond and the C8―N7―Pt angle adjusted to that of the syn
rotamer (126.78°). The G H8 proton and carrier-ligand H4/4' protons are farther apart in the syn
rotamer structure (~3.5 Å) than in the model of the anti rotamer (~2.8 Å). Thus, the NOE intensities
confirm the rotamer assignments using the reasoning in previous work5 based on the effects on H8
shifts of the anisotropy of the tilted carrier-ligand aromatic rings.
The anisotropic guanine in Pt(N(Me)dpa)G,53 Pt(N(H)dpa)G5 and Pt(5,5'-Me2bipy)G237
(5,5'-Me2bipy = 5,5'-dimethyl-2,2'-bipyridine) adducts caused large upfield shifts (∼1.1 ppm) of
the signals of the carrier-ligand protons closest (H6/6') to the coordinated G. Similarly, in the G
adducts of 3a and 4a, the signals of the protons closest (H4/4') to the coordinated G are affected
the most (upfield shifts of ∼0.3 to 0.4 ppm as compared to the H4/4' signal for 3a) by adduct
formation. The non bonded distance from the chloride atom to the H4/4' protons in 3b is ~0.4 Å
longer than the corresponding distance to the H6/6' protons in [Pt(N(H)dpa)Cl]Cl.89 Therefore,
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the coordinated guanine must be closer to the H6/6' protons in Pt(N(H)dpa)G adducts as compared
to the H4/4' protons in Pt(N(H)1,1′-Me2dma)G adducts (Figure 2.9). Hence, the guanine
nucleobase will undoubtedly cause more upfield shifting of the H6/6' signals than the H4/4'
signals, as observed.

Figure 2.9. Overlap of stick drawings of [Pt(N(H)1,1′-Me2dma)Cl]+ (purple) and [Pt(N(H)dpa)Cl]+
(gold) cations (by superimposing the Pt, N1, N2 and N3 atoms). By using GaussView 5.0.8
software, 9-methylguanine (9-MeG) adduct models were constructed from the X-ray data by
replacing the coordinated Cl atoms with a 9-MeG having a Pt―N7 distance of 2.007 Å (the
distance in 5) in the plane bisecting the two halves of the cations. These two halves are almost but
not exactly equivalent (Table 2.2). For simplicity, the illustration replaces the purine with a blue
arrow. The syn orientation is shown. Cones qualitatively indicate that the H4/4' and H6/6' atoms
lie within the shielding region of the purine base. The thin green arrows span the distances to the
center of the purine six-membered ring from the H4 and the H6 atoms in one half of the carrier
ligand. The average of distances (Å) of the H4/4' and H6/6' atoms to the center of the 9-MeG rings
measured using Mercury 3.7 software follow: for the [Pt(N(H)1,1′-Me2dma)(9-MeG)]2+ models
(6-membered ring, syn 4.51 and anti 4.54; 5-membered ring, syn 3.63 and anti 3.63) and for the
[Pt(N(H)dpa)(9-MeG)]2+ models (6-membered ring, syn 4.13 and anti 4.13; 5-membered ring, syn
3.14 and anti 3.14). Thus, for a given adduct and a given ring, the distances are virtually identical
in both the syn and the anti 9-MeG orientations. In all cases, distances are ~0.4–0.5 Å longer for
the [Pt(N(H)1,1′-Me2dma)(9-MeG)]2+ model.
As described above, the chiral ribose in 5'-GMP makes the two halves of the carrier ligand
of each Pt(N(H)1,1′-Me2dma)(5'-GMP) rotamer inequivalent. The effect of chirality is small.
Likewise, the difference in orientation of the nucleobase leads to only small differences in shifts
of carrier-ligand signals. As stated in Figure 2.9, the distances from H4/4' to the center of the
guanine rings in the syn rotamer are almost all identical to the respective distances in the anti
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rotamer. Thus, resolution of the four possible signals can be observed only for signals of nuclei
close to the anisotropic nucleobase of the chiral G. The two rotamers of Pt(N(H)1,1′-Me2dma)(5'GMP) exhibit four closely spaced H4/4' signals. NOE cross-peaks (Figure 2.8) from the anti H8
and syn H8 singlets to the two most downfield and the two most upfield H4/4' signals, respectively,
assign the H4/4' signals (Table 2.3). The H5/5' protons in Pt(N(H)1,1′-Me2dma)(5'-GMP) are far
from the coordinated 5'-GMP and exhibit an apparent singlet with a very small downfield shift
change (0.04 ppm) compared to the H5/5' signal for 3a.
The 13C NMR shifts were determined from 1D NMR spectra (Table 2.5). All of the carrierligand carbons are farther from the anisotropic nucleobase than are the H4/4' protons; thus, there
are usually fewer than the four possible detectable
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C NMR signals arising from the two chiral

rotamers of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct. For example, only three peaks are
assignable to C4/4' in an HSQC experiment for Pt(N(H)1,1′-Me2dma)(5'-GMP) (Supporting
Information) in which four clustered H4/4' signals exhibit one strong cross-peak to the 13C NMR
peaks at 124.4, 124.3, and 124.2 ppm. Similarly, the H5/5' signal has a strong cross-peak to only
two closely associated peaks at 122.5 and 122.4 ppm for C5/5'. In addition, the 1/1'-Me 1H NMR
signal shows a cross-peak to the C1/1' signal at 34.6 ppm (Table 2.5).
The HSQC spectrum of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (Supporting
Information) is in turn useful in locating the methylene endo-CH signals, which fall close to the
HOD solvent peak and are suppressed by presaturation of the HOD signal. The two strong crosspeaks observed involve the C6/6′ signal (at 51 ppm, a characteristic shift for such methylene
carbons5,7,58) and the cluster of peaks at 4.60 ppm and the suppressed signals near 4.73 ppm
(Supporting Information). We can confidently assign these 1H NMR clusters respectively to the
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exo-CH and endo-CH protons because endo-CH signals are invariably downfield, as discussed
above.
Other Pt(N(H)1,1′-Me2dma)G Adducts. With the progression of the reaction between
[Pt(N(H)1,1′-Me2dma)Cl]+ and 3′-GMP (molar ratio = 1:2.5) in D2O at pH 4, the adduct separated
as pale yellow crystals. The carrier-ligand signals in the Pt(N(H)1,1′-Me2dma)(3′-GMP) adduct
have shifts similar to those observed for the 5′-GMP, 5′-GDP and 5′-GTP adducts (Table 2.3).
These observations suggest that the location of the phosphate groups at the 3′ or 5′ position of the
sugar groups does not appear to have a major effect on the properties of the adducts.
For the Pt(N(H)1,1′-Me2dma)(5′-IMP) adduct, the H8 singlets are at 9.40 (anti) and 9.08
ppm (syn), and the H2 signals are at 8.40 (syn) and 8.34 (anti) ppm (Figure 2.10, Table 2.4). The
opposite order of shifts of the H2 and H8 signals in the anti vs the syn rotamer arises because the
imidazolyl anisotropy affects mainly the six-membered ring signals in the anti rotamer and mainly
the five-membered ring signals in the syn rotamer. A similar opposite directional influence on the
H2 and H8 signals by a nearby anisotropic ring was found for other 5′-IMP adducts.5,100 Because
the rotamer abundance for the Pt(N(H)1,1′-Me2dma)(5′-IMP) adduct is very close to 1:1 (Figure
2.10), the relative intensities of the two H1' signals of the adduct were not useful for assigning the
H1' signals. The Pt(N(Me)1,1′-Me2dma)(5′-IMP) adduct has a syn:anti intensity ratio of 1.65:1,
and the relative intensities of the peaks show that the syn H1' signal is upfield and the anti H1'
signal is downfield (Supporting Information); this is the expected shift relationship because H1' is
on the five-membered ring. By analogy, the more upfield H1' signal for Pt(N(H)1,1′-Me2dma)(5′IMP) is assigned to the syn rotamer. For these two Pt(N(R)1,1′-Me2dma)(5′-IMP) adducts, the
order of shifts of the H2 signal compared to the H8 and H1' signals is opposite in the anti vs the
syn rotamer. The effect of ring anisotropy is largest on H8 shifts and smallest on H1' shifts. All

36

these shift relationships were found also for Pt(N(H)dpa)(5′-IMP) (in a solvent mixture),5 but the
shift difference between rotamers for all three types of signals is greatest for Pt(N(H)dpa)(5′-IMP),
consistent with our conclusion below that the anisotropy of the pyridyl ring is greater than that of
the imidazolyl ring in these adducts.

Figure 2.10. 1H NMR spectra (25 °C, D2O, pH 4) of the mixture of [Pt(N(H)1,1′-Me2dma)Cl]+ and
5′-IMP at 15 min after mixing (bottom) and of the Pt(N(H)1,1′-Me2dma)(5′-IMP) adduct 6 days
after mixing (top) (shifts in ppm). The spectral region was selected to show the H8 and H2 signals.
[Pt(N(H)1,1′-Me2dma)(9-EtG)]2+,

[Pt(N(H)1,1′-Me2dma)(Ino)]2+

and

[Pt(N(H)1,1′-

Me2dma)(1-MeGuo)]2+ adducts were studied to assess the influence of the phosphate group on the
formation and properties of the adducts. Complete formation of Pt(N(H)1,1′-Me2dma)G adducts
by reaction of 3a with neutral nucleobases/nucleosides required ∼10 days, a longer time than for
nucleotides (Table 2.3); the relatively shorter reaction times observed for the 3a cation with anionic
nucleotides can be attributed to the electrostatic attraction between the reactants.
The 1H NMR chemical shifts, Δδ values, and syn:anti ratios for these three [Pt(N(H)1,1′Me2dma)G]2+ adducts are similar to those of the adducts with nucleotides (Tables 2.3 and 2.4 and
Supporting Information), indicating that phosphate and ribose groups have at best a small influence
on Δδ and on impeding nucleobase rotation. The absence of the chiral sugar group in the
[Pt(N(H)1,1′-Me2dma)(9-EtG)]2+ adduct results in only one H4/4' signal for each rotamer, giving
a total of two H4/4' signals, not four as found with adducts in which G has a ribose group.
37

Furthermore, correlating the abundance of the two sets of CH2 and CH3 signals with that of the H8
signals establishes that the anti rotamer has the more downfield signals for all of the protons
associated with the five-membered guanine ring (Table 2.4).
Comparison between Pt(N(H)dpa)G and Pt(N(H)1,1′-Me2dma)G Adducts. In order to
compare the properties of the new adducts with those found previously for the Pt(N(H)dpa)G
adducts,5 we conducted a few studies of Pt(N(H)1,1′-Me2dma)G adducts (G = 5'-GMP and 5'GTP) in the solvent mixture (65:35 D2O:DMSO-d6 at pH 4) used previously for the Pt(N(H)dpa)G
adducts.5 The results for both classes of adducts, such as the syn:anti ratios, are comparable
(Supporting Information). Also, the Δδ values (in 65:35 D2O:DMSO-d6) for G = 5'-GMP and 5'GTP are ~0.4 ppm for Pt(N(H)dpa)G adducts and are ~0.3 ppm for Pt(N(H)1,1′-Me2dma)G
adducts. The non bonded distances between the bound Cl and the center of the aromatic rings
found in the molecular structures are shorter to the imidazolyl rings (~4.2 Å) of the [Pt(N(R)1,1′Me2dma)Cl]+ cations than to the pyridyl rings (~4.4 Å) of the [Pt(N(R)dpa)Cl]+ cations.89-90 The
difference in these distances suggests that H8 in adducts is farther from the center of the pyridyl
rings than from the center of the imidazolyl rings. Together with the Δδ values for these adducts
in the solvent mixture, the difference in these distances leaves little doubt that the anisotropy of
the pyridyl ring is greater than that of the imidazolyl ring.
Upon adduct formation, the downfield shift changes of the H8 and H1′ NMR signals
(relative to free G) are comparatively smaller for Pt(N(H)1,1′-Me2dma)G than for Pt(N(H)dpa)G
adducts. As an example, from data in Supporting Information, the H8 shift changes upon adduct
formation are 0.62 and 0.91 ppm for the syn and anti rotamers of Pt(N(H)1,1′-Me2dma)(5'-GMP),
respectively, vs. 0.76 and 1.12 ppm5 for the corresponding rotamers of Pt(N(H)dpa)(5'-GMP).
Because the anisotropic effect of the pyridyl rings on H8 is greater than that of the imidazolyl
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rings, the conclusion is clear that the Pt(II) center exerts a stronger electron-withdrawing effect on
the nucleobase in the Pt(N(H)dpa)G than in the Pt(N(H)1,1′-Me2dma)G adducts. The strength of
this Pt(II) inductive effect provides a rough estimate of the relative electron-donating ability of the
bound aromatic rings. Thus, the imidazolyl rings have a relatively higher donating ability than the
pyridyl rings, as might be expected. This difference, which undoubtedly occurs also in the chlorido
complexes, may be the reason that complete formation of the Pt(N(H)dpa)(5'-GMP) adduct
requires less time (~2 d) than that needed for the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (≥4 d) in
either D2O (100%) or D2O:DMSO-d6 (65:35).
Pt(N(Me)1,1′-Me2dma)G Adducts. To examine the influence of increased bulk at the
central nitrogen of the carrier ligand, we evaluated the properties of the Pt(N(Me)1,1′-Me2dma)G
adducts (Table 2.4). The Pt(N(Me)1,1′-Me2dma)(5'-GMP) adduct showed sharp H8 singlets for
the syn (upfield H8 signal at 8.66 ppm) and the anti (downfield H8 signal at 8.98 ppm) rotamers
(Supporting Information, Table 2.4). The Δδ for the two H8 signals (0.32 ppm) is comparable to
that of Pt(N(H)1,1′-Me2dma)(5'-GMP) (0.31 ppm). The chemical shifts for H1′ doublets of the syn
and anti rotamers of the Pt(N(Me)1,1′-Me2dma)(5'-GMP) adduct are similar to what is observed
for the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (Table 2.4). Similarly, the Pt(N(Me)1,1′Me2dma)(5′-GTP),

Pt(N(Me)1,1′-Me2dma)(3′-GMP),

Pt(N(Me)1,1′-Me2dma)(5′-IMP),

and

Pt(N(Me)1,1′-Me2dma)(Ino) adducts have shifts (Tables 2.3 and 2.4 and Supporting Information)
very similar to those of the corresponding Pt(N(H)1,1′-Me2dma)G adducts. However, the EXSY
cross-peaks connecting the syn and anti H8 signals in a ROESY spectrum of the Pt(N(Me)1,1′Me2dma)(5'-GMP) adduct (Supporting Information) are relatively smaller than those of the
Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (Figure 2.8), suggesting that base rotation is more facile in
the latter.
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Another difference between the Pt(N(Me)1,1′-Me2dma)G adducts and the Pt(N(H)1,1′Me2dma)G adducts was the relative abundance of the rotamers in D2O when G = 5'-GMP, 5'-GTP,
3'-GMP, and 5'-IMP. The Pt(N(Me)1,1′-Me2dma)G adducts have a high syn:anti ratio (≥1.5:1),
whereas the Pt(N(H)1,1′-Me2dma)G adducts have rotamers of nearly equal abundance (Table 2.4).
Comparison of the model of the anti rotamer (Figure A.3 in Supporting Information) with the
molecular structure of the syn rotamer in [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) did not
show any steric interactions that would favor either rotamer, consistent with the similar abundance
of the rotamers. Finally, it is interesting to note 1) that the imidazole ring has a greater degree of
tilting in 5 than in the chlorido complexes and 2) that a methyl group on the central nitrogen
increases tilting. Thus, the greater abundance of the syn rotamer typically found for Pt(N(Me)1,1′Me2dma)G adducts than for Pt(N(H)1,1′-Me2dma)G adducts may arise in part because the tilting
is already greater in the starting [Pt(N(Me)1,1′-Me2dma)Cl]Cl complex.
Relationship of the Phosphate Group to Pt(II) and N7 in GMP Complexes. The
molecular structure of [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) allows us to compare the
proximity of the phosphate group to Pt(II) and N7 to such distances in structurally characterized
5′-GMP complexes, all of which are bis adducts.69-72,77 Non-bonded distances were obtained from
crystallographically determined molecular structures by using Mercury 3.7 software. For our
purposes, we use the central P atom to gauge the distance of the phosphate group to the other
atoms. The Pt-to-P non bonded distance (9.7 Å) in the 3′-GMP complex (5) is much longer than
in the 5′-GMP complexes (5.0-6.2 Å). The NMR and structural data for such bis 5′-GMP adducts,
especially for the ΔHT conformation (head-to-tail orientation of the two bases and right-handed
chirality), suggest that the phosphate group of 5′-GMP interacts electrostatically with the Pt(II)
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center or the carrier ligand.70-71 Thus, the most abundant conformers often differ between bis
adducts formed by 5′-GMP and those formed by 3′-GMP.102
The spatial position of the 3′-phosphate group in 3′-GMP bound via N7 to a metal center
separates the centers of charge. This separation may explain why so few 3′-GMP complexes have
been crystallized. The large number of known structures of 5′-GMP complexes of many metals
may indicate that charge neutralization resulting from the close proximity of the 5′-phosphate
group to the metal center facilitates crystallization.
Furthermore, the inability of 3′-GMP to form such electrostatic interactions explains why
formation of the Pt(N(R)1,1′-Me2dma)(3′-GMP) adduct requires 10 d vs the 6 d or less needed to
form the 5′-GMP, 5′-GDP, 5′-GTP, and 5′-IMP adducts, in which a phosphate group is closer to
the Pt(II) center. The N7-to-P non bonded distance in 5 is 8.0 Å. The attraction of the negative 3′phosphate to the positive Pt(II) center during adduct formation positions the N7 of 3′-GMP too far
from Pt(II) to facilitate N7-to-Pt bond formation. In contrast, the N7-to-P non bonded distances in
5′-GMP adducts range from 5.1 to 6.3 Å.69-72,77 The attraction of the negative 5′-phosphate group
to the positive Pt(II) center positions the N7 of GMP closer to Pt(II) during adduct formation by
5′-GMP than during adduct formation by 3′-GMP. This positioning probably accounts for the
shorter times observed for reactions of 5′-GMP than of 3′-GMP.
2.4 Conclusions
The presence of EXSY cross-peaks in the ROESY spectra of Pt(N(R)1,1′-Me2dma)(5′GMP) adducts but not in the ROESY spectrum of the Pt(N(H)dpa)(5′-GMP) adduct5 revealed that
rotamer interchange is more facile for Pt(N(H)1,1′-Me2dma)G adducts than for Pt(N(H)dpa)G
adducts; we conclude that this finding establishes that the N(R)1,1′-Me2dma carrier-ligand steric
effect is relatively lower than the N(H)dpa carrier-ligand steric effect. We believe that this lower
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steric effect is a consequence of the greater distance of the H4/4′ protons from the G nucleobase
in Pt(N(H)1,1′-Me2dma)G adducts as compared to the distance of the corresponding H6/6′ protons
in Pt(N(H)dpa)G adducts.
The structural data for [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) confirm that the
3′-phosphate group is too far from the carrier ligand or the positive Pt(II) center to influence the
properties of the complex. This finding nicely complements a study with Pt(Me5dien)(5'/3'-GMP)
adducts, which exhibited properties independent of the 3′ or 5′ position of the phosphate group on
the ribose.96 The Me5dien carrier ligand has considerable steric bulk projecting out of the
coordination plane, and the 5′-phosphate group cannot easily approach the positive Pt(II) center.
In analogs of Pt(Me5dien)(5'/3'-GMP) adducts in which protons occupied the positions of some of
the carrier-ligand N-Me groups,96-97 the rotamer distribution greatly favored the rotamer in which
the 5′-phosphate group could form a hydrogen bond to the carrier-ligand NH proton. The solidstate structure of 5 in the present study thus fully supports previous less direct evidence regarding
the role of the phosphate group in influencing rotamer abundance when the carrier ligand has NH
groups in the cis position.
Finally, the structure of [Pt(N(H)1,1′-Me2dma)(3′-GMPH)]NO3•5H2O (5) establishes the
validity of features deduced from NMR results for Pt(N(H)dpa)G adducts5 that have a related
tridentate ligand. In particular, the structure of 5 shows that the G nucleobase has low canting and
that the carrier-ligand aromatic rings in a G adduct are tilted, as found in the parent chlorido
complexes. In studies of Pt(N(H)dpa)G adducts,5 the tilting of the pyridyl rings served to assign
signals to the syn or anti rotamer. The structure of 5 provides a basis for creating models of the
syn and anti rotamers. These models indicate that the H8-to-H4/4′ distance is longer in the syn
than in the anti rotamer. The relevant cross-peak intensity is larger for the anti than for the syn
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signals, a finding that provides strong support for the validity of previous rotamer assignments 5
based on the effect of carrier-ligand anisotropic groups on H8 chemical shifts.
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CHAPTER 3. NNN-TRIDENTATE LIGANDS WITH CENTRAL SULFONAMIDE AND
TERMINAL PYRIDYL RING N-DONORS. COMPARISON OF FACTORS AFFECTING
LIGAND COORDINATION MODE AND BINDING STRENGTH TO fac-[Re(I)(CO)3]+
AND Pt(II)Cl2 "CORES" AS ELUCIDATED BY X-RAY STRUCTURAL AND NMR
SPECTRAL METHODS
3.1 Introduction
New properties can be introduced into metal complexes by linking dangling groups with
targeting moieties or fluorophores onto carrier ligands. Typically, the most useful linking
chemistry avoids creating new asymmetric centers in the complexes, especially when the ultimate
goal is to identify a diagnostic or therapeutic agent. One common approach is to attach the dangling
group to the central N atom of N,N',N''-donor tridentate ligands (Figure 3.1).1-15 Various metal
complexes of tridentately bound ligand derivatives of 2-dipicolylamine (N(H)dpa) (Figure 3.2),
di-(2-methylimidazolyl)amine (N(H)dma), or diethylenetriamine (dien) with a suitable group
attached to the central N possess useful properties, such as enhanced targeting ability,2,7-8
fluorescence,3,10,13 high anticancer/antitumor activity,9,11-12 or new bioconjugation chemistry.4-6 In
almost all cases, the dangling group is attached to the chelate ligand via an N–C bond. As one
example, naphthalimide derivatives (R) are attached via an N–C bond to the central N atom of the
N(R)dpa ligand in fac-[Re(CO)3(N(R)dpa)]BF4 complexes, which have promising cell-imaging
properties.3 In particular, complexes of Pt(II) with chelate ligands having dangling groups9-17 have
been widely explored because such complexes often exhibit anticancer or antiviral activity.9,11-12,17
Recent studies from our laboratory have shown that N(SO2R)dpa (Figure 3.2) or
N(SO2R)dien type ligands, in which the central N-donor atom is part of a tertiary sulfonamide
group, function as a new class of tridentate ligands and form Re(I) complexes,

fac-

[Re(CO)3(N(SO2R)dpa)]PF64 and fac-[Re(CO)3(N(SO2R)dien)]PF65 (R = Me and Tol (p-tolyl)).
Such ligands, in which the dangling group is attached via an N–S bond to the central N atom,
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expand the scope of dangling-group properties that can be employed. The relevance of such Re(I)
compounds to the development of

99m

Tc(I) and Re(I) radiopharmaceutical diagnostic and

therapeutic agents has been discussed.4-5

Figure 3.1. Components of a biological targeting therapeutic or diagnostic metal-containing agent.
*
Component with no geometrical or optical isomers. #Non-chiral linking component attached to
the central donor of the chelate ligand, thereby avoiding the introduction of geometrical or optical
isomers.
The fac-[Re(CO)3(N(SO2R)dpa)]+ and fac-[Re(CO)3(N(SO2R)dien)]+ cations are the first
examples of any metal complex with the sulfonamide as part of a noncyclic linear tridentate ligand
having a normal metal-to-sulfonamide nitrogen bond length (~2.2 Å).4-5 More recently, closely
related complexes of Mn(I) have been described.18-19 Resonance stabilization within the
sulfonamide group results in the sulfonamide nitrogen lacking a readily available lone pair of
electrons for metal coordination. For a M–N bond to form, the bond must be energetically
favorable enough to convert the hybridization of the sulfonamide N from sp2 (resonance stabilized)
to sp3 (stabilized by the M–N bond). A key factor favoring coordination of the tertiary sulfonamide
N of N(SO2R)dpa- and N(SO2R)dien-type ligands to Re(I) is the formation of two adjacent 5membered chelate rings, the most favorable ring size for chelate formation. In this study, we
investigate whether the normally highly favorable Pt–N bond could also form when the N atom is
within the sulfonamide group in N(SO2R)dpa-type ligands; in such a case, new types of dangling
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groups could be employed with Pt(II) complexes that possess a metal center forming agents known
to have widespread use in biomedicine.

Figure 3.2. Line drawing and numbering scheme for N(SO2R)Mendpa ligands based on the parent
(P) ligand framework, N(SO2R)dpa: N,N-di(3,5-dimethyl-2-picolyl)methanesulfonamide,
N(SO2Me)3,3',5,5'-Me4dpa
(1);
N,N-di(3,5-dimethyl-2-picolyl)-p-tolylsulfonamide,
N(SO2Tol)3,3',5,5'-Me4dpa (2); N,N-di(6-methyl-2-picolyl)methanesulfonamide, N(SO2Me)6,6'Me2dpa (3); and N,N-di(6-methyl-2-picolyl)-p-tolylsulfonamide, N(SO2Tol)6,6'-Me2dpa (4). Note
that the p-tolyl group numbering is italicized to prevent confusion with the pyridyl ring numbering.
Unlike the situation with the Re(I) complexes, for which adduct formation with biological
molecules is usually not a key feature for biological applications, Pt(II) complexes typically act by
forming adducts and require one or two leaving groups for functionality. Because aromatic protons
have 1H NMR signals complicating such studies, we chose to prepare and study N(SO2R)dpa-type
ligands with methyl groups replacing some of the aromatic protons characteristic of known
ligands. Furthermore, methyl groups can increase the steric bulk on the carrier ligand, a factor
influencing anticancer activity of Pt(II) compounds.20-25 Therefore, we prepared Pt(II) complexes
utilizing four new N(SO2R)Mendpa ligands (Figures 3.2 and 3.3, R = Me or Tol and with n
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indicating

different

methyl

substitution

patterns

on

the

pyridyl

ring).

fac-

[Re(CO)3(N(SO2R)Mendpa)]PF6 complexes of these new ligands were synthesized to confirm that
they are capable of binding tridentately to Re(I), despite the presence of methyl substituents on the
pyridyl ring, especially for N(SO2R)6,6'-Me2dpa. All of the fac-[Re(CO)3(chelate)]PF6 complexes
discussed below have facial geometry, and thus from this point onward we omit the facdesignation when discussing specific compounds.

Figure 3.3. Synthetic routes for the ligands, N(SO2R)dpa (Route 1) and N(SO2R)Mendpa (Route
2). (i) dioxane, RT, 24 h. (ii) K2CO3, acetonitrile at reflux, N2, 18 h.
Previous studies from this laboratory have shown that the N(R)dpa and N(R)1,1'-Me2dma
ligands (R = H or Me) readily bind to the Pt(II) metal center in a tridentate fashion to form
[Pt(Ltri)Cl]+ (Ltri = N,N',N''-donor tridentate carrier ligand) complexes.26-27 However, the new
N(SO2R)Mendpa ligands form Pt(II) complexes with bidentate N(SO2R)Mendpa ligands having an
8-membered chelate ring with the tertiary sulfonamide nitrogen not bound directly to Pt(II) but
serving as an atom in the chain of the chelate ring. Structural characterizations of Pt(II) complexes
with bidentate ligands having 8-membered chelate rings such as those found here are very few in
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number, as compared to bifunctional Pt(II) complexes with smaller 5-, 6-, and 7-membered chelate
rings of bidentate pyridyl/imidazolyl ligands28-50 or with two pyridyl/imidazolyl monodentate
ligands.51-55 The rarity and unusual properties of the new bifunctional Pt(II) compounds with a
large 8-membered chelate ring in the current work led us to compare their structural features with
these features in related bifunctional Pt(II) complexes. The relevance of binding at G residues in
DNA by anticancer-active Pt(II) compounds28,33,43-44,55 has led to many studies of adduct formation
of guanine derivatives with mono- and bi-functional Pt(II) complexes bearing carrier ligands with
5- and 6-membered chelate rings.26-27,56 In rare cases the guanine derivatives disrupt and open the
chelate ring.57 We found that the chelate rings in the new complexes open relatively easily but that
this process is not facilitated in the presence of guanine derivatives.
3.2 Experimental Section
Starting

Materials.

Methanesulfonamide

(MeSO2NH2),

p-tolylsulfonamide

(TolSO2NH2), 2,3,5-collidine, 6-methyl-2-pyridinemethanol, tetraethylammonium chloride
([Et4N]Cl), and K2PtCl4 were used as received from Aldrich. cis-Pt(DMSO)2Cl2,58 aqueous
[Re(CO)3(H2O)3]OTf (OTf = trifluoromethanesulfonate),59 2-(chloromethyl)-6-methylpyridine,60
and 2-(chloromethyl)-3,5-dimethylpyridine61 were prepared by known methods.
NMR Measurements. 1H NMR spectra were recorded on a 400 MHz or on an Avance-III
Prodigy 500 MHz Bruker spectrometer. Peak positions are relative to TMS or solvent residual
peak with TMS as reference. All NMR data were processed with TopSpin and MestReNova
software. A presaturation pulse to suppress the water peak was employed when necessary.
Mass Spectrometric Measurements. High resolution mass spectra were recorded on an
Agilent 6210 ESI TOF LCMS mass spectrometer.
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X-ray Data Collection and Structure Determination. Diffraction data were collected on
a Bruker Kappa Apex-II DUO CCD diffractometer with Mo K radiation (λ = 0.71073 Å),
equipped with an Oxford Cryosystems Cryostream. All X-ray structures were determined by direct
methods and difference Fourier techniques and refined by full-matrix least-squares by using
SHELXL201462 with H-atoms in idealized positions.
General Synthesis of Ligands. A solution of the desired 2-chloromethyl pyridine
derivative (~6 mmol), K2CO3 (~1.7 g, 12 mmol), and the appropriate sulfonamide (~2.5 mmol) in
acetonitrile (95 mL) was heated at reflux under nitrogen for 18 h. After removal of acetonitrile
under reduced pressure, the residue was dissolved in water (45 mL) and the solution extracted with
CH2Cl2 (3 x 45 mL). The organic layers were combined, washed with saturated aqueous sodium
chloride solution, dried over sodium sulfate, and taken to dryness under reduced pressure. The
residue was dissolved in ethyl acetate:hexane (80:20) and purified by chromatography on a silica
column with the same eluent. Fractions were collected and spotted on TLC plates by using the
same eluent. The cleanest fractions, as assessed by 1H NMR spectroscopy, were combined and
taken to dryness by rotary evaporation to afford the desired ligand in sufficient purity to use in the
synthesis of the corresponding Pt(II) complex.
N(SO2Me)3,3',5,5'-Me4dpa (1). The general ligand synthesis described above carried out
with 2-(chloromethyl)-3,5-dimethylpyridine (0.98 g, 6.2 mmol) and MeSO2NH2 (0.23 g, 2.4
mmol) produced an orange residue, which was purified by using column chromatography to afford
N(SO2Me)3,3',5,5'-Me4dpa as a white solid (0.54 g, 67% yield). 1H NMR signals (ppm) in CDCl3:
8.19 (s, 2H, H6/6'), 7.23 (s, 1H, H4/4'), 4.60 (s, 4H, CH2), 3.15 (s, 3H, CH3), 2.28 (s, 6H, CH3),
2.21 (s, 6H, CH3). 1H NMR signals (ppm) in DMSO-d6: 8.17 (s, 2H, H6/6'), 7.33 (s, 2H, H4/4'),
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4.45 (s, 4H, CH2), 3.13 (s, 3H, CH3), 2.23 (s, 6H, CH3), 2.12 (s, 6H, CH3). ESI-MS (m/z): [M +
H]+ = 334.1596. Calcd for [M + H]+ = 334.1584.
N(SO2Tol)3,3',5,5'-Me4dpa (2). The general ligand synthesis with 2-(chloromethyl)-3,5dimethylpyridine (1.04 g, 6.6 mmol) and TolSO2NH2 (0.46 g, 2.6 mmol) yielded an orange residue,
which was purified by using column chromatography to afford N(SO2Tol)3,3',5,5'-Me4dpa as a
pale yellow solid (0.88 g, 79% yield). 1H NMR signals (ppm) in CDCl3: 7.98 (s, 2H, H6/6'), 7.70
(d, J = 8.1 Hz, 2H, H2/6), 7.26 (masked by the solvent peak, 2H, H3/5), 7.07 (s, 2H, H4/4'), 4.48
(s, 4H, CH2), 2.43 (s, 3H, CH3), 2.25 (s, 6H, CH3), 2.19 (s, 6H, CH3). 1H NMR signals (ppm) in
DMSO-d6: 7.94 (s, 2H, H6/6'), 7.62 (d, J = 7.8 Hz, 2H, H2/6), 7.32 (d, J = 7.9 Hz, 2H, H3/5), 7.21
(s, 2H, H4/4'), 4.41 (s, 4H, CH2), 2.39 (s, 3H, CH3), 2.16 (s, 6H, CH3), 2.13 (s, 6H, CH3). ESI-MS
(m/z): [M + H]+ = 410.1876. Calcd for [M + H]+ = 410.1897.
N(SO2Me)6,6'-Me2dpa) (3). The general ligand synthesis with 2-(chloromethyl)-6methylpyridine (0.90 g, 6.4 mmol) and MeSO2NH2 (0.24 g, 2.5 mmol) yielded an orange residue,
which was purified by using column chromatography to afford N(SO2Me)6,6'-Me2dpa as a
colorless oil (0.68 g, 88% yield). 1H NMR signals (ppm) in CDCl3: 7.55 (t, J = 7.7 Hz, 2H, H4/4'),
7.18 (d, J = 7.7 Hz, 2H, H5/5'), 7.05 (d, J = 7.7 Hz, 2H, H3/3'), 4.54 (s, 4H, CH2), 3.15 (s, 3H,
CH3), 2.51 (s, 6H, CH3). 1H NMR signals (ppm) in DMSO-d6: 7.63 (t, J = 7.7 Hz, 2H, H4/4'),
7.12 (d, J = 7.8 Hz, 4H, H3/3' and H5/5'), 4.42 (s, 4H, CH2), 3.14 (s, 3H, CH3), 2.41 (s, 6H, CH3).
ESI-MS (m/z): [M + H]+ = 306.1269. Calcd for [M + H]+ = 306.1271.
N(SO2Tol)6,6'-Me2dpa (4). The general ligand synthesis with 2-(chloromethyl)-6methylpyridine (1.00 g, 7.1 mmol) and TolSO2NH2 (0.58 g, 3.4 mmol) yielded an orange residue,
which was purified by using column chromatography to afford N(SO2Tol)6,6'-Me2dpa as a yellow
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oil (1.14 g, 89% yield). 1H NMR signals (ppm) in CDCl3: 7.71 (d, J = 8.1 Hz, 2H, H2/6), 7.43 (t,
J = 7.7 Hz, 2H, H4/4'), 7.24 (d, J = 8.1 Hz, 2H, H3/5), 7.14 (d, J = 7.8 Hz, 2H, H3/3'), 6.92 (d, J
= 7.7 Hz, 2H, H5/5'), 4.56 (s, 4H, CH2), 2.42 (s, 3H, CH3), 2.37 (s, 6H, CH3). 1H NMR signals
(ppm) in DMSO-d6: 7.67 (d, J = 8.2 Hz, 2H, H2/6), 7.53 (t, J = 7.7 Hz, 2H, H4/4'), 7.33 (d, J = 8.0
Hz, 2H, H3/5), 7.04 (quasi t, 4H, H3/3' and H5/5'), 4.43 (s, 4H, CH2), 2.37 (s, 3H, CH3), 2.28 (s,
6H, CH3). ESI-MS (m/z): [M + H]+ = 382.1591. Calcd for [M + H]+ = 382.1584.
General Synthesis of Platinum Complexes. A stirred solution of the ligand (0.1 mmol)
and cis-Pt(DMSO)2Cl2 (0.1 mmol) in methanol (5 mL) was heated at reflux overnight (~16 h). The
yellow precipitate that formed overnight was collected by filtration, washed with methanol and
ether, and air-dried (Method A). X-ray quality crystals were obtained by mixing equal volumes (1
mL) of solutions of cis-Pt(DMSO)2Cl2 (12.5 mM) and the ligand (12.5 mM) in acetonitrile and
allowing the mixture to stand at room temperature. Needle-like crystals were obtained within 2
days to 2 weeks (Method B). The 1H NMR data are identical for the products obtained by Methods
A and B.
Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5). With N(SO2Me)3,3',5,5'-Me4dpa (1, 33 mg, 0.1
mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol), Method A afforded a pale yellow solid (26 mg,
44% yield). Yellow crystals obtained by Method B were characterized by single-crystal X-ray
crystallography. 1H NMR signals (ppm) in DMSO-d6: 8.98 (s, 2H, H6/6'), 7.56 (s, 2H, H4/4'), 5.99
(d, J = 14.7 Hz, 2H, CH2), 5.37 (d, J = 14.9 Hz, 2H, CH2), 3.35 (s, 3H, CH3), 2.37 (s, 6H, CH3),
2.23 (s, 6H, CH3). ESI-MS (m/z): [M-H]- = 597.0450. Calcd for [M-H]- = 597.0463.
Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6). With N(SO2Tol)3,3',5,5'-Me4dpa (2, 41 mg, 0.1
mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol), Method A afforded a pale yellow solid (25 mg,
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37% yield). Yellow crystals obtained by Method B were characterized by single-crystal X-ray
crystallography. 1H NMR signals (ppm) in DMSO-d6: 8.90 (s, 2H, H6/6'), 8.03 (d, J = 8.2 Hz, 2H,
H2/6), 7.60 (d, J = 8.1 Hz, 2H, H3/5), 7.56 (s, 2H, H4/4'), 5.55 (d, J = 14.3 Hz, 2H, CH2), 5.47 (d,
J = 14.3 Hz, 2H, CH2), 2.45 (s, 6H, CH3), 2.21 (s, 6H, CH3); the phenyl methyl signal is masked
by the solvent peak. ESI-MS (m/z): [M + H]+ = 676.0926. Calcd for [M + H]+ = 676.0913.
[trans-Pt(DMSO)Cl2]2(N(SO2Me)6,6'-Me2dpa) (7). With N(SO2Me)-6,6'-Me2dpa (3, 30
mg, 0.1 mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol), Method A afforded a pale yellow solid
(16 mg, 28% yield). 1H NMR signals (ppm) in DMSO-d6: 7.85 (t, J = 7.8 Hz, 2H, H4/4'), 7.68 (d,
J = 7.9 Hz, 2H, H3/3'), 7.46 (d, J = 7.8 Hz, 2H, H5/5'), 5.55 (s, 4H, CH2), 3.33 (s, 3H, CH3), 3.12
(s, 6H, CH3). ESI-MS (m/z): [M + H]+ = 993.9522. Calcd for [M + H]+ = 993.9569.
[trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8). With N(SO2Tol)6,6'-Me2dpa (4, 38
mg, 0.1 mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol), Method A afforded a pale yellow solid
(14 mg, 22% yield). Yellow needle-shaped crystals obtained by Method B were characterized by
single-crystal X-ray crystallography. 1H NMR signals (ppm) in DMSO-d6: 7.91 (d, J = 8.0 Hz, 2H,
H2/6), 7.76 (t, J = 7.9 Hz, 2H, H4/4'), 7.57 (d, J = 8.0 Hz, 2H, H3/3'), 7.52 (d, J = 8.0 Hz, 2H,
H3/5), 7.43 (d, J = 7.9 Hz, 2H, H5/5'), 5.46 (s, 4H, CH2), 3.11 (s, 6H, CH3), 2.43 (s, 3H, CH3).
ESI-MS (m/z): [M + H]+ = 1069.9921 Calcd for [M + H]+ = 1069.9884. The solvent of the resultant
clear, pale yellow filtrate (Method A) was removed under reduced pressure, leaving a residue. The
1

H NMR spectrum of this residue in DMSO-d6 shows peaks for free ligand 4 and for ligand 4

bound to Pt(II) in an unsymmetric monodentate fashion.
Isolation of trans-[Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) Crystals (8a). In a
preparation that led to the isolation of the new complex detected in the residue just mentioned, an
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aqueous solution of K2PtCl4 (0.208 g, 0.5 mmol in 10 mL) was heated to 70 °C and treated with
70 µL (1 mmol) of DMSO followed after 10 min by N(SO2Tol)-6,6'-Me2dpa (4, 191 mg, 0.5
mmol). The mixture was heated and stirred for 1 h at 95 °C. The yellow solid (78 mg, 15%) that
precipitated was collected by filtration, washed with methanol and ether, and identified as complex
8 by its 1H NMR spectrum. Yellow X-ray quality crystals of 8a (53 mg, 15%) deposited overnight
from the clear yellow filtrate. The 1H NMR signals (in DMSO-d6) of the 8a crystals are identical
to those for the complex in the residue obtained with Method A (see above). 1H NMR signals
(ppm) in DMSO-d6: 7.88 (t, J = 8.0 Hz, 1H, H4bound), 7.78 (d, J = 8.0 Hz, 2H, H2/6), 7.54 (t, J =
7.9 Hz, 1H, H4dangling), 7.49 (d, J = 8.0 Hz, 1H, H3bound), 7.42 (d, J = 8.0 Hz, 3H, H3/5 & H5bound),
7.14 (d, J = 7.9 Hz, 1H, H3dangling), 7.04 (d, J = 7.9 Hz, 1H, H5dangling), 5.40 (s, 2H, CH2bound), 4.50
(s, 2H, CH2dangling), 3.09 (s, 3H, CH3bound), 2.42 (s, 3H, CH3), 2.27 (s, 3H, CH3dangling). MALDITOF (m/z): [M + Na]+ = 748.096. Calcd for [M + Na]+ = 748.052.
General Synthesis of [Re(CO)3(N(SO2R)Mendpa)]PF6 Complexes. Ligands 1-4 were
employed to synthesize [Re(CO)3(N(SO2R)Mendpa)]PF6 complexes according to the following
general procedure: a methanol solution of the ligand (30−41 mg, 0.1 mmol in 2 mL) was treated
with aqueous [Re(CO)3(H2O)3]OTf (0.1 mmol in 2 mL).59 Methanol (2─3 mL) was added to
dissolve any precipitate that formed, and the clear reaction mixture was heated at reflux for 16 h.
An excess of NaPF6 (0.16 g, 1 mmol) was added to the cooled clear solution, and the resulting
precipitate was collected on a filter, washed with water, and air-dried. A concentrated covered
solution of each compound in acetone was kept at room temperature to allow the solvent to
evaporate slowly and crystals to form. Two solutions produced X-ray quality crystals, and two
yielded powders.
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[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9). With N(SO2Me)3,3',5,5'-Me4dpa (1, 33
mg 0.1 mmol), and [Re(CO)3(H2O)3]OTf (0.1 mmol), the general preparation described above
produced [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 as a white solid (34 mg, 42% yield) after the
addition of NaPF6 (∼0.16 g). Slow evaporation of a concentrated solution of this compound in
acetone produced yellow needle-like crystals that were characterized by single-crystal X-ray
crystallography.

1

H NMR signals (ppm) in DMSO-d6: 8.60 (s, 2H, H6/6'), 7.75 (s, 2H, H4/4'),

5.29 (d, J = 17.2 Hz, 2H, CH2), 5.07 (d, J = 17.0 Hz, 2H, CH2), 3.96 (s, 3H, CH3), 2.34 (s, 6H,
CH3), 2.29 (s, 6H, CH3).
[Re(CO)3(N(SO2Tol)3,3',5,5'-Me4dpa)]PF6 (10). With N(SO2Me)3,3',5,5'-Me4dpa (2, 41
mg 0.1 mmol), and [Re(CO)3(H2O)3]OTf (0.1 mmol), the general preparation described above
produced [Re(CO)3(N(SO2Tol)3,3',5,5'-Me4dpa)]PF6 as a white solid (38 mg, 57% yield) after the
addition of NaPF6 (∼0.16 g). 1H NMR signals (ppm) in DMSO-d6: 8.63 (s, 2H, H6/6'), 8.33 (d, J
= 8.2 Hz, 2H, H2/6), 7.75 (d, J = 8.5 Hz, 2H, H3/5), 7.72 (s, 2H, H4/4'), 5.48 (d, J = 17.0 Hz, 2H,
CH2), 4.55 (d, J = 17.0 Hz, 2H, CH2), 2.56 (s, 3H, CH3), 2.28 (s, 6H, CH3), 2.20 (s, 6H, CH3). ESIMS (m/z): [M]+ = 678.1210. Calcd for [M]+ = 678.1195.
[Re(CO)3(N(SO2Me)6,6'-Me2dpa)]PF6 (11). With N(SO2Me)3,3',5,5'-Me4dpa (3, 30 mg
0.1 mmol), and [Re(CO)3(H2O)3]OTf (0.1 mmol), the general preparation described above
produced [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 as a white solid (25 mg, 34% yield) after the
addition of NaPF6 (∼0.16 g). 1H NMR signals (ppm) in DMSO-d6: 8.06 (t, J = 7.7 Hz, 2H, H4/4'),
7.65 (d, J = 7.8 Hz, 2H, H3/3'), 7.47 (d, J = 7.7 Hz, 2H, H5/5'), 5.36 (d, J = 16.9 Hz, 2H, CH2),
5.03 (d, J = 17.0 Hz, 2H, CH2), 3.90 (s, 3H, CH3), 2.88 (s, 6H, CH3). ESI-MS (m/z): [M]+ =
574.0583. Calcd for [M]+ = 574.0569.
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[Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12). With N(SO2Tol)6,6'-Me2dpa (4, 38 mg, 0.1
mmol) and [Re(CO)3(H2O)3]+ (0.1 mmol), the general preparation described above produced
[Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 as a pale yellow solid (41 mg, 51% yield) after the addition
of NaPF6 (∼0.16 g). Slow evaporation of a concentrated solution of this compound in acetone
produced pale yellow, needle-like crystals that were characterized by single-crystal X-ray
crystallography. 1H NMR signals (ppm) in DMSO-d6: 8.21 (d, J = 8.0 Hz, 2H, H2/6), 8.02 (t, J =
7.8 Hz, 2H, H4/4'), 7.75 (d, J = 7.7 Hz, 2H, H3/5), 7.63 (d, J = 8.0 Hz, 2H, H3/3'), 7.52 (d, J = 7.6
Hz, 2H, H5/5'), 5.23 (d, J = 16.8 Hz, 2H, CH2), 4.52 (d, J = 16.6 Hz, 2H, CH2), 2.90 (s, 6H, CH3),
2.57 (s, 3H, CH3).
Solution Studies of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5). A solution of 5 (10 mM) in
DMSO-d6 (Solution 1), at 25 °C was monitored by 1H NMR spectroscopy for at least 21 d. Another
10 mM solution of 5 in DMSO-d6 was treated with 10 molar equiv of [Et4N]Cl (10 mg) after 1 d
(Solution 2). In another experiment, 5 (3.6 mg) was added to a solution of [Et4N]Cl (100 mM) in
DMSO-d6 to make the solution 10 mM in 5 (Solution 3). In a similar experiment, a sufficient
amount of ligand 1 (1.3 mg) was added to a solution containing cis-Pt(DMSO)2Cl2 (10 mM) and
[Et4N]Cl (100 mM) in DMSO-d6 to make the solution 10 mM in ligand 1 (Solution 4). Another 10
mM solution of 1 in DMSO-d6 was treated with 1 molar equiv of cis-Pt(DMSO)2Cl2 (1.7 mg,
Solution 5). Solutions 2, 3, 4, and 5 were monitored with time by 1H NMR spectroscopy. Solutions
of 6 (4.0 mg, 10 mM) in DMSO-d6 or in DMF-d7 (partially dissolved) were kept at 25 °C and
monitored by 1H NMR spectroscopy. Furthermore, 10 mM solutions of 7, 8, and Re(I) complexes,
9–12, in DMSO-d6 were kept at 25 °C and monitored over time by 1H NMR spectroscopy.

59

3.3 Results and Discussion
Synthesis of N(SO2R)Mendpa Derivatives and Their Pt(II) and Re(I) Complexes. Our
previous synthesis of N(SO2R)dpa4 ligands utilized the commercially available parent ligand,
N(H)dpa (Figure 3.2), which was coupled with the appropriate sulfonyl chloride (Route 1, Figure
3.3). However, the N(H)Mendpa parent ligands needed in this study, N(H)3,3',5,5'-Me4dpa and
N(H)6,6'-Me2dpa, are not commercially available. Thus, the new N(SO2R)Mendpa (1-4) ligands
were synthesized by a different route, in which the desired 2-chloromethyl pyridyl derivative (2
equiv) was coupled with the appropriate sulfonamide under basic conditions (Route 2, Figure 3.3).
This route gave the expected ligand as the main product, and the side-products were readily
removed by column chromatography. These isolated ligands were treated with cis-Pt(DMSO)2Cl2
in methanol at reflux to obtain the neutral Pt(II) complexes in this study, 5–8 (Figure 3.4). Using
a synthesis similar to that reported for [Re(CO)3(N(SO2R)dpa)]PF6,4 we obtained
[Re(CO)3(N(SO2R)Mendpa)]PF6 complexes 9–12 (Figure 3.5).

Figure 3.4. General reaction conditions for forming complexes 5-8.
X-ray Structural Results. Crystal data and details of the structural refinement for Pt (5,
6, 8 and 8a) and Re (9 and 12) complexes are summarized in Table 3.1. The ORTEP plots 5, 6, 8,
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and 8a and cations of 9 and 12 (Figures 3.6 and 3.7) show the numbering system used to describe
the solid-state data. Selected bond lengths and angles are reported in Tables 3.2 and 3.3. Crystals
of 6 contain two independent molecules in the asymmetric unit, only one of which (B) is shown in
Figure 3.6 and used in the discussion. Structural metrics of the two halves of complex 8 are slightly
different in the solid state and are reported separately in Table 3.2 as Pt1 and Pt2.
The molecular structures (Figure 3.6) and other properties of the pseudo octahedral
complexes,

[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6

(9)

and

[Re(CO)3(N(SO2Tol)6,6'-

Me2dpa)]PF6 (12), are compared to features of the new Pt(II) complexes below. In 9 and 12, all
three nitrogen atoms of the tridentate ligands (1 and 4, respectively) occupy one face, and the three
carbonyl ligands occupy the other face. The lengths of the Re−N(sulfonamide) bonds (Table 3.3)
in both complexes are in the typical range (∼2.23−2.29 Å) reported for Re−N(sp3) bonds.63-64 The
Re−N1 and Re−N3 bond distances in 9 are in the typical range (2.14−2.18 Å) for Re−N(sp2)
bonds.4,63,65-66 However, 12 has significantly longer Re−N1 and Re−N3 bonds [2.228(3) Å]), an
observation we attribute to the steric effect of the ortho methyl groups of ligand 4, as discussed
later.

Figure 3.5. General reaction procedures for obtaining complexes 9-12.
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Table 3.1. Crystal Data and Structure Refinement for Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5), Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6),
[trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa)
(8),
[trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa)
(8a),
[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9), and [Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12)
5
empirical
formula

6

8

8a

9

C17H23Cl2N3 C23H27Cl2N3O2 C25H35Cl4N3O4Pt2 C23H29Cl2N3O3Pt C20H23N3O5ReS.P
O2PtS
PtS
S3
S2
F6

12
C24H23N3O5ReS.
PF6.C2H3N

fw

599.43

675.52

1069.72

725.60

748.64

837.74

crystal system

triclinic

triclinic

triclinic

monoclinic

monoclinic

triclinic

Pī

Pī

Pī

P21/n

P21/c

Pī

a (Å)

9.3872(5)

9.6341(13)

11.1641(13)

13.4349(2)

18.3654(18)

7.9263(7)

b (Å)

10.7446(6)

15.4229(18)

13.1322(16)

10.4611(2)

10.1944(10)

13.2608(12)

c (Å)

11.0369(6)

17.847(2)

13.7223(16)

20.4190(4)

13.5371(13)

14.6563(12)

α (deg)

85.528(3)

66.561(5)

68.349(7)

90

90

90.652(5)

 (deg)

84.236(3)

82.411(7)

70.784(7)

108.118(1)

105.056(5)

91.950(5)

γ (deg)

79.345(3)

80.900(5)

68.683(7)

90

90

106.425(5)

V (Å3)

1086.47(10)

2395.3(5)

1697.2(4)

2727.48(9)

2447.5(4)

1476.4(2)

T (K)

110

105

99

102

111

100

2

4

2

4

4

2

calc (g/m3)

1.832

1.873

2.093

1.767

2.032

1.884

abs coeff (mm-1)

6.82

6.19

8.77

5.52

5.20

4.32

space group

Z

(Table 3.1. continued)
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a

5

6

8

8a

9

12

2max ()

78.4

61.0

66.6

80.6

52.8

61.0

R[F2>2σ(F2)]

0.025

0.028

0.062

0.020

0.022

0.031

Rw

0.068

0.060

0.180

0.047

0.046

0.079

res. dens. (e Å-3)

2.85, -1.45

0.92, -1.16

7.91, -4.42

1.51, -1.30

0.97, -0.63

2.74, -2.08

data/parameters

12704/240

14452/587

12716/377

17149/312

4987/339

8815/401

R = (||F| - |Fc||)/|F|. b Rw = [[w(F2 - Fc2)2]/[w(F2)2]]1/2, in which w = 1/[2(F2) + (dP)2 + (eP)] and P = (F2 + 2Fc2)/3.
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Figure 3.6. ORTEP plots of complexes Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5) and
Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6) and cations of [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6
(9) and [Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12). Thermal ellipsoids are drawn with 50%
probability.
In contrast to the findings with the [Re(CO)3(N(SO2R)Mendpa)]PF6 complexes 9–12,
molecular structures of the pseudo square planar Pt(II) complexes of ligands 1, 2 and 4 reveal that
the sulfonamide N does not form a Pt−N bond in any of the complexes (5, 6, 8 and 8a, Figures 3.6
and 3.7). The only Pt−N bonds found involve a pyridyl group, and all Pt−N bonds have lengths
(Table 3.2) falling in the range typically reported for Pt−N(sp2) bonds (1.99−2.08 Å).27,67 The
64

bidentate coordination mode in Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes (5, R = Me and 6, R =
Tol, Figure 3.6) creates a relatively large and uncommon 8-membered chelate ring. The
N(SO2R)6,6'-Me2dpa ligands, 3 and 4, do not bind to Pt(II) as chelate ligands, and the complexes
formed are discussed later.

Figure 3.7. ORTEP plots of complexes [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8) and
[trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a). Thermal ellipsoids are drawn with 50%
probability.
Structural Features Arising from the Different Chelate Binding Modes of Re(I) and
Pt(II) Complexes. The angles around the sulfonamide N in the Re(I) complexes, 9 and 12, are
close to tetrahedral values (Table 3.3), indicating that the sulfonamide N hybridization changed
from sp2 to sp3. When a tertiary sulfonamide N is bound to Re(I)4-5 or to other metals [e.g., Mn(I),
Cu(II), Ni(II), Co(II)],1,18-19,68-69 the angles around the sulfonamide N atom are consistent with sp3
hybridization. In contrast, the angles around the tertiary sulfonamide N in 5 and 6 (Table 3.2) are
closer to 120° than to 109.5° (tetrahedral geometry), indicating that sp2 hybridization for the
sulfonamide N atom is retained.
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Table 3.2. Selected Bond Distances (Å) and Angles (deg) for Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2
(5), Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6), [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8),
and [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a)
5

6 (B)

8

8a

Pt1

Pt2

Pt–N1

2.023(2)

2.027(3)

2.062(9)

-

2.0757(9)

Pt−N2a

3.693(2)

3.317(3)

3.744(8)

4.51(1)

4.5556(9)

Pt–N3

2.031(2)

2.032(3)

-

2.066(8)

-

Pt–Cl1/3

2.2939(6)

2.2888(8)

2.303(2)

2.297(2)

2.2922(3)

Pt–Cl2/4

2.2990(6)

2.3009(8)

2.304(2)

2.320(3)

2.3030(3)

S1–O1

1.436(3)

1.430(3)

1.429(8)

1.4358(10)

S1–O2

1.435(3)

1.434(3)

1.431(7)

1.4327(9)

N2–S1

1.6565(19)

1.630(3)

1.642(8)

1.6390(10)

Pt–S2/3

-

-

N1–Pt–N3

87.98(8)

95.21(10)

-

-

S1–N2–C6

113.77(17)

118.10(2)

116.0(6)

116.85(8)

S1–N2–C7

113.83(17)

117.0(2)

118.9(6)

118.66(7)

C6–N2–C7

114.78(17)

121.30(2)

115.3(7)

116.15(9)

N1–Pt–Cl2/4

176.99(6)

176.62(8)

89.4(2)

-

89.70(3)

N1−Pt−Cl1/3

89.51(6)

86.18(8)

86.9(2)

-

87.15(3)

N3–Pt–Cl1/3

175.88(6)

178.51(7)

-

86.2(2)

-

N3−Pt−Cl2/4

90.22(6)

86.92(8)

-

89.4(2)

-

Cl1/3–Pt–Cl2/4

92.15(2)

90.66(3)

176.05(9)

dihedral angleb

77.18, 82.61

86.47, 87.17

75.13

82.91

85.23

Pt−N−centroid

174.82, 174.23

169.84, 166.56

173.49

179.52

174.16

2.816(3)

2.998(4)

N1−N3a
a

2.217(3)

2.219(3)

2.2218(3)

175.57(9) 175.68(12)

5.15(1)

4.632(1)

Non-bonded distance between the two atoms. bAngle between the coordination plane (defined
by the Pt, N1, N3, and two Cl atoms) and the pyridyl ring planes.
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Table 3.3. Selected Bond Distances (Å) and Angles (deg) for [Re(CO)3(N(SO2Me)3,3',5,5'Me4dpa)]PF6 (9), and [Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12)
9

12

Re–N1

2.180(3)

2.228(3)

Re–N2

2.253(3)

2.263(3)

Re–N3

2.176(3)

2.228(3)

Re–C1

1.926(4)

1.933(3)

Re–C2

1.899(4)

1.917(3)

Re–C3

1.919(3)

1.919(3)

S1–O4

1.431(2)

1.428(3)

S1–O5

1.425(2)

1.428(3)

N2–S1

1.749(3)

1.752(3)

N1–Re–N2

74.21(10)

74.38(10)

N1–Re–N3

89.37(9)

90.49(10)

N2–Re–N3

77.26(9)

77.19(10)

S1–N2–C9

111.34(19)

111.2(2)

S1–N2–C10

110.4(2)

110.9(2)

C9–N2–C10

109.9(2)

109.0(2)

Re–N2–S1

109.34(13)

111.31(13)

Re–N2–C9

105.51(18)

104.27(18)

Re–N2–C10

110.26(18)

109.93(19)

N1–Re–C2

96.13(13)

100.28(12)

N1–Re–C3

90.02(12)

87.33(12)

N3–Re–C2

98.31(12)

103.07(13)

N3–Re–C1

91.59(12)

90.49(10)

dihedral anglea

74.23, 77.72

72.18, 79.53

Re−N−centroid

173.88, 173.92

171.33, 171.64

N1−N3b
3.063(4)
3.164(4)
a
Angle between the coordination plane (defined by the Re, N1, N3, O1 and O3 atoms) and
the pyridyl ring planes. bNon-bonded distance between the two atoms.
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The N−S bond distances are generally longer (1.73−1.78 Å)1,4,18-19,68-69 in metal complexes
with an N-coordinated tertiary sulfonamide than in complexes with an uncoordinated sulfonamide
N (1.62−1.64 Å).1,4,68,70 Accordingly, the N−S bond distances in the Pt(II) complexes reported here
are shorter than those for Re(I) complexes (Tables 3.2 and 3.3). Shorter N−S bond distances in an
uncoordinated sulfonamide group indicate a considerable amount of double-bond character of the
N−S bond owing to the delocalization of the lone pair of the N atom.1,4,71
Coordination geometry could be another factor leading to the different chelate ligand
binding modes in the new Pt(II) and Re(I) complexes. The N(SO2R)dpa-type ligands (including 14) act as tridentate chelators in the pseudo octahedral compounds, 9-12, as well as in the known
complexes, (fac-[Re(CO)3(N(SO2R)dpa)]+ and fac-[Mn(CO)3(N(SO2R)dpa)]+).4,18-19 In these
complexes, the metal atom and the three donor N atoms (sulfonamide N and the two N atoms of
the adjacent pyridyl rings) do not define a common plane: the three N-donor atoms are facially
coordinated. Similarly, in almost all of the metal complexes in which the metal is bound to a
tertiary sulfonamide nitrogen, the three N-donor atoms occupy the face of an octahedron or have
a similar arrangement in complexes with other geometries (such as distorted trigonal bipyramidal
or square pyramidal).4,18,72 In square-planar Pt(II) complexes, the central donor atom of a tridentate
ligand forming two 5-membered chelate rings must be able to accommodate the meridional
coordination mode. A clear case in which a tertiary sulfonamide group anchors two chelate rings
having a meridional disposition has been reported for a square planar Cu(II) complex of a
derivative of cyclam (a cyclic tetradentate macrocyclic N-donor ligand with alternating 5- and 6membered chelate rings).72 One of the four donor nitrogens in the derivative bears a tosyl
group. The angles and other parameters involving the sulfonamide N are normal for a coordinated
sulfonamide. Even in this case with 5- and 6-membered chelate rings anchored by the sulfonamide
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N, the complex is distorted relative to the complex of the parent cyclam lacking the tosyl group. In
the complex having the tosyl group, the Cu(II) atom deviates by ~0.2 Å from the planes defined
either by all four ligating N atoms or by any three ligating N atoms. However, in the cyclam
complex, the Cu(II) atom lies in all such planes (deviation ~0.002 Å). We believe that our analysis
of this reported data makes a strong case that there is a steric requirement that the N of a tertiary
sulfonamide group with two adjacent 5-membered chelate rings must anchor a facially coordinated
rather

than

a

meridionally

coordinated

tridentate

ligand.

Hence, ligands 1 and 2 coordinate bidentately in Pt(II) complexes 5 and 6, respectively.
Comparison of Structural Features of the New Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2
Complexes with Other Bifunctional Pt(II) Complexes. The 8-membered chelate ring in
the Pt(N(SO2R)Mendpa)Cl2 complexes is a rare and hence interesting feature. Indeed, only limited
types of Pt(II) complexes containing 8-membered chelate rings have molecular structures reported
in the Cambridge Crystallographic Data Centre (CCDC). Most examples have very closely related
bidentate ligand derivatives with Pt(II) bound to the pyridyl N of a fused bicyclic 7-azaindo-1-yl
group.45-46,49 Only one Pt(II) complex contains a linear ligand terminated with two simple aromatic
rings (pyridyl). Other complexes commonly have macrocyclic N-donor (mostly sp3) ligands
bound in a bidentate mode.47-48 We found that there are only three Pt(II) complexes of 8-membered
chelate rings containing two aromatic ring nitrogens (pyridyl/imidazolyl) and two halides as the
other ligating atoms listed in the CCDC data base;48-50 in contrast, there are seven, seventeen and
one hundred eight for 7-, 6-, and 5-membered chelate rings, respectively.28-44 Data for fiftythree complexes (all of the complexes containing 8-, 7- and 6-membered chelate rings, plus
twenty-six randomly chosen complexes of 5-membered chelate rings) were utilized in the
following structural comparisons with the structural data for 5 and 6.
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In bifunctional Pt(II) complexes with two cis aromatic planar N-donor rings (one bidentate
or two monodentate), the tilting of each ring can be gauged by the dihedral angle between the plane
of the aromatic ring (defined by the C and N atoms in the ring) and the coordination plane (defined
by Pt and the four ligating atoms). If the dihedral angle is close to 90°, the aromatic ring is
described as not being tilted. As the angle decreases, the ring is said to become more tilted. The
two pyridyl rings in 5 and 6 are only slightly tilted, with the dihedral angles ranging from 77° to
87° (Table 3.2); thus, the 8-membered ring allows the pyridyl rings to be oriented roughly
perpendicular to the coordination plane. In contrast, other known bifunctional Pt(II) complexes
with a bidentate ligand terminated by pyridyl or imidazolyl rings [and the remaining coordination
site(s) occupied by halide(s)] and forming 5-, 6-, or 7-membered chelate rings28-44 have relatively
smaller average dihedral angles (Figure 3.8). However, the three known Pt(II) complexes with 8membered chelate rings48-50 used in the plot have high dihedral angles (73−89°), values close to

Figure 3.8. Relationship between the average dihedral angle (blue line, left axis, degrees) and the
chelate ring size plotted for the reported molecular structures of bifunctional platinum(II)
complexes with linear bidentate ligands terminated by pyridyl or imidazolyl donor rings (the
remaining two coordination sites are occupied by halide ligands). The orange line shows the
number of donor rings utilized for each chelate ring size. The red dot shows the average (83.4°) of
the dihedral angles for 5 and 6. Note: All published data in this figure and in Figure 3.9 are from
the Cambridge Crystallographic Data Centre, ConQuest 1.19. Of the 108 structures available for
complexes with a 5-membered chelate ring, data from 26 randomly selected structures were used
to prepare the plot.
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the dihedral angles observed in the complexes reported here (Figure 3.8). Furthermore, the dihedral
angles of the known bifunctional Pt(II) complexes increase almost linearly with increasing chelate
ring size (Figure 3.8). Therefore, the low degree of tilting in 5 and 6 reflects the structural freedom
allowed by the relatively large 8-membered chelate ring.
The N1−Pt−N3 bite angle of 5 (87.98°) is at the high end of the range (78° to 91°) in reports
for Pt complexes with mono- or bidentately coordinated ligands terminated by pyridyl or
imidazolyl rings.28-55 Known Pt complexes containing 8-membered chelate rings have higher bite
angles (average 89.5°) than the average bite angle values of the Pt complexes containing smaller
chelate rings (Figure 3.9).28-50 In fact, the bite angles of the complexes with 8-membered chelate
rings are quite close to the corresponding angles observed in monodentate complexes (average
89.4°).51-55 We attribute this finding to the greater spatial freedom provided by the large chelate
ring; this freedom allows the rings to be located in the same relative position as monodentate
ligands. Complex 6 has a high bite angle (95.21°) but this may be a solid-state effect because the
solution behavior of 6 is close to that of 5, see below.

Figure 3.9. Relationship of the average N−Pt−N bite angle (degrees, from reported molecular
structures) to the chelate ring size of bifunctional Pt(II) complexes of bidentate ligands terminated
by pyridyl or imidazolyl donor rings (with the remaining coordination sites occupied by halide
ligands). Note: of the 108 structures available for complexes with a 5-membered chelate ring, data
from 26 randomly selected structures were used to prepare the plot. The average (89.4°) of the bite
angles for 8 cis bifunctional Pt(II) complexes of monodentately bound pyridyl or imidazolyl rings
is shown by the red dot in the figure for comparison.
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In an ideal situation, the lone pair of the N atom in the ring of an aromatic N donor ligand
is positioned directly toward the Pt(II) center to allow excellent overlap of bonding orbitals,
thereby creating a strong bond. The angle between the N-donor aromatic ring plane and the Pt
atom is a good structural parameter for assessing how close the Pt is to being in this plane. This
angle can be defined as Pt−N−centroid angle (N = N1 or N3, centroid = aromatic ring center).
When this angle is ~180°, the Pt atom lies in the plane of the aromatic ring. The Pt−N−centroid
angle ranges from 164−180° for known Pt(II) complexes of imidazolyl or pyridyl ligands bound
monodentately, bidentately, or tridentately;27-57,73-80 for 5 this angle is >174° (Table 3.2). This
finding is another indication that the large chelate rings permit the pyridine rings to adopt a location
for binding with the same freedom as that of monodentate ligands (Supporting Information).
NMR Spectroscopy. All of the complexes (in DMSO-d6) and ligands (in CDCl3 and
DMSO-d6) reported here were characterized by 1H NMR spectroscopy. In freshly prepared
DMSO-d6 solutions, all of the new complexes gave one set of signals, consistent with the presence
of one time-averaged symmetrical complex and agreeing with the solid-state molecular structure,
when it was available. The atom-numbering scheme in Figure 3.2 was used for NMR data. Signals
were assigned by analyzing their chemical shifts, splitting pattern, integration, and data from 1H1

H ROESY NMR experiments (the ROESY spectra of selected complexes are presented in

Supporting Information). 1H NMR data and assignments appear in the Experimental Section; see
also Table 3.4 for selected data.
Effects of Coordination Binding Mode on the Methylene 1H NMR Signals of 1 to 4. Inversion
at the sulfonamide N of ligands 1 to 4 leads to time averaging and makes the methylene protons
magnetically equivalent, and the methylene 1H NMR signal is a singlet. When the ligand is
coordinated bidentately (as in the Pt(II) complexes 5 and 6) or tridentately (as in the Re(I)
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complexes 9−12), the methylene protons are no longer made equivalent by a time-averaging
process. The protons projecting toward and away from the Cl or CO ligands are designated as
endo-CH and exo-CH protons, respectively (Figure 3.10). The endo-CH and exo-CH protons in
the complexes produce either an AB pattern or two doublets in 1H NMR spectra (Figure 3.11 and
Supporting Information). Similar methylene group NMR features have been reported for Pd(II),70
Pt(II),26-27,56 and Re(I)4-5 complexes. Whereas an AB pattern or two doublets for the methylene
signals is a good indication that the bound ligand is symmetrical, the observation of an AB pattern
or two doublets cannot be used to distinguish between a bidentate or tridentate coordination mode.
The assignment of the AB features/doublets as endo-CH or exo-CH for 5 and 6 (explained in
Supporting Information) can be found in Figure 3.11 and in Table 3.4. The 1H NMR assignments
of the methylene signals of [Re(CO)3(N(SO2R)Mendpa)]PF6 (9−12, Table 3.4) were based on
ROESY spectra, and the approach to the assignments followed the rationale used for 5, 6, and for
the previously reported [Re(CO)3(N(SO2R)dpa)]PF6 complexes.4

Figure 3.10. Designation of the methylene endo-CH and exo-CH protons, illustrated for the
structure of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5).
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Table 3.4. Selected 1H NMR Chemical Shifts for the N(SO2R)Mendpa Free Ligands (1-4) and for Their Pt(II) (5-8a) and Re(I) (9-12)
Complexes (ppm, DMSO-d6, 25 °C)
complex/
ligand
1
5
9

H6/6′
8.17
8.98
8.60

H5/5′
-

H4/4′
7.33
7.56
7.75

H3/3′
-

CH2
4.45
5.99a, 5.37b
5.29a, 5.07b

2
6
10

7.94
8.90
8.63

-

7.21
7.56
7.72

-

4.41
5.55b, 5.47a
5.48a, 4.55b

3
7
7a
11

-

7.12
7.46
7.49c, 7.16d
7.47

7.63
7.85
7.97c, 7.60d
8.06

7.12
7.68
7.57c, 7.18d
7.65

4.42
5.55
5.44c, 4.52d
5.36a, 5.03b

2.41
3.12
3.23c, 2.44d
2.88

4
7.04
7.53
8
7.43
7.76
c
d
8a
7.42 , 7.04
7.88c, 7.54d
12
7.52
8.02
a
b
c
d
endo-CH. exo-CH. Bound. Dangling.

7.04
7.57
7.49c, 7.14d
7.63

4.43
5.46
5.40c, 4.50d
5.23a, 4.52b

2.28
3.11
3.09c, 2.27d
2.90
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6/6′-Me
-

5/5′Me
2.12
2.23
2.29

3/3′Me
2.23
2.37
2.34

SO2Me
3.13
3.35
3.96

2.13
2.21
2.20

2.16
2.45
2.28

-

-

-

3.14
3.33
3.22
3.90

-

-

-

From

the

NMR

data

for

5

and

9−12

and

for

the

previously reported

[Re(CO)3(N(SO2R)dpa)]PF6,4 [Pt(N(H)dpa)]Cl,26 and [Pt(N(H)6,6'-Me2dpa)]Cl56-57 complexes,
the endo-CH signal is normally clearly downfield of the exo-CH signal for both Pt(II) and Re(I)
complexes. The only exception is the endo-CH signal (5.47 ppm) of 6, which is slightly upfield of
the exo-CH signal (5.55 ppm) at 25 °C. These signals appear in an overlapped AB pattern, and the
assignments were aided by a study of temperature dependence of the chemical shifts (Supporting
Information).

Figure 3.11. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of (a)
N(SO2Me)3,3',5,5'-Me4dpa
(1);
(b)
Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2
(5);
(c)
[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9); (d) N(SO2Tol)3,3',5,5'-Me4dpa (2); (e)
Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6); and (f) Re(CO)3(N(SO2Tol)3,3',5,5'-Me4dpa)]PF6 (10).
The structures of [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8) and [transPt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a) (Figure 3.7) and the NMR data for complexes 7, 7a,
8, and 8a establish that, unlike 1 and 2, the N(SO2R)6,6'-Me2dpa ligands (3, R = Me and 4, R =
Tol) coordinate monodentately (not bidentately) to the Pt(II) center to form binuclear or
mononuclear complexes. 1H NMR spectra (Figure 3.12) obtained for fresh solutions of the X-ray
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quality crystals of 8 or of 8a in DMSO-d6 are consistent with symmetric binuclear and
unsymmetric mononuclear complexes, respectively. Also, the signal corresponding to the
methylene protons is a singlet (Figure 3.12), indicating that ligand 4 coordinates monodentately to
Pt(II) (Figure 3.7). The methylene signal remains a singlet, as occurs in the free ligands, because
inversion at the sulfonamide N (N2) is not inhibited when the ligand is bound monodentately.
Similar NMR features were observed for 7 (Table 3.4, Figure 3.12), thus confirming that ligand 3
(N(SO2Me)6,6'-Me2dpa) forms a binuclear complex similar to 8.

Figure 3.12. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of (a)
N(SO2Me)6,6'-Me2dpa (3), (b) [trans-Pt(DMSO)Cl2]2(N(SO2Me)6,6'-Me2dpa) (7), (c)
N(SO2Tol)6,6'-Me2dpa (4), (d) [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8) and (e) [transPt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a). Line drawing of 8a shown on the right.
The methylene singlets at 4.42 ppm in 3 and 4.43 ppm in 4 have shifted downfield upon
Pt(II) metal binding to 5.55 ppm in 7 and to 5.46 ppm in 8 (Figure 3.12). Furthermore, in the
mononuclear Pt(II) compound (8a) with ligand 4 bound monodentately and unsymmetrically
(Figure 3.7), the methylene protons produce two singlets (Figure 3.12). From the characteristic
shift, the more downfield singlet (5.40 ppm) is assigned to CH2bound (the methylene group attached
to the bound pyridyl ring; see Figure 3.12 for atom designations). The other 8a singlet at 4.50 ppm
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has a shift close to that of the free ligand methylene signal (4.42 ppm) and thus is assigned to
CH2dangling. Even though the compound 7a was not isolated, it is undoubtedly the analog of 8a,
from the methylene singlets at 5.44 (CH2bound) and 4.52 ppm (CH2dangling).
Other 1H NMR Signal Assignments for Pt and Re Complexes. The 1H NMR
assignments of [Re(CO)3(N(SO2R)Mendpa)]PF6 (9−12) were based on ROESY spectra
(Supporting Information) and arguments similar to those used for the previously reported
[Re(CO)3(N(SO2R)dpa)]PF6 complexes;4 this assignment approach is also illustrated next for the
Pt(II) chelate complexes, 5 and 6.
The observation of one set of 1H NMR signals within 10 min of dissolution of
Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5, 10 mM) in DMSO-d6 (Figure 3.11) indicates that 5 dissolves
as one species. The signals are consistent with a symmetrical complex, such as the dichloro
complex. For example, there is one aromatic singlet at 8.98 ppm with a shift and intensity of two
protons consistent with assignment of the peak to H6/6' of 5. This assignment is confirmed by an
NOE cross-peak to one of the two pyridyl ring methyl singlets (at 2.23 ppm, integrating to 6
protons) in a ROESY spectrum of 5 in DMSO-d6 (Supporting Information). This pyridyl ring
methyl singlet can be assigned to 5/5'-Me because it is the only methyl group near the H6/6'
protons, and thus the other pyridyl ring methyl singlet (2.37 ppm) can be assigned to the 3/3'-Me.
The more upfield aromatic singlet at 7.56 ppm has NOE cross-peaks to both 3/3'-Me and 5/5'-Me
singlets and thus can be assigned to the H4/4' protons. The 1H NMR signals for
Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6) likewise occur as one set, indicating that fresh solutions
contain the symmetrical dichloro complex. The 1H NMR signals for 6 were assigned as for 5, by
using a ROESY spectrum of 6 in DMSO-d6 (Supporting Information). (The p-tolyl group
numbering is italicized to prevent confusion with the pyridyl ring numbering, Figure 3.2.) The
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H2/6 signal was identified as the doublet at 8.03 ppm from an NOE cross-peak to the methylene
AB feature.
Assignments of the methylene signals of 7, 8, 7a, and 8a in DMSO-d6 were discussed
above. Other signals were assigned by using ROESY spectra (Supporting Information). All
spectral features of fresh solutions are consistent with a single complex that has the molecular
structure expected from the solid-state data (Figure 3.7). The only triplet in the 1H NMR spectrum
of 7 is assigned to the H4/4' protons (Figure 3.12). Singlets at 3.12, 3.33 and 5.55 ppm are
respectively assigned to the 6/6'-Me, the sulfonamide methyl (SO2Me), and the methylene groups,
based on the integration (6, 3, and 4 protons, respectively). In the ROESY spectrum
of 7 (Supporting Information), the more upfield (7.46 ppm) of the two aromatic doublets has NOE
cross-peaks to the 6/6'-Me signal and the H4/4' signal and can thus be assigned to H5/5'. The other
aromatic doublet (7.68 ppm) is therefore assigned to H3/3', an assignment further supported by the
observed NOE cross-peaks from this signal to the H4/4', the SO2Me, and the methylene
signals. The 1H NMR ROESY spectrum of 8 (Supporting Information) was used for assignments
in a similar way as for 7.
The atom-numbering scheme for 8a shown in Figure 3.12 is used to discuss the NMR data.
In the ROESY spectrum of 8a (Supporting Information), a doublet at 7.14 ppm shows NOE crosspeaks to the two methylene singlets (the NOE cross-peak to the CH2dangling is stronger than the NOE
peak to the CH2bound) and is assigned to H3dangling. This doublet has an NOE cross-peak to the triplet
at 7.54 ppm, which can be assigned to H4dangling, because only the H4 protons are close to the H3
protons and can produce triplet peaks. Therefore, the other triplet in the spectrum (at 7.88 ppm)
can be assigned to H4bound. The H4dangling peak has an NOE cross-peak to the doublet at 7.04 ppm,
which can be assigned to H5dangling, the only other proton near the H4dangling proton. This doublet
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(H5dangling) has an NOE cross-peak to a singlet at 2.27 ppm (integrating to 3 protons), which can
be assigned to 6-Medangling. There are two more singlets with similar integrations in the aliphatic
region at 3.09 and 2.41 ppm. The singlet at 3.09 ppm can be assigned to 6-Mebound, because it has
a similar shift to the 6/6'-Me singlet of 8. Therefore, the other singlet at 2.41 ppm can be assigned
to the tolyl Me group. The H4bound triplet has two NOE cross-peaks to two doublets at 7.49 and
7.42 ppm. The doublet at 7.49 ppm (integrating to one proton) has an NOE cross-peak to the
CH2bound singlet, thus can be assigned to H3bound. The doublet at 7.42 ppm integrates for three
protons, indicating that it consists of overlapping aromatic signals. This doublet has NOE crosspeaks to the 6-Mebound and to the tolyl-Me signals, indicating that the doublet is a combination of
the H5bound and H3/5 signals. Furthermore, this doublet has another NOE cross-peak to a doublet
at 7.78 ppm (with an integration of 2 protons), which can be assigned to H2/6 in the tolyl group.
Because all of the 1H NMR peaks of 7a have chemical shifts similar to those of 8a and are
consistent with the unsymmetrically bound ligand 3 (Table 3.4), the 7a signals were assigned as
for 8a. As an example, two triplets corresponding to the H4/4' protons in 7a are observed at 7.97
(for H4bound) and at 7.60 ppm (for H4dangling). Note that because of rapid inversion at the
sulfonamide N in the dangling group, 7a and 8a have time-averaged symmetry.
Solution Studies of 1H NMR Spectral Features and Robustness of Pt(II) and Re(I)
Complexes of N(SO2R)3,3',5,5'-Me4dpa Ligands 1 and 2. All of the corresponding 1H NMR
signals of ligands 1 and 2 are shifted downfield in Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 (5 and 6) and
[Re(CO)3(N(SO2R)3,3',5,5'-Me4dpa)]PF6 (9 and 10) (Table 3.4). The 1H NMR spectra of the
complexes 5 and 9 of ligand 1 (having R = Me) are less complicated than the spectra of the
complexes 6 and 10 of ligand 2 (having R = Tol). Hence, the data for 5 and 9 are utilized here for
comparison. For example, the H6/6' singlet of the free ligand 1 shifted downfield by 0.79 ppm
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upon formation of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5) and by 0.41 ppm upon formation of
[Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9). The greater downfield shift of the H6/6' singlet
of 5 compared to the shift of 9 is a result of the greater electron-withdrawing inductive effect of
Pt(II) when compared to Re(I).4 The J coupling constants (15−17 Hz) of the methylene doublets
are similar for the Pt(II) and Re(I) complexes. Regardless of the coordination mode, the chemical
shifts of the methylene proton signals for a given carrier ligand are more downfield when bound
to Pt(II) than when bound to Re(I) (Table 3.4). For example, the chemical shifts of the endo-CH
and exo-CH signals are at 5.99 and 5.37 ppm in 5 at 5.29 and 5.07 ppm in 9.
The downfield shift change of the sulfonamide methyl (SO2Me) singlet observed for ligand
1 upon metal coordination is 0.83 ppm for [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9) and 0.22
ppm for Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5). This difference can be attributed to the inductive
effect acting through the direct Re−N(sulfonamide) bond in 9, compared to the transmission of the
inductive effect of Pt(II) through several bonds in 5. This SO2Me signal is thus diagnostic of
sulfonamide metal binding. Although complexes of ligand 2 have more complicated NMR spectra
owing to the Tol group, the observations noted for ligand 1 complexes apply also to ligand 2
complexes. These results show that the pyridyl groups of ligands 1 and 2 can adopt a position very
favorable for bonding to Pt(II) and that such interactions lead to good electron donation from the
pyridyl groups to Pt(II) in complexes 5 and 6.
1

H NMR spectra of 10 mM solutions of [Re(CO)3(N(SO2Me)3,3',5,5'-Me4dpa)]PF6 (9) and

[Re(CO)3(N(SO2Tol)3,3',5,5'-Me4dpa)]PF6 (10) in DMSO-d6 show no change even after more than
3 years, indicating that the Re(I) complexes of ligands 1 and 2 are very robust. The Pt(II)
complexes Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 (5 and 6) of these ligands in DMSO-d6, however, are
much less robust. We examined the solution chemistry of the R = Me complex 5 in more detail
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because 5 has fewer and simpler NMR signals than 6. One hour after "Solution 1"
[Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5), 10 mM in DMSO-d6] was prepared, its spectrum showed,
in addition to the peaks for 5, a small but detectable new set of 1H NMR peaks; these new peaks
gradually increased with time (Figure 3.13). The intensity of the H6/6' singlet of 5 at 8.98 ppm
gradually decreased. The presence of two new equally intense singlets arising at 9.17 and 8.76
ppm indicates that the new product contains geometrically inequivalent pyridyl groups, both still
bound to Pt(II). These new aromatic H6 and H6' signals are consistent with formation of the
solvolysis product, [Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO-d6)Cl]+ (5sol). Unlike the H6/6'
protons, the H4/4' protons of 5sol appear as one overlapped signal (7.74 ppm) with an intensity
twice that of the H6 or H6' signals. The H4/4' protons are located farther from the Pt(II) center
than are the H6/6' protons, accounting for the presence of an overlapped H4/4' signal. A different
solution (Solution 2) but otherwise identical to Solution 1 was allowed to sit for one day and then
10 molar equiv of [Et4N]Cl was added. The 5sol peaks converted within 4 h almost completely to
signals of the original dichloro complex 5 (Supporting Information).

Figure 3.13. Selected region of 1H NMR spectra of Solution 1 (Pt(N(SO2Me)3,3′,5,5′-Me4dpa)Cl2
(5) in DMSO-d6, 10 mM, 25 °C, shifts in ppm). Spectra at various times after dissolution of 5
reveal its solvolysis to form [Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO)Cl]+ (5sol, shown in line
drawing on the right) and free ligand 1. The top trace at 9 d records the equilibrated solution.
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This result further confirms that the new set of signals arises from [Pt(N(SO2Me)3,3',5,5'Me4dpa)(DMSO-d6)Cl]+ (5sol). This conclusion is supported by the absence of the 5sol signals when
solid 5 (10 mM) is dissolved in a DMSO-d6 solution containing 100 mM [Et4N]Cl (Solution 3).
Other reported examples of mono-solvolysis in DMSO-d6 of Pt(II) dichloro complexes include
complexes with a bidentate pyridyl ligand (Pt(bis(pyridine-2-yl)amine)Cl2),43 a bidentate
ethylenediamine (Pt(en)Cl2),81 or a bidentate ligand bearing a deprotonated sulfonamide group
(Pt(DNSH-dienH)Cl2).10
The changes over time in the species arising in solutions of 5 are revealing. In addition to
the appearance of 5sol NMR signals in Solution 1 as just described, signals of the free
N(SO2Me)3,3',5,5'-Me4dpa (1) ligand became detectable 4 h after 5 was dissolved in DMSO-d6
(Figure 3.13). At 24 h, the ratio of 5:5sol:1 was 59:34:7 (Figure 3.14). At 9 d, the major species
was 5sol (5:5sol:1 = 12:46:42); this is the equilibrium composition, as no further change in the ratio
was detected even after 21 d. As discussed below, this finding indicates that the large chelate ring
formed by ligand 1 in 5 leads to dissociation of the chelate even though the pyridyl rings interact
favorably with Pt(II).

Figure 3.14. Percent distribution of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5, orange),
[Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO)Cl]+ (5sol, green), and free N(SO2Me)3,3',5,5'-Me4dpa (1,
blue) in Solution 1 (10 mM solution of 5 in DMSO-d6) at 25 °C plotted versus time. Percent
distribution values were calculated by using integrations of H4/4' signals of each species.
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Solution 2, which was created from a one-day-old 10 mM solution of 5 in DMSO-d6 with
NMR signals indicating 5:5sol:1 = 54:38:8, was also followed with time. When 10 molar equiv of
[Et4N]Cl was added to this solution, the abundance of 5 increased (to 66%) and that of 5sol
decreased (to 20%) during the first hour; thereafter the abundance of 5 began to decline
(Supporting Information). By 24 h, almost no 5sol remained, while 42% of 5 remained. The
decrease of 5 continued until the only NMR signals present were those for free 1 (~12 days).
Solution 3 was made by dissolving 3.6 mg of solid 5 (10 mM) in a 100 mM [Et4N]Cl solution. At
1 h, the amount of 5sol in Solution 3 was only 1%. For this solution, a maximum amount of 3% of
5sol was detected in the spectrum recorded at 8 h, and by 24 h this amount had decreased again to
1%. (In contrast, the abundance of 5sol reached 5% and 35% at 1 h and 24 h after the preparation
of Solution 1 of 5, having no added [Et4N]Cl). In Solution 3, the 5sol peaks were no longer
detectable by 3 d. Furthermore, 1H NMR peaks of free ligand 1 were first detected in the spectrum
of Solution 3 recorded after 4 h, and these increased until 100% free 1 was present by ~12 days
(Figure 3.15). Collectively this evidence indicates that the chloride ions facilitate ligand 1
dissociation from 5 or 5sol.

Figure 3.15. Percent distribution of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5, orange),
[Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO)Cl]+ (5sol, green), and free N(SO2Me)3,3',5,5'-Me4dpa (1,
blue) in Solution 3 [a mixture of 5 (3.6 mg, 1 molar equiv) added to a 100 mM solution of [Et4N]Cl
in DMSO-d6] at 25 °C plotted versus time. Percent distribution values were calculated by using
integrations of H4/4' signals of each species.
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In another experiment, a freshly prepared 10 mM solution of ligand 1 was made by addition
of 1.3 mg of 1 to 600 L of a cis-Pt(DMSO)2Cl2 (10 mM) and [Et4N]Cl (100 mM) solution in
DMSO-d6. This "Solution 4" showed no NMR signals for 5 or 5sol even after 4 days, indicating
that a high chloride ion concentration prevents 1 from coordinating to Pt(II). In contrast, when
only ligand 1 and cis-Pt(DMSO)2Cl2 were mixed together in a 1:1 ratio (Solution 5, 10 mM) in
DMSO-d6, NMR signals for 5sol were detectable in a spectrum recorded after 1 h. By 24 h after
mixing, the 5:5sol:1 distribution was = 3:38:59, indicating that ligand 1 can coordinate to Pt(II) in
the absence of an excess of competing chloride ions and that at 10 mM its affinity for Pt(II) is
comparable to that of the DMSO-d6 solvent (the solvent molecule concentration is 14 M).
NMR evidence for solvolysis and ligand dissociation over time as found for 5 in DMSOd6 solution was also observed for Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6). Spectra recorded for a
DMSO-d6 solution of 6 (10 mM) show signals for 6sol and 2 for the first time in 1 h and 4 h after
dissolving, respectively. The equilibrated composition of this solution observed by 9 days (6:6sol:2
= 17:51:32) is similar to the composition of 10 mM solution of 5, indicating that the dangling
group has minimal influence on the robustness of these complexes. In contrast to the results in
DMSO-d6, 5 and 6 show no sign of solvolysis or chelate ligand dissociation even after 7 d in DMFd7. Thus, 5 and 6 are rather robust in DMF-d7, although both are much less soluble in DMF-d7 than
in DMSO-d6.
Complexes 5 and 6, with a relatively large 8-membered chelate ring, exhibit low robustness
in solution when compared to the known robust Pt(II) complexes of related ligands that have 5membered,26-28,57 6-membered33,43 or 7-membered55 chelate rings. However, the Pt−N−centroid
angles of 5 are similar to the values of other bifunctional Pt(II) complexes of monodentate pyridyl
ligands, which can adopt optimal metrics not limited by the chelate ring (Supporting Information).
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These structural metrics as well as the greater downfield shifting of NMR signals noted above
indicate that 5 has enthalpically favorable pyridyl-Pt bonding interactions; however, the
unfavorable entropy component of an 8-membered chelate ring and possibly strain within the large
chelate ring itself decrease the robustness of 5 and 6 in DMSO-d6. The relatively high robustness
of 9 and 10 versus 5 and 6 can be attributed to a third bond, the Re−N(sulfonamide) bond, present
in 9 and 10, which allows tridentate coordination to an octahedral face.
The reactivity of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5) with simple G derivatives, 9-MeG
or Guo, was assessed at 25 °C. Because 5 is stable in DMF-d7, a 1:2.5 molar equiv mixture of 5 (5
mM) and Guo in DMF-d7 (solution was cloudy because of poor solubility) was monitored by 1H
NMR spectroscopy. No reaction was detected even after 4 days. In DMSO-d6, 5 (10 mM) was
treated with 2.5 molar equiv of 9-MeG or Guo. For both solutions, new 1H NMR peaks for 5sol and
for free 1 were first detectable after ~1 h and ~4 h, respectively. These results are very similar to
those observed in the absence of added 9-MeG or Guo. Several new peaks consistent with the
formation of G adducts were observed only at later times. However, even at 24 h the integration
of these new peaks indicated a very low amount of G adduct formation as compared to reactions
forming 5sol and free ligand 1. In addition, three reaction mixtures of 5 in DMSO-d6 solutions (10
mM) with 2.5 molar equiv of ligands known to bind Pt(II) (1-methylimidazole, 5,5'-Me2bpy or
Me4dt)28,44,82 were studied. During the first few hours, all three solutions exhibited new 1H NMR
peaks for 5sol and for free 1, which appeared over a time course similar to that found for solutions
of 5. These results in DMF-d7 and DMSO-d6 indicate that G derivatives and other ligands do not
promote chelate ring opening in 5. In contrast, 9-EtG (2.5 equiv) immediately promoted chelate
ring opening of the tridentate ligand in [Pt(N(H)6,6'-Me2dpa)Cl]Cl (10 mM in a 64:36
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D2O/DMSO-d6 mixture, pH ≈ 4, 25 °C).57 The carrier ligand is bidentate in the adduct,
[Pt(N(H)6,6'-Me2dpa)(9-EtG)2]2+, indicating that 9-EtG facilitates chelate ring opening.57
Solution Studies of 1H NMR Spectral Features and Robustness of Pt(II) and Re(I)
Complexes of N(SO2R)6,6'-Me2dpa Ligands 3 and 4. All of the corresponding 1H NMR signals
of ligands 3 and 4 are shifted downfield in [trans-Pt(DMSO)Cl2]2(N(SO2R)6,6'-Me2dpa) (7 and 8)
and [Re(CO)3(N(SO2R)6,6'-Me2dpa)]PF6 (11 and 12) (Table 3.4). The 1H NMR spectra of the
complexes 7 and 11 of ligand 3 (having R = Me) are less complicated than those of 8 and 12 of
ligand 4 (having R = Tol). Hence, the data for 7 and 11 are utilized here for comparison.
As mentioned, [Re(CO)3(N(SO2R)3,3',5,5'-Me4dpa)]PF6 (9 and 10) are much more robust
in DMSO-d6 than the Pt(II) complexes of the same ligands 1 and 2. However, a 1H NMR spectrum
of a 10 mM solution of [Re(CO)3(N(SO2Me)6,6'-Me2dpa)]PF6 (11) in DMSO-d6 recorded after 8
d shows signals for free ligand 3 (9%, with no other signals except for the tridentately bound or
free ligand signals). Similarly, a 12-days-old, 10 mM solution of [Re(CO)3(N(SO2Tol)6,6'Me2dpa)]PF6 (12) in DMSO-d6 also shows 16% of free ligand 4. Furthermore, the ~3-years-old
solutions of 11 and 12 show signals for the corresponding free ligand only.
Ligand dissociation from an octahedral Re(I) complex ordinarily occurs via a dissociative
mechanism. In chelate complexes such as the [Re(CO)3(N(SO2R)Mendpa)]PF6 complexes, a
terminal Re−N(sp2) bond is expected to be the first Re−N bond to start chelate ligand dissociation.
This first step would be followed by solvent addition. Unlike the Re(I) complexes 11 and 12, 9
and 10 do not show ligand dissociation, indicating that the carrier-ligand Re–N bonds are stronger
in 9 and 10 than in 11 and 12. This conclusion is further supported by the normal Re−N bond
distances observed for 9 (~2.18 Å; the typical Re−N(sp2) bond distance range is 2.14−2.18
Å).4,63,65-66 In contrast, complex 12, which has long terminal Re−N bonds (~2.23 Å, Table 3.3),
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undergoes ligand dissociation, indicating that the Re−N bonds are weak and likely to break. A
molecular structure of [Re(CO)3(N(H)6,6'-Me2dpa)]PF6 obtained by our group (unpublished) also
shows relatively long terminal Re−N(sp2) bonds (2.23 Å). Furthermore, the molecular structures
of [Re(CO)3(N(H)6,6'-Me2dpa)]PF6 and 12 overlap well when superimposed through Re and the
three ligating N atoms, indicating that the structural features of the two complexes are similar.
Also, the Re−N−centroid angles of the molecular structures of 9 (~174°) and 12 (~171°) are not
very different from those angles for [Re(CO)3(N(H)6,6'-Me2dpa)]PF6 (169° and 173° for the two
rings), indicating that the long terminal Re−N(sp2) bonds are not a result of the orientation of the
pyridyl rings or the structural effects of the sulfonamide group. Therefore, we believe that the
steric repulsion between the carbonyl ligands and the 6/6' Me groups in 3 and 4 weaken the
Re−N(sp2) bonds, thereby facilitating the release of ligands 3 and 4 from complexes 11 and 12.
The 1H NMR spectrum of a 1-day-old solution of [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6'Me2dpa) (8) in DMSO-d6 (10 mM) shows new peaks corresponding to the mononuclear species
[trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a). Peaks corresponding to the free ligand 4 were
first observed after 5 days. The peaks of 8a and 4 grew with time; by 18 d, the composition of the
8:8a:4 mixture was 37:56:7 (based on methylene signal integrations). Furthermore, a 1H NMR
spectrum recorded for another ~3-year-old solution of 8 shows signals chiefly for the free ligand
(~90%).

Similarly,

spectra

recorded

for

a

10

Pt(DMSO)Cl2]2(N(SO2Me)6,6'-Me2dpa) (7) in DMSO-d6 also

mM

solution

of

show that new peaks

[transstart

appearing in 24 h. The chemical shifts of these new peaks (Table 3.4) indicate that they belong to
the corresponding mononuclear species, 7a, as discussed above. In addition to the 7a signals, this
10 mM solution of 7 showed signals of the free ligand 3 for the first time in a spectrum recorded
5 d after dissolution. The new peaks for 7a and 3 grew with time, and the change in composition
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of the solution of 7 with time was similar to observations for 8 (e.g., by 18 d, 7:7a:3 = 42:50:8 vs
8:8a:4 = 37:56:7). Also, an ~3-year-old solution of 7 showed peaks for only free ligand 3.
Under the same conditions, free ligand 1 or 2 appeared more quickly in DMSO-d6 solutions
of Pt(II) complexes of these bidentate ligands than the free ligand 3 or 4 appeared from solutions
of Pt(II) complexes of these monodentate ligands. As an example, by 9 d, the composition of the
10 mM solution of 7, [trans-Pt(DMSO)Cl2]2(N(SO2Me)6,6'-Me2dpa), mentioned above was
7:7a:3 = 60:37:3. In contrast, at a similar point in elapsed time (9 d), the 10 mM solution of
Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5) in DMSO-d6 exhibited a composition of 5:5sol:1 = 12:46:42.
The ligand dissociation of the square planar Pt(II) complexes is initiated by the associative axial
attack of a DMSO molecule. As shown in Figure 3.16, we believe that, in 7 and 8, a steric block
created by the 6/6' methyl groups and the rest of the dangling ligand near the coordination sphere
impedes the axial approach of the solvent molecule. In contrast, ligands 1 and 2 in complexes 5
and 6 cannot move freely (bound bidentately) and do not contain any methyl groups near the axial
attack site; thus, the solvent can approach the Pt(II) axial position more easily in 5 and 6 than in 7
and 8.
The partial (~40%) ligand release process for complexes 5 and 6 (bidentately bound ligand)
reached completion in less time than the essentially complete (>90%) ligand release process for 7
and 8 (monodentately bound ligand). This result indicates that the bidentate coordination of the
ligands 1 and 2 leads to more thermodynamically stable complexes than does the monodentate
coordination of ligands 3 and 4, as might be expected. However, the reasons for the slower release
of ligands 3 and 4 are not so obvious. The Pt−N bond distances for 8 (2.062(9) and 2.066(8) Å)
and for 8a (2.0757(9) Å) are not statistically different from these distances for 5 (2.023(2) and
2.031(2) Å) and for 6 (2.027(3) and 2.032(3) Å). Although the differences ranging from 0.03 to
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0.05 Å are not all statistically justified, there are enough consistent reports of Pt(II) structures to
suggest that having a monodentate pyridine substituted at both the 2 and the 6 positions with groups
having CH2Y (Y various groups such as OH) will increase the Pt−N bond distance by ~0.02 to
~0.03 Å, and having a trans DMSO ligand will add a further ~0.01 to ~0.02 Å.83-86 Therefore, it is
likely that the known trans influence of the DMSO ligand87-88 and the steric effect of the 2,6
substituents weaken the Pt−N bond, leading to the more complete release of ligands 3 and 4, as
compared to ligands 1 and 2.

Figure 3.16. Possible role of the pyridine ring substituents in impeding axial solvent attack from
the axial direction shown for Pt(N(SO2Tol)3,3',5,5'-Me4dpa)Cl2 (6), for [transPt(DMSO)Cl2]2(N(SO2Tol)6,6'-Me2dpa) (8), and for [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'Me2dpa) (8a). The axial attack (red arrow) is less sterically impeded for 6, with no substituents
projecting toward the bottom axial approach pathway, as compared to axial attack (green double
arrows) for 8 and 8a, both with substituents projecting toward the two axial approach pathways.
One-half of the carrier ligand in 8 is removed for clarity.
Possible Causes for the Absence of Bidentate Coordination to Pt(II) by N(SO2R)6,6'Me2dpa ligands (3 and 4). No evidence was found for bidentate coordination to the Pt(II)Cl2 core
by N(SO2R)6,6'-Me2dpa ligands (3, R = Me and 4, R = Tol). In contrast, no direct evidence was
found for monodentate coordination to the Pt(II)Cl2 core by N(SO2Me)3,3',5,5'-Me4dpa ligands 1
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and 2 (1, R = Me and 2, R = Tol). Because [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6'-Me2dpa) (8a)
was structurally characterized (Figure 3.7), we focus on studies with the N(SO2Tol)6,6'-Me2dpa
ligand (4). Ligand 4 did not coordinate bidentately to Pt(II) but instead formed the binuclear
compound (8) even under favorable conditions, such as longer reaction time of 4 with cisPt(DMSO)Cl2 under reflux in MeOH or heating a dilute methanol solution of 8a (3.6 mg/5 ml, 1
mM) at reflux overnight. Furthermore, a 5 mM solution of 8a in DMF-d7 was heated at 50 °C for
several days, and the solution was monitored by 1H NMR spectroscopy at 24-h intervals. These
spectra showed no change, indicating that the absence of bidentate coordination does not depend
on the solvent.
In the preceding section, we compared the release of all these bidentate ligands and
monodentate ligands from Pt(II) in DMSO-d6 solution. It is noteworthy that we did not detect any
buildup of monodentate intermediates as complexes 5 and 6 with bidentate ligands released free
ligands 1 and 2, respectively. NMR spectra showed that ligands 1 and 2 were either free or
coordinated in a bidentate mode. This finding means that the dangling pyridyl ring of the
undetectably small amount of monodentate intermediates (5a and 6a), with only one pyridyl ring
bound (the analogs of 7a and 8a) rapidly added to Pt(II), creating the 8-membered chelate ring
present in 5 and 6.
Solutions of 8a in DMSO-d6 gave no NMR spectral evidence for any bidentate chelate
complex. If chelation were favorable, these DMSO-d6 conditions should have allowed such chelate
ring closure because closure occurs readily in analogous intermediates having ligands 1 and 2.
Factors that could inhibit or prevent ring closure in 7a and 8a most likely involve the 2,6substituents of the bound pyridyl ring. These 2,6-substituents might prevent this bound ring from
tilting sufficiently to allow the dangling pyridyl ring to approach the axial attack site on Pt(II).
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Also, these substituents could offer a steric barrier to axial attack. Finally, the 2,6-substituents on
the attacking dangling pyridyl ring itself would create very high steric hindrance to Pt–N bond
formation. Only five structures of complexes containing two 2,6-substituted pyridyl ligands bound
to the same Pt(II) center are in the CCDC data base, indicating that steric hindrance makes it
difficult for two 2,6-substituted pyridyl ligands to coordinate to the same Pt(II). Only one such
complex has the two 2,6-substituted pyridyl ligands in cis positions, and in this case the pyridyl
rings form part of a macrocycle.48 The 2,6-substituted pyridyl ligands in the other four complexes
are in trans positions.89-90 In fact Kong et al. stated that it is almost impossible to form Pt(2,6lutidine)2Cl2 complexes.91
Furthermore, the two 2-methyl groups in cis-Pt(2-picoline)2Cl2 are anti to each other,52
minimizing the steric repulsion between the two syn 2-methyl groups. In contrast, if the
N(SO2R)6,6'-Me2dpa ligands coordinated bidentately to Pt(II), as in 5 and 6, the 6/6' methyl groups
would be syn; the resulting sterically unfavorable proximity of the 6/6' methyl groups would make
bidentate coordination of 3 and 4 thermodynamically unlikely. Thus, we believe that both
thermodynamic and kinetic factors make bidentate coordination of N(SO2R)6,6'-Me2dpa ligands
to Pt(II) unfavorable.
3.4 Conclusions
The N(SO2R)Mendpa ligands investigated here bind tridentately to the fac-[Re(I)(CO)3]+
core in the [Re(CO)3(N(SO2R)Mendpa)]PF6 complexes but bind in diverse modes to the cisPt(II)Cl2 core. The two types of ligands, N(SO2R)3,3',5,5'-Me4dpa and N(SO2R)6,6'-Me2dpa, bind
bidentately and monodentately to Pt(II), respectively. We suggest that these differences in ligand
binding modes arise mainly from electronic factors involving the central sulfonamide donor and
from steric factors involving the 6/6' methyl groups of the terminal pyridyl N-donors.
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Because of the steric preferences of the central tertiary sulfonamide donor, we propose that
tridentate coordination by the new carrier ligands requires a facial rather than a meridional binding
geometry.

Therefore, ligands 1 to 4 all bind readily and facially to Re(I) in fac-

[Re(CO)3(N(SO2R)Mendpa)]PF6 complexes. In cases we can find in which ligands having a
tertiary sulfonamide donor bind meridionally, one of the adjacent chelate rings is 6-membered and
one is 5-membered (see, for example, a Cu complex).72 Thus, we conclude that ligands such as
N(SO2R)3,3',5,5'-Me4dpa (1 and 2), which would have two adjacent 5-membered chelate rings if
bound tridentately, cannot bind tridentately to Pt(II) and must instead adopt the bidentate mode.
The [Re(CO)3(N(SO2R)3,3',5,5'-Me4dpa)]PF6 complexes (9 and 10) formed by the two
N(SO2R)3,3',5,5'-Me4dpa ligands, in which two protons are present at the 6/6' positions instead of
the two methyl groups, are stable indefinitely in DMSO-d6. These complexes have relatively short
Re–N bond lengths. In contrast, longer Re–N bond lengths to the pyridyl N are found for
[Re(CO)3(N(SO2R)6,6'-Me2dpa)]PF6 complexes (11 and 12) and the analog, [Re(CO)3(N(H)6,6'Me2dpa)]PF6. The longer bonds are a result of the steric repulsion between the 6/6' methyl groups
of coordinated tridentate ligands and the CO ligands in these complexes. However, only 11 and 12
release tridentate ligand with time in DMSO-d6. Thus, both the steric repulsions involving the 6/6'
methyl groups and the poor donor ability of the central sulfonamide of coordinated N(SO2R)6,6'Me2dpa tridentate ligands in 11 and 12 contribute to release of the tridentate ligand in DMSO-d6.
The Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes (5 and 6) of the bidentately bound ligands
(1 and 2) have an unusually large 8-membered chelate ring. These complexes release free ligand,
and eventually an equilibrium is established. The process occurs more rapidly than the release of
free ligands from the [trans-Pt(DMSO)Cl2]2(N(SO2R)6,6'-Me2dpa) complexes (7 and 8) of
monodentately bound ligands (3 and 4). The monodentate coordination mode is caused by steric
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hindrance of the 6/6' methyl groups in N(SO2R)6,6'-Me2dpa (3 and 4). However, the 6/6' methyl
groups and the dangling part of the ligand act as barriers to the axial attack by solvent, accounting
for the slower release of monodentately bound ligands 3 and 4 from 7 and 8 [trans(Pt(DMSO)Cl2]2(N(SO2R)6,6'-Me2dpa)) than release of the bidentately bound ligands 1 and 2
from 5 and 6 (Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2). Because there is no buildup of the monodentate
intermediate during the ligand release process, we do not know whether the trans ligand in the
intermediate is chloride or DMSO. However, 7a and 8a have DMSO in the trans position, and
DMSO has a larger trans effect than chloride.87-88 Thus, the slower release of ligands 3 and 4 from
7a and 8a is clearly steric in nature; the steric effect undoubtedly involves the inhibition of axial
attack of solvent DMSO.
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CHAPTER 4. NNN-TRIDENTATE LIGANDS WITH TERMINAL IMIDAZOLYL RING
AND CENTRAL SULFONAMIDE N-DONORS COORDINATED TO fac-[Re(I)(CO)3]+
AND Pt(II)Cl2 "CORES". DYNAMIC PROPERTIES OF THE 8-MEMBERED CHELATE
RING IN THE PT(II) COMPLEXES AND IN THEIR ADDUCTS FORMED WITH
MONODENTATE N-DONOR AROMATIC HETEROCYCLIC LIGANDS
4.1 Introduction
Identification of new linking strategies useful in modifying chelating ligands is crucial in
developing new metal-mediated diagnostic or therapeutic drug molecules; new properties can be
introduced to the drug molecules by linking groups such as fluorophores.1-15 A linear symmetrical
tridentate ligand with an easily functionalizable central donor is a good framework to study and
develop such new linking chemistries (Figure 4.1). Over the last few years our group was
particularly interested in studying new bioconjugation possibilities involving a N−S linker within
a similar framework (Figure 4.1). These studies have shown that N(SO2R)dpa6,16 and
N(SO2R)dien7 type ligands in which the central N-donor atom is part of a tertiary sulfonamide
group function as a new class of tridentate ligands; these ligands were derived from the parent
ligands N(H)dpa (2-dipicolylamine) and dien (diethylenetriamine), respectively.

Figure 4.1. Left: Schematic representation of a linear symmetrical tridentate carrier-ligand bound
to a metal ion (M). Right: Sulfonamide group containing parent ligands studied by Marzilli Group
(R = Me, Tol, etc.). The N(SO2R)1,1'-Me2dma-type ligands are employed in this study.
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Use of non-radioactive Re(I) complexes as models in developing new ligand systems for
99m

Tc diagnostic agents and

186/188

Re(I) therapeutic agents is common.17-21 Therefore, the

N(SO2R)dpa and N(SO2R)dien ligands were utilized to synthesize a number of Re(I) complexes
(fac-[Re(CO)3(N(SO2R)dpa)]+ and fac-[Re(CO)3(N(SO2R)dien)]+, R = Me, Tol, etc.) and their
relevance to the development of

99m

Tc radiopharmaceutical agents was discussed.6-7 These

complexes are the first examples to have a normal metal-to-N(sulfonamide) bond length when any
metal is bound to a noncyclic linear tridentate ligand through a sulfonamide N-donor.6-7
Furthermore, in order to introduce the N−S linker in ligands employed in Pt chemistry,
N(SO2R)Mendpa-type ligands (N(SO2R)dpa derivatives with methyl groups replacing some of the
pyridyl ring protons; N(SO2R)3,3',5,5'-Me4dpa and N(SO2R)6,6'-Me2dpa, R = Me and Tol) were
utilized to synthesize Pt(II) complexes.16 These ligands coordinated to Pt center either bidentately
(to

form

Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2)

or

monodentately

(to

form

[trans-

Pt(DMSO)Cl2]2(N(SO2R)6,6'-Me2dpa).16 The sulfonamide nitrogen was not coordinated to the
Pt(II) center in any of these complexes. Thus, the bidentate N(SO2R)3,3',5,5'-Me4dpa ligand forms
an unusually large 8-membered chelate ring. The N(SO2R)6,6'-Me2dpa ligand binds
monodentately because the 6,6'-methyl groups inhibit chelate ring formation.16 We concluded that
the reason the tertiary sulfonamide N did not bind to Pt(II) was because such a donor group cannot
anchor two adjacent 5-membered chelate rings in a meridional geometry.
A key feature to be evaluated in Pt(II) complexes designed for biological applications is
the ability to form adducts with biological molecules (such as guanine derivatives used to test
propensity for reactivity toward G residues in DNA, a feature correlating with Pt drug anticancer
activity). Unfortunately, none of the Pt complexes mentioned above were robust in DMSO-d6 and
the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes did not exhibit any useful reactivity towards
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biomolecules such as guanine derivatives.16 Based on an extensive NMR and X-ray structural
analysis, we hypothesized that the main reason for the low robustness and poor biomolecule
reactivity of the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes is the bulk of the 6-membered pyridyl
donor groups of the carrier-ligands, N(SO2R)Mendpa. There was no evidence that the steric effect
of this ring lacking a substituent in the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes prevents the
binding of the tertiary sulfonamide N, but this possibility cannot be ruled out.
In this study, we designed N(SO2R)1,1'-Me2dma ligands (Figure 4.1) with smaller 5membered imidazolyl rings (compared to 6-membered pyridyl rings in N(SO2R)dpa and
N(SO2R)Mendpa ligands); these new carrier ligands (R = Me and Tol, Figure 4.2) are derivatives
of the parent ligand, N(H)1,1'-Me2dma (bis(1-methyl-2-methylimidazolyl)amine). As observed for
the N(SO2R)3,3',5,5'-Me4dpa ligands, the N(SO2R)1,1'-Me2dma ligands coordinate tridentately in
fac-[Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 and bidentately in Pt(N(SO2R)1,1'-Me2dma)Cl2
complexes (Figure 4.2). All of the fac-[Re(CO)3(chelate)]Y (Y = ClO4 or PF6) complexes
discussed below have facial geometry, and thus from this point onward we omit the facdesignation when discussing specific compounds.
In addition to the characterization of the new carrier ligands and their metal complexes by
1

H NMR spectroscopy and single-crystal X-ray crystallography or mass spectrometry, we studied

the dynamic properties of the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes. EXSY cross-peaks
between the two 1H NMR signals of the methylene groups in DMF reveal that the 8-membered
chelate ring undergoes dynamic motion involving rotation around the Pt–N bond. This process
was not observed for the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes, consistent with a steric
effect of the larger terminal 6-membered pyridyl rings.
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Figure 4.2. General reaction route for forming N(SO2R)1,1'-Me2dma ligands: N,N-di(1-methyl-2methylimidazolyl)methanesulfonamide, N(SO2Me)1,1'-Me2dma (1) and N,N-di(1-methyl-2methylimidazolyl)-p-tolylsulfonamide,
N(SO2Tol)1,1'-Me2dma
(2)
and
their
[Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 (3, R = Me and 4, R = Tol) and Pt(N(SO2R)1,1'Me2dma)Cl2 (5, R = Me and 6, R = Tol) complexes. The numbering scheme shown here is
employed in the NMR discussion. Note that the p-tolyl group numbering is italicized to prevent
confusion with the imidazolyl ring numbering.
Finally, we describe the use of 1H NMR spectroscopy and in some cases X-ray
crystallography to examine adducts formed by the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes with
small N-donor ligands (such as 4-picoline) and guanine derivatives (G) such as guanosine and 9methylguanine. The substitution of the chloride ligands by biomolecules is important for biological
applications of platinum(II) agents. In a previous study, we have shown that G readily form
monoadducts in solutions with the monofunctional [Pt(N(R)1,1'-Me2dma)Cl]+ cation in which the
N(H)1,1'-Me2dma parent ligand and its methyl derivative, N(Me)1,1'-Me2dma, are bound
tridentately to Pt(II).22 Furthermore, similar monofunctional platinum(II) complexes of N(H)dpa
and

its

derivatives,

[Pt(N(H)dpa)Cl]Cl,23

[Pt(N(H)6-Medpa)Cl]Cl24 and
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[Pt(N(H)6,6′-

Me2dpa)Cl]Cl,25 also form G monoadducts in solution. As mentioned, the Pt(N(SO2R)3,3',5,5'Me4dpa)Cl2 complexes did not exhibit useful reactivity towards guanine derivatives or other Ndonor ligands.16 In the current study, we find that the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes do
form mono adducts ([Pt(N(SO2R)1,1'-Me2dma)GCl]+) in the presence of an excess of G (G = 9MeG and Guo). Thus, reducing the size of the terminal rings does facilitate reaction. Indeed, the
Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes also form bis adducts with monodentate pyridyl ligands
(4-picoline, 4-dimethylaminopyridine, and 3,5-lutidine). 1H NMR spectral and X-ray structural
results of these bis complexes exhibit the existence of two bis conformers, Bis1 and Bis2 in which
the SO2R group is projecting towards and away from the coordination sphere, respectively.
Because the sulfonamide group is not coordinated to the Pt(II) center, the 8-membered ring of the
Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes and their adducts has a degree of dynamic freedom; the
imidazolyl rings can rotate around the Pt–N bond and inversion can occur at the N(sulfonamide)
atom. We believe that the observed monofunctional behavior of the Pt(N(SO2R)1,1'-Me2dma)Cl2
complexes is due to a combination of the steric bulk of the chelate ligand and the guanine base,
which is bulkier than the added monodentate pyridyl ligands. The monodentate pyridyl ligands are
small enough to form bis adducts but the two bound cis monodentate pyridyl ligands decrease the
dynamic motion of the 8-membered ring.
4.2 Experimental Section
Starting

Materials.

Methanesulfonamide

(MeSO2NH2),

p-tolylsulfonamide

(TolSO2NH2), 1-methyl-2-imidazolecarboxaldehyde, tetraethylammonium chloride ([Et4N]Cl),
guanosine (Guo), 9-methylguanine (9-MeG), 4-methylpyridine (4-pic), 3,5-lutidine (3,5-lut) and
4-dimethylaminopyridine (DMAP) were used as received from Aldrich. cis-Pt(DMSO)2Cl2,26
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[Re(CO)3(CH3CN)3]ClO4,27 and 2-(chloromethyl)-1-methylimidazole hydrochloride28 were
prepared by known methods.
NMR Measurements. 1H NMR spectra were recorded on a 400 MHz or on an Avance-III
Prodigy 500 MHz Bruker spectrometer. Peak positions are relative to TMS or solvent residual
peak with TMS as reference. All NMR data were processed with TopSpin and MestReNova
software. A presaturation pulse to suppress the water peak was employed when necessary.
Mass Spectrometric Measurements. High resolution mass spectra were recorded on an
Agilent 6210 ESI TOF LCMS mass spectrometer.
X-ray Data Collection and Structure Determination. Diffraction data were collected on
a Bruker Kappa Apex-II DUO CCD diffractometer with Mo K radiation (λ = 0.71073 Å),
equipped with an Oxford Cryosystems Cryostream. All X-ray structures were determined by direct
methods and difference Fourier techniques and refined by full-matrix least-squares by using
SHELXL201429 with H-atoms in idealized positions.
N(SO2Me)1,1'-Me2dma) (1). A solution of 2-(chloromethyl)-1-methylimidazole
hydrochloride (1.00 g, 5.98 mmol), K2CO3 (~1.7 g, 12 mmol), and MeSO2NH2 (0.23 g, 2.4 mmol)
in acetonitrile (95 mL) was heated at reflux under nitrogen for 18 h. The brown residue obtained
after the removal of acetonitrile under reduced pressure was dissolved in water (45 mL) and the
solution was extracted with CH2Cl2 (3 x 45 mL). The organic layers were combined, washed with
saturated aqueous sodium chloride solution, dried over sodium sulfate, and taken to dryness under
reduced pressure. The residue was dissolved in a solvent mixture of acetone:5.0 M NH4OH (90:10)
and purified by chromatography on a silica column with the same eluent. Fractions were collected
and spotted on TLC plates by using the same eluent. The cleanest fractions, as assessed by 1H
NMR spectroscopy, were combined and taken to dryness by rotary evaporation to afford
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N(SO2Me)1,1'-Me2dma as a pale yellow oil (0.55 g, 82% yield). 1H NMR signals (ppm) in CDCl3:
6.98 (2H, H5/5'), 6.86 (2H, H4/4'), 4.52 (s, 4H, CH2), 3.70 (s, 6H, CH3), 2.97 (s, 3H, CH3). 1H
NMR signals (ppm) in DMSO-d6: 7.12 (2H, H5/5'), 6.86 (2H, H4/4'), 4.40 (s, 4H, CH2), 3.61 (s,
6H, CH3), 3.05 (s, 3H, CH3). ESI-MS (m/z): [M + H]+ = 284.1171. Calcd for [M + H]+ = 284.1176.
N(SO2Tol)1,1'-Me2dma) (2). A similar procedure as for ligand 1 with 2-(chloromethyl)1-methylimidazole hydrochloride (1.00 g, 5.98 mmol), K2CO3 (~1.7 g, 12 mmol), and TolSO2NH2
(0.41 g, 2.4 mmol) afforded a brown residue, which was purified by using a solvent mixture of
acetone:5.0 M NH4OH (90:10) to afford N(SO2Tol)1,1'-Me2dma as a white solid (0.15 g, 20%
yield). 1H NMR signals (ppm) in CDCl3: 7.62 (d, J = 7.3 Hz, 2H, H2/6), 7.30 (d, J = 8.2 Hz, 2H,
H3/5), 6.87 (2H, H5/5'), 6.75 (2H, H4/4'), 4.43 (s, 4H, CH2), 3.60 (s, 6H, CH3), 2.43 (s, 3H, CH3).
1

H NMR signals (ppm) in DMSO-d6: 7.56 (d, J = 8.3 Hz, 2H, H2/6), 7.34 (d, J = 8.1 Hz, 2H,

H3/5), 7.01 (2H, H5/5'), 6.70 (2H, H4/4'), 4.30 (s, 4H, CH2), 3.54 (s, 6H, CH3), 2.38 (s, 3H, CH3).
ESI-MS (m/z): [M + H]+ = 360.1499. Calcd for [M + H]+ = 360.1489.
[Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3). A solution of N(SO2Me)1,1'-Me2dma (1,
28 mg, 0.1 mmol) and [Re(CO)3(CH3CN)3]ClO4 (49 mg, 0.1 mmol) in acetonitrile (5 mL) was
heated at reflux overnight (~16 h). The resultant clear pale-yellow solution was kept at room
temperature to allow the solvent to evaporate slowly to produce white X-ray quality crystals
overnight (34 mg, 52% yield). 1H NMR signals (ppm) in DMSO-d6: 7.34 (d, J = 1.5 Hz, 2H, H5/5'),
7.13 (d, J = 1.5 Hz, 2H, H4/4'), 5.20 (d, J = 16.5 Hz, 2H, CH2), 4.98 (d, J = 16.4 Hz, 2H, CH2),
3.85 (s, 3H, CH3), 3.66 (s, 6H, CH3).
[Re(CO)3(N(SO2Tol)1,1'-Me2dma)]ClO4 (4). A solution of N(SO2Tol)1,1'-Me2dma (2,
36 mg, 0.1 mmol) and [Re(CO)3(CH3CN)3]ClO4 (49 mg, 0.1 mmol) in acetonitrile (5 mL) was
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heated at reflux overnight (~16 h). The resultant clear pale-yellow solution was kept at room
temperature to allow the solvent to evaporate slowly to produce white crystalline solid overnight
(55 mg, 76% yield). 1H NMR signals (ppm) in DMSO-d6: 8.19 (d, J = 8.1 Hz, 2H, H2/6), 7.74 (d,
J = 8.2 Hz, 2H, H3/5), 7.29 (s, 2H, H5/5'), 7.13 (s, 2H, H4/4'), 5.40 (d, J = 16.2 Hz, 2H, CH2),
4.44 (d, J = 16.5 Hz, 2H, CH2), 3.54 (s, 6H, CH3), 2.56 (s, 3H, CH3). ESI-MS (m/z): [M]+ =
630.0825. Calcd for [M]+ = 630.0815.
Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5). A solution of N(SO2Me)1,1'-Me2dma (1, 28 mg, 0.1
mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol) in methanol (5 mL) was heated at reflux
overnight (~16 h) to afford a pale yellow solid, which was collected by filtration, washed with
methanol and ether, and air-dried (17 mg, 36% yield). X-ray quality crystals were obtained by
mixing equal volumes (1 mL) of cis-Pt(DMSO)2Cl2 (12.5 mM) and N(SO2Me)-1,1'-Me2dma (12.5
mM) in acetonitrile and allowing the mixture to stand at room temperature. Yellow crystals
collected within 2 days were characterized by single-crystal X-ray crystallography. The 1H NMR
data for the solid and the crystals are identical. 1H NMR signals (ppm) in DMSO-d6: 7.20 (2H,
H5/5'), 7.10 (2H, H4/4'), 5.25 (d, J = 17.6 Hz, 2H, CH2), 5.13 (d, J = 17.8 Hz, 2H, CH2), 3.72 (s,
6H, CH3), 3.28 (s, 3H, CH3). 1H NMR signals (ppm) in DMF-d7: 7.28 (2H, H5/5'), 7.18 (2H,
H4/4'), 5.47 (d, J = 16.5 Hz, 2H, CH2), 5.29 (d, J = 16.3 Hz, 2H, CH2), 3.87 (s, 6H, CH3), 3.41 (s,
3H, CH3).
Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6). A similar procedure as for complex 5 with
N(SO2Tol)1,1'-Me2dma (2, 36 mg, 0.1 mmol) and cis-Pt(DMSO)2Cl2 (42 mg, 0.1 mmol) afforded
a pale yellow solid (20 mg, 32% yield). X-ray quality crystals were obtained by mixing equal
volumes (1 mL) of cis-Pt(DMSO)2Cl2 (12.5 mM) and N(SO2Tol)-1,1'-Me2dma (12.5 mM) in
acetonitrile and allowing the mixture to stand at room temperature. Yellow crystals obtained within
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4 days were characterized by single-crystal X-ray crystallography. The 1H NMR data for the solid
and the crystals are identical. 1H NMR signals (ppm) in DMSO-d6: 7.97 (d, J = 7.9 Hz, 2H, H2/6),
7.58 (d, J = 8.0 Hz, 2H, H3/5), 7.22 (s, 2H, H5/5'), 7.10 (s, 2H, H4/4'), 5.30 (d, J = 16.1 Hz, 2H,
CH2), 4.77 (d, J = 15.7 Hz, 2H, CH2), 3.79 (s, 6H, CH3); the phenyl methyl signal is masked by
the solvent peak. 1H NMR signals (ppm) in DMF-d7: 8.10 (d, J = 8.1 Hz, 2H, H2/6), 7.63 (d, J =
8.1 Hz, 2H, H3/5), 7.31 (2H, H5/5'), 7.18 (2H, H4/4'), 5.40 (d, J = 15.7 Hz, 2H, CH2), 5.08 (d, J
= 15.6 Hz, 2H, CH2), 3.97 (s, 6H, CH3), 2.52 (s, 3H, CH3).
Reactions of Pt(N(SO2R)1,1'-Me2dma)Cl2 (5, R = Me and 6, R = Tol) with N-donor
Monodentate Ligands (DMAP, 4-pic, and 3,5-lutidine). A 20 mM solution of DMAP in DMSOd6 (0.9 mg in 600 µl) was treated with 1.6 mg of 5 (5 mM) and the solutions were monitored by
1

H NMR spectroscopy. Another 1 day-old 5 mM solution of 5 in DMSO-d6 was treated with 4

molar equiv of DMAP (0.9 mg, 20 mM) and the solution was monitored by 1H NMR spectroscopy.
Further, a 20 mM solution of DMAP in DMSO-d6 was treated with 1.9 mg of Pt(N(SO2Tol)1,1'Me2dma)Cl2 (6, 5mM) and the solution was monitored by 1H NMR spectroscopy. Isolation of
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2-type solids/X-ray quality crystals (N-donor = 4-pic
and 3,5-lut) was performed as follows.
Isolation of [Pt(N(SO2R)1,1'-Me2dma)(4-pic)2](PF6)2 Complexes (7, R = Me and 8, R
= Tol). A suspension of 3 mg of 5 in 150 µl of 4-pic was heated at 60 °C and a clear pale-yellow
solution was obtained overnight. Then the solution was treated with 3.7 mg of Na2PF6 (4 molar
equiv) dissolved in 1 ml of H2O. The resultant milky white mixture was heated for ~5 min until
became clear with two layers (a pale yellow 4-pic layer at the bottom and the aqueous layer at the
top). X-ray quality white crystals of 7, [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2, were collected
by allowing the clear solution to stand at room temperature for 2 days. 1H NMR signals (ppm) in
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DMSO-d6 Bis1: 8.79 (d, J = 6.0 Hz, 4H, H2/64-pic), 7.44 (d, J = 6.0 Hz, 4H, H3/54-pic), 7.32 (s, 2H,
H5/5'), 7.16 (s, 2H, H4/4'), 4.95 (s, 4H, CH2), 3.64 (s, 6H, CH3), 3.46 (s, 3H, CH3), 2.36 (s, 6H,
CH3). Bis2: 8.93 (d, J = 5.9 Hz, 4H, H2/64-pic), 7.50 (d, J = 6.0 Hz, 4H, H3/54-pic), 7.32 (s, 2H,
H5/5'), 7.37 (s, 2H, H4/4'), 5.54 (d, J = 16.4 Hz, 2H, CH2), 5.20 (d, J = 16.4 Hz, 2H, CH2), 3.73
(s, 6H, CH3), 2.36 (s, 6H, CH3), the sulfonamide methyl signal is masked by the HOD peak. From
a similar experiment performed using 6 produced pale-orange color X-ray quality crystals of
[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2.Me2CO (8) (One drop of acetone is added to the final
solution to aid the crystallization). 1H NMR signals (ppm) in DMSO-d6 Bis1: 8.87 (d, J = 5.7 Hz,
4H, H2/64-pic), 8.09 (d, J = 8.1 Hz, 2H, H2/6), 7.64 (m, 2H, H3/5), 7.49 (d, J = 6.0 Hz, 4H, H3/54pic),

7.33 (s, 2H, H5/5'), 7.21 (s, 2H, H4/4'), 4.84 (s, 4H, CH2), 3.60 (s, 6H, CH3), the phenyl methyl

signal is masked by the solvent peak, 2.38 (s, 6H, CH3). Bis2: 8.87 (s, 4H, H2/64-pic), 8.03 (d, J =
8.0 Hz, 2H, H2/6), 7.64 (m, 2H, H3/5), 7.45 (d, J = 6.3 Hz, 4H, H3/54-pic), 7.33 (s, 2H, H5/5'), 7.37
(s, 2H, H4/4'), 5.35 (d, J = 16.3 Hz, 2H, CH2), 5.20 (d, J = 16.4 Hz, 2H, CH2), 3.84 (s, 6H, CH3),
the phenyl methyl signal is masked by the solvent peak, 2.34 (s, 6H, CH3).
Isolation of [Pt(N(SO2R)1,1'-Me2dma)(3,5-lut)2](PF6)2 Complexes (9, R = Me and 10,
R = Tol). A suspension of 3 mg of 5 in 150 µl of 3,5-lutidine was heated at 80 °C. A white solid
has deposited overnight, which was filtered and treated with 1 ml of aqueous solution of Na2PF6
(4 molar equiv, 3.7 mg). Another 1 ml of acetone was added to the resultant milky white mixture.
The resultant clear colorless solution was kept at room temperature to allow the solvent to
evaporate slowly. A white crystalline solid of 9, [Pt(N(SO2Me)1,1'-Me2dma)(3,5-lut)2](PF6)2 was
obtained overnight. 1H NMR signals (ppm) in DMSO-d6 Bis1: 8.77 (s, 4H, H2/63,5-lut), 7.67 (s, 2H,
H43,5-lut), 7.32 (s, 2H, H5/5'), 7.15 (s, 2H, H4/4'), 4.95 (s, 4H, CH2), 3.64 (s, 6H, CH3), 3.49 (s, 3H,
CH3), 2.24 (s, 12H, CH3). Bis2: 8.87 (s, 4H, H2/63,5-lut), 7.67 (s, 2H, H43,5-lut), 7.32 (s, 2H, H5/5'),
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7.41 (s, 2H, H4/4'), 5.50 (d, J = 16.1 Hz, 2H, CH2), 5.23 (d, J = 16.1 Hz, 2H, CH2), 3.74 (s, 6H,
CH3), 3.35 (s, 3H, CH3), 2.29 (s, 12H, CH3). ESI-MS (m/z): [M]2+ = 346.1106. Calcd for [M]2+ =
346.1105. A similar experiment performed using 6 produced white color X-ray quality crystals of
[Pt(N(SO2Tol)1,1'-Me2dma)(3,5-lut)2](PF6)2.2Me2CO (10). 1H NMR signals (ppm) in DMSO-d6
Bis1: 8.87 (s, 4H, H2/63,5-lut), 8.13 (d, J = 7.8 Hz, 2H, H2/6), 7.71 (s, 2H, H43,5-lut), 7.66 (bs, 2H,
H3/5), 7.32 (s, 2H, H5/5'), 7.20 (s, 2H, H4/4'), 4.76 (s, 4H, CH2), 3.59 (s, 6H, CH3), the phenyl
methyl signal is masked by the solvent peak, 2.28 (s, 12H, CH3). Bis2: 8.83 (s, 4H, H2/63,5-lut),
8.04 (d, J = 8.0 Hz, 2H, H2/6), 7.66 (bs, 2H, H3/5), 7.66 (bs, 2H, H43,5-lut), 7.33 (s, 2H, H5/5'),
7.41 (s, 2H, H4/4'), 5.33 (d, J = 16.3 Hz, 2H, CH2), 5.21 (d, J = 16.4 Hz, 2H, CH2), 3.85 (s, 6H,
CH3), the phenyl methyl signal is masked by the solvent peak, 2.24 (s, 12H, CH3).
G Adduct Formation with Pt(N(SO2R)1,1'-Me2dma)Cl2 (5 and 6). Two 25 mM
solutions of 9-MeG and Guo were treated separately with 1.6 mg of 5 in DMSO-d6 to make each
solution 5 mM in complex 5. The solutions were maintained at 25 °C and monitored by 1H NMR
spectroscopy until there was no change in the bound vs free H8 signal intensity. Another 50 mM
solution of 9-MeG was treated with 1.6 mg of 5 (5 mM) in DMSO-d6. In another experiment, a 1day old 5 mM solution of 5 in DMSO-d6 was treated with 5 molar equiv of 9-MeG (2.5 mg, 25
mM). Another 25 mM solution of 9-MeG was treated with 1.6 mg of 5 (5 mM) in DMF-d7. The
solutions were maintained at 25 °C and monitored by 1H NMR spectroscopy. Two 25 mM
solutions of 9-MeG and Guo) were treated with 1.9 mg of 6 in DMSO-d6 to make each solution 5
mM in complex 6 and the solutions were monitored with time by 1H NMR spectroscopy.
4.3 Results and Discussion
Synthesis of N(SO2R)1,1'-Me2dma Derivatives and Their Re(I) and Pt(II) Complexes.
The N(SO2R)1,1'-Me2dma ligands (1 and 2) were synthesized by coupling the appropriate
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sulfonamide compound with two equiv of 2-(chloromethyl)-1-methylimidazole under basic
conditions (Figure 4.2), a similar synthetic route to that used in the synthesis of the analogous
ligands containing pyridyl rings (N(SO2R)Mendpa).16 However, the purification of the new ligands
was more difficult and required more polar eluents (see Experimental Section) compared to the
N(SO2R)Mendpa16 ligands, perhaps owing to the higher hydrophilicity of the new ligands than the
latter ligands. Using a slightly modified method reported in literature30 we obtained
[Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 complexes 3 and 4 by using [Re(CO)3(CH3CN)3]ClO4 as
the metal precursor (Figure 4.2). The Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes (5 and 6) were
synthesized by employing a similar procedure as used in the synthesis of Pt(N(SO2R)Mendpa)Cl2
complexes (using cis-Pt(DMSO)2Cl2 in methanol to react with the ligands at reflux), which
produced the neutral Pt(II) complexes (5 and 6) in good yield. Even after several years, no evidence
for chelate ligand dissociation was found in DMSO-d6 (complexes 3−6) or in DMF-d7 (complexes
5 and 6) indicating that the ligands 1 and 2 can form robust [Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4
and Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes.
Structural Results. Crystal data and details of the structural refinement for all complexes
are summarized in Table 4.1. Selected bond lengths and angles are reported in Tables 4.2 and 4.3.
The ORTEP plots of 5 and 6 and cations of 3, 7, 8, and 10 (Figures 4.3 and 4.4) show the numbering
system used to describe the solid-state data.
The molecular structures of [Re(CO)3(N(SO2Me)1,1'-Me2dma)]+ (3) and Pt(N(SO2R)1,1'Me2dma)Cl2 (5, R = Me and 6, R = Tol) complexes (Figure 4.3) confirm that the new imidazolyl
ligands (1 and 2) coordinate tridentately to the fac-[Re(I)(CO)3]+ core and bidentately to the
Pt(II)Cl2 core. In [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3), all three nitrogen atoms of the
tridentate ligand occupy one face, and the three carbonyl ligands occupy the other face. In the Pt
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Table 4.1. Crystal Data and Structure Refinement for [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3), Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5),
Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6), [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7), [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2 (8), and
[Pt(N(SO2Tol)1,1'-Me2dma)(3,5-lut)2](PF6)2 (10)
3

5

C14H17N5O5
ReS·ClO4

C11H17Cl2N5
O2PtS

653.03

549.34

625.44

954.64

1088.81

1174.93

monoclinic

orthorhombic

triclinic

triclinic

triclinic

monoclinic

C2/c

Pnma

Pī

Pī

Pī

P21/n

a (Å)

18.9064(3)

9.1464(9)

9.2992(3)

10.5913(9)

10.4923(2)

9.8237(10)

b (Å)

10.3460(2)

15.1789(17)

9.7727(4)

11.3539(9)

13.6072(4)

8.9302(9)

c (Å)

22.1733(4)

12.055(1)

12.2223(6)

15.9287(14)

15.1738(4)

53.291(6)

α (deg)

90

90

112.967(3)

71.804(6)

75.610(2)

90

 (deg)

100.861(1)

90

91.062(3)

85.583(6)

89.200(2)

90.185(5)

γ (deg)

90

90

94.381(3)

62.623(5)

77.032(5)

90

V (Å3)

4259.53(13)

1673.6 (3)

1018.29(8)

1610.8 (2)

2042.88 (9)

4675.0(8)

T (K)

105

90

90

90

90

150

8

4

2

2

2

4

2.037

2.180

2.040

1.968

1.770

1.669

formula
fw
crystal system
space group

Z

calc (g/m3)

6

7

8

10

C17H21Cl2N C23H31N7O2P C29H35N7O2PtS·2(PF6)· C31H39N7O2PtS·2(PF6)·
tS·2(PF6)
Me2CO
2Me2CO
5O2PtS

(Table 4.1. continued)
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a

3

5

6

7

8

10

abs coeff (mm-1)

5.99

8.84

7.28

4.63

3.66

7.52

2max ()

95.2

51.4

54.2

61.2

66.6

136.8

R[F2>2σ(F2)]

0.028

0.032

0.029

0.040

0.037

0.039

Rw

0.057

0.062

0.101

0.080

0.086

0.090

res. dens. (e Å-3)

3.37, -2.30

1.84, -1.00

2.95, -1.94

2.34, -1.47

2.50, -2.06

0.82, -1.22

data/parameters

19874/283

1659/108

4005/256

9846/438

15504/567

32022/663

R = (||F| - |Fc||)/|F|. b Rw = [[w(F2 - Fc2)2]/[w(F2)2]]1/2, in which w = 1/[2(F2) + (dP)2 + (eP)] and P = (F2 + 2Fc2)/3.
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complexes 5 and 6, two cis coordination positions are occupied by the imidazolyl nitrogen atoms
creating a large 8-membered chelate ring. The remaining coordination positions are occupied by
two Cl atoms. As discussed in our previous work of the analogous ligands containing pyridyl rings,
N(SO2R)Mendpa,16 we believe that the different coordination modes exhibited by the new ligands
in Pt(N(SO2R)1,1'-Me2dma)Cl2 and [Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 complexes could be
mainly due to steric restraints as a tertiary sulfonamide N with two adjacent 5-membered chelate
rings must anchor a facially coordinated rather than a meridionally coordinated ligand.
Table 4.2. Selected Bond Distances (Å) and Angles (deg) for [Re(CO)3(N(SO2Me)1,1'Me2dma)]ClO4 (3)
Bonds

Angles

Re–N1

2.1493(11) N1–Re–N2

75.29(4)

Re–N2

2.3706(10) N1–Re–N3

83.59(4)

Re–N3

2.1536(10) N2–Re–N3

75.45(4)

Re–C1

1.9040(14) S1–N2–C9

108.16(7)

Re–C2

1.9233(13) S1–N2–C10

108.69(7)

Re–C3

1.9274(13) C9–N2–C10

111.39(9)

S1–O4

1.4315(10) Re–N2–S1

110.62(5)

S1–O5

1.4328(11) Re–N2–C9

109.45(8)

N2–S1

1.7477(10) Re–N2–C10

108.54(7)

N1−N3a

2.868(2)

N1–Re–C2

95.11(5)

N1–Re–C3

93.51(5)

N3–Re–C2

97.76(5)

N3–Re–C1

93.93(5)

dihedral angleb

87.67, 82.29

Re−N−centroid

170.65, 171.28
a
Non-bonded distance between the two atoms. bAngle between the coordination plane (defined by
the Re, N1, N3, O1 and O3 atoms) and the pyridyl ring planes.
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Table 4.3. Selected Bond Distances (Å) and Angles (deg) for Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5), Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6),
[Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7), [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2 (8) and [Pt(N(SO2Tol)1,1'-Me2dma)(3,5lut)2](PF6)2 (10)
5

6

7

8

10

Pt–N1

2.004(5)

2.020(6)

2.002(3)

2.011(3)

2.015(4)

N2−Pta

3.912

3.765(5)

3.050(4)

3.083(3)

3.0840(4)

Pt–N3

2.004(5)

2.027(6)

2.004(3)

2.023(2)

2.016(4)

Pt–Cl1/N6

2.3051(15)

2.313(2)

2.018(3)

2.022(2)

2.017(4)

Pt–Cl2/N7

2.3051(15)

2.2925(16)

2.021(3)

2.014(3)

2.017(4)

S1–O1

1.425(5)

1.434(6)

1.424(3)

1.423(3)

1.428(4)

S1–O2

1.425(5)

1.433(6)

1.436(3)

1.428(3)

1.430(4)

N2–S1

1.641(7)

1.641(7)

1.626(3)

1.641(3)

1.649(4)

S1−Pta

5.532

5.343(2)

3.726(1)

3.7266(8)

3.877(2)

N1–Pt–N3

88.8 (3)

93.2 (2)

90.60 (13)

91.49(10)

89.00(14)

S1–N2–C4

116.3 (4)

116.9 (4)

119.6 (3)

118.0(2)

117.3(3)

S1–N2–C5

116.3 (4)

119.3 (5)

117.3 (3)

118.4(2)

117.0(3)

(Table 4.3 continued)
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5

6

7

8

10

114.7 (7)

118.5 (6)

118.8 (3)

117.8(3)

117.1(4)

N1–Pt–Cl2/N7

177.87 (15)

176.52 (19)

176.98 (14)

176.62(10)

177.86(16)

N1−Pt−Cl1/N6

89.56(14)

88.3(2)

90.75(13)

88.83(11)

91.61(14)

N3–Pt–Cl1/N6

177.87 (15)

178.36 (15)

178.23 (14)

178.48(10)

178.44(16)

N3−Pt−Cl2/N7

89.56(14)

87.31(15)

91.58(14)

89.63(11)

91.59(15)

Cl1/N6–Pt–Cl2/N7

92.07 (8)

91.10 (7)

87.11 (14)

89.97(11)

87.75(15)

dihedral angleb

74.85

66.61, 71.56

84.96, 54.19

72.39, 57.69

84.99, 57.88

Pt− N−centroid

176.87

167.81, 173.67

176.66, 176.82

175.44, 174.19

177.72, 175.63

2.805(6)

2.941(8)

2.847(5)

2.890(3)

2.825(5)

C4–N2–C5

N1−N3a
a

Non-bonded distance between the two atoms. bAngle between the coordination plane (defined by the Pt, N1, N3, and two Cl atoms)
and the imidazolyl ring planes.
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The length of the Re−N(sulfonamide) bond (Table 4.2) in 3 (2.3706(10) Å) is longer than
the typical range (2.23−2.29 Å) reported for Re−N(sp3) bonds,31-32 while the Re−N1 and Re−N3
bond distances of 3 (2.1493(11) and 2.1536(10) Å) are in the typical range (2.14−2.18 Å) for
Re−N(sp2) bonds.6,31,33-34 As discussed in the previous work of [Re(CO)3(N(SO2R)Mendpa)]+ and
Pt(N(SO2R)Mendpa)Cl2 complexes,16 the structural features such as the angles around the
sulfonamide N and the N−S bond lengths of the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes (5 and 6)
are consistent with the uncoordinated tertiary sulfonamide group, while these structural features
of 3 ([Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4) are consistent with the coordinated NSO2Me group
(Tables 4.2 and 4.3). Similarly, the structural metrics of the molecular structures of 7 =
[Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2, 8 = [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2, and
10 = [Pt(N(SO2Tol)1,1'-Me2dma)(3,5-lut)2](PF6)2 are also consistent with the uncoordinated
sulfonamide group (Table 4.3).

Figure 4.3. ORTEP plots of complexes [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3),
Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5), and Pt(N(SO2Me)1,1'-Me2dma)Cl2 (6). Thermal ellipsoids are
drawn with 50% probability.
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The Pt−N(1) and Pt−N(3) bond lengths (Table 4.3) in all the Pt complexes (5, 6, 7, 8, and
10) are in the range typically reported for Pt−N(sp2) bonds (1.99−2.08 Å).16,22,24-25,35 The
N1−Pt−N3 bite angles (~90°, Table 4.3) of these complexes are comparable to the angles of the
reported platinum complexes containing relatively large uncommon 8-membered chelate rings
(average 89.5°).16,36-38 The dihedral angles (defined as the angle between the coordination plane
and the imidazolyl ring planes) of 5 and 6 (67-75°, Table 4.3) are not as large as the dihedral
angles of the reported platinum complexes containing 8-membered chelate rings (average value
~83°),16,36-38 but significantly larger than the values reported for complexes of smaller chelating
ligands (<65° for platinum(II) complexes of 5-, 6- and 7-membered chelate rings).16 In order to
understand the special structural features of relatively rare square planar Pt(II) complexes
containing 8-membered chelate rings, in a previous work we have analyzed more than fifty
molecular structures of cis Pt(II) complexes containing two aromatic ring nitrogens
(pyridyl/imidazolyl) and two halides as the ligating atoms (data obtained from the CCDC data
base).16 The study indicated that the certain structural features such as the dihedral angles and the
N1−Pt−N3 bite angles of the complexes differ based on the chelate ring size; the dihedral angles
of the studied complexes increase almost linearly with the increasing chelate ring size. Also, the
N1−Pt−N3 bite angles increase with the increasing ring size. These structural features in 5 and 6
follow the trends we found in our previous analysis of structural features of chelate in platinum
complexes, including the few containing relatively large 8-membered chelate rings.16
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2 crystalline solids (7 = [Pt(N(SO2Me)1,1'Me2dma)(4-pic)2](PF6)2,

8

=

[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2,

and

10

=

[Pt(N(SO2Tol)1,1'-Me2dma)(3,5-lut)2](PF6)2) were isolated by treating 5 and 6 (Pt(N(SO2R)1,1'Me2dma)Cl2) with the N-donor ligand. The molecular structures of 7, 8 and 10 (Figure 4.4) confirm
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that the chelate ligand in 5 and 6 are not displaced by the high temperature conditions (60 °C or
80 °C). In contrast, 40% of the bound chelate ligand dissociated within 9 days when
Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 complexes were dissolved in DMSO-d6 at room temperature.16

Figure 4.4. ORTEP plots of complexes [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7),
[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2.Me2CO (8), and [Pt(N(SO2Tol)1,1'-Me2dma)(3,5lut)2](PF6)2.2Me2CO (10). Thermal ellipsoids are drawn with 50% probability.
The location of the sulfonamide group is the main structural difference between the chelate
ligands in the dichloro complexes, 5 and 6, and the chelate ligands in [Pt(N(SO2R)1,1'Me2dma)(N-donor)2](PF6)2 (7, 8 and 10, Figure 4.4). In order to explain the difference in location
of the sulfonamide group in the two types of complexes, a new plane (plane A) is defined as
follows: Plane A is perpendicular to the coordination plane and goes through the two N atoms of
the imidazolyl rings of the carrier ligand (Figure 4.5). In 5 and 6 and in the previously reported
Pt(N(SO2R)Mendpa)Cl2 complexes (R = Me or Tol), the sulfonamide group and the rest of the
carrier ligand are almost completely on the same side of Plane A as the sulfonamide group, which
projects out from the coordination sphere (chelate ligand conformation SO2R-out). In contrast, in
7, 8, and 10, most of the carrier ligand is on the opposite side of Plane A as the sulfonamide group,
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which projects toward the coordination sphere (chelate ligand conformation SO2R-in).
Furthermore, the reported molecular structures of fac-[Re(CO)3(chelate)]Y complexes of the
similar sulfonamide-incorporated tridentate ligands6-7,16 and of [Re(CO)3(N(SO2Me)1,1'Me2dma)]ClO4 (3, Figure 4.3) show that the chelate ligand conformation is “SO2R-in” to allow
formation of the Re–N(sulfonamide bond). The observation of the sulfonamide group in two
different locations in different molecular structures of Pt(II) complexes indicates that a bidentate
chelate ligand with the sulfonamide group uncoordinated to Pt(II) center has enough dynamic
freedom to exchange between SO2R-in and SO2R-out conformations. 1H NMR data discussed
below also provide evidence for the inversion of the SO2R group at the N(sulfonamide) atom
and/or the rotation around the Pt–N bond in the Pt(II) complexes studied here.

Figure 4.5. Line drawings of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5, left) and [Pt(N(SO2Me)1,1'Me2dma)(4-pic)2](PF6)2 (7, right) showing the location of the sulfonamide group in each complex.
Plane A is indicated as an orange broken-line. The 1/1′-Me groups, hydrogen atoms in 5 and 7 and
4-pic rings in 7 are hidden for clarity.
NMR Spectroscopy. The ligands, 1 and 2 (in CDCl3 and DMSO-d6) and their Re and Pt
complexes, 3−10 (in DMSO-d6 and/or in DMF-d7) reported here were characterized by 1H NMR
spectroscopy. Using the atom-numbering scheme in Figure 4.2, we assigned the proton signals of
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the complexes by analyzing the chemical shift, splitting pattern, integration and data from 1H-1H
ROESY NMR experiments as discussed below. 1H NMR data and assignments are presented in
the Experimental Section; see also Tables 4.4 and 4.5.
1H

NMR Assignments of [Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 Complexes (3, R =

Me and 4, R = Tol) and Pt(N(SO2R)1,1'-Me2dma)Cl2 (5, R = Me and 6, R = Tol). The 1H NMR
spectra recorded in DMSO-d6 (and also in DMF-d7 for 5 and 6) show that all the aromatic signals
of the free ligands 1 and 2 upon metal coordination to form 3−6 were shifted downfield, a result
caused by the inductive effect of the Pt(II) or Re(I) metal center (Figure 4.6). The
[Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 complexes (3 and 4) in DMSO-d6 do not show any change
in the spectra with time. The 1H NMR assignments of 3 and 4 were based on their ROESY spectra
recorded in DMSO-d6 (a selected region of the ROESY spectrum of 3 is presented in Supporting
Information) and

arguments

similar

to

those

used

for

the

previously

reported

[Re(CO)3(N(SO2R)Mendpa)]PF616 and [Re(CO)3(N(SO2R)dpa)]PF66 complexes.

Figure 4.6. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of
N(SO2Me)1,1'-Me2dma (1), [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3), Pt(N(SO2Me)1,1'Me2dma)Cl2 (5), N(SO2Tol)1,1'-Me2dma (2), [Re(CO)3(N(SO2Tol)1,1'-Me2dma)]ClO4 (4), and
Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6).
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Table 4.4. Selected 1H NMR Chemical Shifts for the N(SO2R)1,1'-Me2dma Free Ligands (1 and 2) and for Their Re(I) (3 and 4) and
Pt(II) (5 and 6) Complexes (ppm, DMSO-d6, 25 °C). 1H NMR Chemical Shifts of the Platinum Complexes in DMF-d7 also Presented
within Brackets
H5/5′

a

H4/4′

CH2

1/1′-Me

SO2Me

SO2Tol
H2/6

H3/5

Me

1
3
5

7.12
7.34
7.20 (7.28)

6.86
7.13
7.10 (7.18)

4.40
5.20a, 4.98b
5.25 (5.47)a, 5.13 (5.29)b

3.61
3.85
3.72 (3.87)

3.05
3.66
3.28 (3.41)

-

-

-

2
4
6

7.01
7.29
7.22 (7.31)

6.70
7.13
7.10 (7.18)

4.30
5.40a, 4.44b
5.30 (5.40)a, 4.77 (5.08)b

3.54
3.54
3.79 (3.97)

-

7.56
8.19
7.97 (8.10)

7.34
7.74
7.58 (7.63)

2.38
2.56
2.50c (2.52)

Endo-CH. bExo-CH. cSignal is masked by the solvent peak.
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Table 4.5. Selected 1H NMR Chemical Shifts for the [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]2+ Adducts or Complexes (R = Me or Tol, NDonor = DMAP, 4-pic or 3,5-lut) (ppm, DMSO-d6, 25 °C)
N-donor

H2/6DMAP/4-pic/3,5-lut

H5/5′

H4/4′

CH2

1/1′-Me

Bis1

Bis2

Bis1

Bis2

Bis1

Bis2

Bis1

Bis2

Bis1

Bis2

Bis1:Bis2

DMAPa

Me

8.23

8.52

7.31

7.28

7.13

7.42

4.91

5.80, 5.17

3.65

3.75

2.19:1

a

Tol

8.33

8.40

7.33

7.31

7.19

7.44

4.82

5.46, 5.18

3.62

3.84

1.38:1

DMAP

a

SO2R

7

4-pic

Me

8.79

8.93

7.32

7.32

7.16

7.37

4.95

5.54, 5.20

3.64

3.73

2.54:1

8

4-pic

Tol

8.87

8.87

7.33

7.33

7.21

7.37

4.84b

5.35, 5.20

3.60

3.84

1.23:1

9

3,5-lut

Me

8.77

8.87

7.32

7.32

7.15

7.41

4.95b

5.50, 5.23

3.64

3.74

2.55:1

10
3,5-lut
Tol
8.87
8.83
7.32
7.33
7.20
Spectra are recorded for a solution with excess of DMAP. bVery broad.

7.41

4.76b

5.33, 5.21

3.59

3.85

1.27:1
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Our experience is that PtLCl2 complexes in DMSO-d6 change and also form adducts with
added ligands but PtLCl2 complexes usually do not change or from adducts in DMF-d7. The 1H
NMR spectra recorded for freshly prepared DMSO-d6 solutions of X-ray quality crystals of 5 and
6 are consistent with symmetrical Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes, as found in the solid.
However, within the first 10 min of dissolution of 5 or 6 in DMSO-d6, a new set of minor signals
(denoted as 5m or 6m, discussed later) start to appear. In contrast, the spectra recorded for 5 or 6 in
DMF-d7 do not change or produce new signals with time but are similar to the major set of 5 or 6
signals, respectively, in DMSO-d6.
NMR spectra recorded in DMF-d7 were used in assigning the signals of 5 (R = Me) and 6
(R = Tol). Both complexes have two apparent 1H NMR singlets in the aromatic region, as expected
for the H4/4' and H5/5' protons. As discussed previously for [Pt(N(R)1,1'-Me2dma)Cl]Cl
complexes (R = H and Me),22 owing to the nearby quadrupolar nitrogens, these signals appear as
singlets rather than doublets. In the 1H-1H ROESY spectrum of 5 (Figure 4.7), a strong NOE crosspeak from the 1/1′-Me signal at 3.87 ppm (assigned based on integration) to the more downfield
(7.28 ppm) of two aromatic singlets allows the signal to be assigned to H5/5'. The other aromatic
peak (7.18 ppm) thus can be assigned to H4/4', an assignment supported by the absence of any
NOE cross-peaks from this signal to any other peaks except to the H5/5' signal. The methylene
protons of 5 show an AB pattern in the 1H NMR spectrum, an observation reported for many
similar compounds and extensively discussed in our previous work.22-25 The inequivalent
methylene protons in the complex 5 (also in 6) project toward and away from the Cl ligands and
are designated as endo-CH and exo-CH protons, respectively (Figure 4.8). In the ROESY spectrum
of 5, the more upfield AB signal (5.29 ppm) showed a strong cross-peak to the 1/1′-Me signal, thus
assigning it to the exo-CH (Figure 4.7). In the molecular structure of 5, the 1/1′-Me protons are
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closer to the exo-CH protons (2.97 Å) than the endo-CH protons (4.23 Å). The downfield AB peak
(5.47 ppm) is thus assigned to the endo-CH.

Figure 4.7. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Me)1,1′-Me2dma)Cl2 (5) (25
°C, 10 mM, DMF-d7, shifts in ppm).
The carrier-ligand signals including the methylene signals (two doublets instead of an AB
signal) of the complex 6 were assigned in a similar manner as for 5 except for the Tol (p-tolyl)
signals (8.10, 7.63 and 2.52 ppm). Between the two aromatic doublets corresponding to the Tol
group, the more upfield doublet (8.10 ppm) was assigned to H3/5 because it showed an NOE crosspeak to the tolyl methyl signal at 2.52 ppm in a ROESY spectrum of 6 in DMF-d7 (Supporting
Information). Therefore, the other doublet at 8.10 ppm was assigned to the H2/6 protons.
Furthermore, the ROESY spectra of 5 and 6 in DMF-d7 recorded at RT (25 °C), have EXSY
cross-peaks between the endo and exo-CH signals (Figure 4.7 and Supporting Information). These
cross-peaks indicate that the endo- and exo-CH protons are made magnetically equivalent by a
dynamic process. At high T, these two doublets merge into a broad singlet, indicating that this
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dynamic process becomes faster at high T. We suggest that a similar dynamic process as observed
within Bis1 conformer (see below) in the [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]2+-type complexes
takes place in the symmetrical Pt(N(SO2R)1,1'-Me2dma)Cl2 dichloro complexes, 5 and 6. In
contrast, the ROESY spectrum of the [Re(CO)3(N(SO2Me)1,1'-Me2dma)]ClO4 (3, Supporting
Information) or of other reported Pt(II) complexes of analogous ligands such as [Pt(N(R)1,1'Me2dma)Cl]Cl,22

[Pt(N(H)dpa)Cl]Cl,23

[Pt(N(H)6-Medpa)Cl]Cl,24

and

[Pt(N(H)6,6′-

Me2dpa)]Cl,25 do not show any EXSY cross-peaks (but show NOE cross-peaks) between the
methylene doublets. In these complexes, the ligands are bound tridentately. Therefore, the
inversion of the central N atom and also the rotation of the pyridyl/imidazoyl rings are restricted;
thus, a dynamic process making the endo- and exo-CH protons magnetically equivalent is unlikely
to occur. However, the Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 (R = Me or Tol) complexes in which the
ligands are bound bidentately also do not show any EXSY cross-peaks (but show NOE crosspeaks) between the methylene doublets, indicating that a process in which a methylene proton's
position changes between the endo- and exo-CH positions is not fast enough to give cross-peaks.

Figure 4.8. Designation of the endo-CH and exo-CH methylene protons illustrated for the structure
of Pt(N(SO2Me)1,1′-Me2dma)Cl2 (5).
The Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes (5 and 6) dissolved in DMSO-d6 (10 mM) do
not show any free ligand signals even in years-old solutions (~3 years), indicating that the
imidazolyl ligands 1 and 2 remain robustly bound to Pt(II). In contrast, the analogous pyridyl
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complexes, Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 (R = Me or Tol), in DMSO-d6 eventually (within a 9
d period) released the free ligand until only 60% of the ligand remained bound.16 The relatively
high robustness of the chelate in Pt(N(SO2R)1,1'-Me2dma)Cl2 (5 and 6) compared to
Pt(N(SO2R)3,3',5,5'-Me4dpa)Cl2 could be explained by the less steric hindrance in the
coordination sphere of 5 and 6 as imidazole rings are smaller than the pyridyl rings and also by the
higher basicity of the imidazolyl N donors (pKa (DMSO) = 6.26) than the pyridyl N donors (pKa
(DMSO) = 3.4).39
After 5 (Pt(N(SO2Me)1,1'-Me2dma)Cl2, 10 mM) was dissolved in DMSO-d6, the new
signals, 5m, gradually increased for ~7 h. The results for a 10 mM solution of 6 (Pt(N(SO2Tol)1,1'Me2dma)Cl2) in DMSO-d6 were similar. Interestingly, the formation of these species (5m or 6m)
giving the initial minor set of signals did not affect the yield of products in the adduct formation
reactions; the solutions of 5 and 6 in DMSO-d6 readily react with different G derivatives (9-MeG
and Guo) and with other N-donor ligands (DMAP, 4-pic and 3,5-lut) to produce expected mono
or bis products (confirmed based on the NMR and X-ray structural data). Thus, the species, 5m or
6m, will not be further discussed.
Reactions of Pt(N(SO2R)1,1'-Me2dma)Cl2 Complexes (5 and 6) with DMAP, 4-pic,
and 3,5-lut. A spectrum of the reaction mixture of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5, 5 mM) and
4 molar equiv of DMAP (20 mM) in DMSO-d6 recorded about 1 h after mixing contained a new
set of peaks for the mono adduct, [Pt(N(SO2Me)1,1'-Me2dma)(DMAP)Cl]+, in addition to the 5
and 5m peaks (Figure 4.9). A spectrum recorded about 7 h after mixing had peaks for a mono
adduct (deduced from the integration of the bound DMAP signals and the carrier-ligand aromatic
signals) along with another two new sets of peaks (in 2 to 1 ratio), but no peaks for 5m or 5. The
mono adduct signals disappeared in 9 d, leaving only the two sets of peaks having a ~2:1
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abundance ratio (Figure 4.9). Each of these two sets of peaks are consistent with a symmetric
compound and have integrations between the bound DMAP signals and the carrier-ligand aromatic
signals indicating that each is a bis adduct, [Pt(N(SO2Me)1,1'-Me2dma)(DMAP)2]2+. These two
sets of peaks are denoted as Bis1 (more abundant species) and Bis2 (Figure 4.9). (Very similar
results were obtained when a 1 day-old 5 mM solution of 5 containing more 5m than fresh solutions
was treated with 4 molar equiv of DMAP). Similarly, a solution of Pt(N(SO2Tol)1,1'-Me2dma)Cl2
(6, 5mM) and DMAP (20 mM) in DMSO-d6 at ~9 d gave similar results as found for 5 but with a
slightly different final Bis1:Bis2 ratio of a ~1.4:1 (Table 4.5 and Supporting Information).

Figure 4.9. Selected region of 1H NMR spectra showing the formation of mono (red) and bis
adducts (Bis1-purple and Bis2-green) of 5 with DMAP at various time points after 1.6 mg of
Pt(N(SO2Me)1,1′-Me2dma)Cl2 (5, blue) was dissolved in a 20 mM solution of DMAP in DMSOd6 (25 °C, shifts in ppm).
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A ROESY spectrum of the final solution of the reaction between 5 and DMAP (in DMSOd6 at 25 °C) shows EXSY peaks between Bis1 and Bis2, indicating that the two sets of peaks are
for two conformers of the same bis adduct (Figure 4.10). This finding prompted us to prepare and
isolate crystals of such a bis adduct. As described in the Experimental Section, we used liquid Ndonor ligands (4-pic and 3,5-lut; this method is not suitable to use with DMAP because it is a solid
at RT) to prepare [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2. The molecular structures of the
resultant X-ray quality crystals (7, 8, and 10) show cis configuration in each bis complex (Figure
4.4) and 1H NMR spectra of each isolated complex 7−9 (solid or crystals) recorded immediately
after dissolving in DMSO-d6 show two sets of peaks similar to what is observed for the bis adducts
of 5 and 6 with DMAP (Figure 4.11). Furthermore, as observed for the [Pt(N(SO2Me)1,1'Me2dma)(DMAP)2]2+ adduct, ROESY spectra recorded at 25 °C for all the isolated bis complexes
(in DMSO-d6 or DMF-d7) show EXSY cross-peaks between Bis1 and Bis2. The 1H NMR shifts
of the corresponding signals of 7−9 are similar and are listed in Table 4.5 (selected regions of the
ROESY spectra of the complexes are presented in Supporting Information).
Structural and Spectral Assignment Strategy for [Pt(N(SO2R)1,1'-Me2dma)(Ndonor)2]2+ Conformers. As mentioned in the Structural Section, the location of the sulfonamide
group with respect to Plane A in the molecular structures of the [Pt(N(SO2R)1,1'-Me2dma)(Ndonor)2]2+ complexes 7, 8, and 10 (SO2R-in, Pt−S distance is <3.8 Å) is different from the location
of the sulfonamide group in the molecular structures of the dichloro Pt(N(SO2R)1,1'-Me2dma)Cl2
complexes 5 and 6 (SO2R-out, Pt−S distance is >5.3 Å) (Figure 4.5). This observation suggests
that dynamic motion of the chelate ring occurs such that there is interchange between the SO2R-in
and SO2R-out conformers in Pt(N(SO2R)1,1'-Me2dma)Cl2 and [Pt(N(SO2R)1,1'-Me2dma)(Ndonor)2]2+-type complexes. If this conformer interchange is slow enough on the NMR time scale,
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two sets of peaks can be observed corresponding to the two conformers, which is the case for the
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]2+complexes/adducts analyzed in this study. Therefore, we
suggest that the two conformers (Bis1 and Bis2) detected in the 1H NMR studies for
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]2+ are likely to be to the two conformers, SO2R-in and
SO2R-out. Below, we use 2D NMR data to assign the two sets of 1H NMR signals to each
conformer.

Figure 4.10. 1H-1H ROESY spectrum (selected region) of the [Pt(N(SO2Me)1,1′Me2dma)(DMAP)2]2+ bis adducts, Bis1 (purple) and Bis2 (green) at 25 °C in DMSO-d6 (shifts in
ppm). *Indicates the free DMAP signals.
NOE cross-peaks from the SO2R group signals to signals of the carrier-ligand or the bound
N-donor can be analyzed to indicate whether the location of the sulfonamide group for a given set
of signals is most consistent with the Bis1 or Bis2 conformer. This task could be difficult for
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SO2Me adducts because SO2Me signals appear near the HOD peak. However, the SO2Me singlet
of Bis1 (3.49 ppm) of [Pt(N(SO2Me)1,1'-Me2dma)(3,5-lut)2](PF6)2 (9) is well resolved from the
HOD peak and has an NOE cross-peak to the H2/63,5-lut singlet (8.77 ppm) of the Bis1 conformer
(Figure C.4). No such NOE cross-peak is observed for the Bis2 conformer. This information
indicates that Bis1 has the SO2R-in conformation, because the SO2Me group is closer to the bound
3,5-lut ligands in the SO2R-in conformer than in the SO2R-out conformer (Figure 4.5). Therefore,
Bis2 can be assign to the SO2R-out conformer. Furthermore, in the ROESY spectra of
[Pt(N(SO2Tol)1,1'-Me2dma)(N-donor)2](PF6)2 (8 and 10), the H2/6 doublets of the Tol group of
Bis1 are connected to the H2/6 signals of the N-donor (4-pic and 3,5-lut) through NOE cross-peaks
(Figures C.5 and C.6). In contrast, the Bis2 signals do not show such NOE cross-peaks. In order
to relate this information with structural data, we superimposed the molecular structure of
[Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6) with its corresponding bis complexes [Pt(N(SO2Tol)1,1'Me2dma)(N-donor)2](PF6)2 (8 and 10) through Pt, N1, and N2 atoms and then the non-bonded
distances between the H2/6 protons of the Tol group and the H2/6 protons of the N-donor were
measured (Figures C.7). In both cases, the shortest non-bonded distances between the H2/6 protons
of the Tol group and the H2/6 protons of the N-donor measured (Figures C.7) in the SO2R-in
conformer (~ 4.0 Å) is shorter than these distances in the SO2R-out conformer (~ 6.6 Å), supporting
the above conclusion.
The 1H NMR signals for the methylene protons of the Bis2 conformer in all of the
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]2+complexes/adducts are sharp doublets which are
connected to each other through NOE cross-peaks. The more upfield methylene doublet of each
complex is assigned to exo-CH, as this doublet exhibited an NOE cross-peak to the 1/1′-Me singlet
(Figure 4.10 and Supporting Information). Therefore, the downfield doublet of the Bis2 conformer
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in each complex is assigned to endo-CH; no or relatively very weak NOE cross-peak can be
observed between this doublet and the 1/1′-Me singlet. In the ROESY spectra of all the
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]2+complexes/adducts, the endo-CH signal of the Bis2
conformer is connected to the H2/6 doublet of the N-donor (DMAP, 4-pic, and 3,5-lut) through a
sharp NOE cross-peak.

Figure 4.11. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of the
[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2 bis complexes (Bis1-purple and Bis2-green),
[Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7), [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2 (8),
[Pt(N(SO2Me)1,1'-Me2dma)(3,5-lut)2](PF6)2 (9), and [Pt(N(SO2Tol)1,1'-Me2dma)( 3,5lut)2](PF6)2 (10). *Free 4-pic as an impurity.
In contrast, no such NOE cross-peak is observed between the broad Bis1 methylene signal
and the N-donor H2/6. This observation indicates that the endo-CH protons in the Bis2 conformer
is relatively closer to the N-donor aromatic ring than the endo-CH protons of the Bis1 conformer.
In superimposed molecular structures of [Pt(N(SO2R)1,1'-Me2dma)Cl2 (5 or 6) with their
corresponding bis complexes [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2](PF6)2 (7, 8, or 10) through Pt,
N1, and N2 atoms, the non-bonded distances between the endo-CH and the H2/6 protons of the N-

131

donor were measured; the overlay of [Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6) and [Pt(N(SO2Tol)1,1'Me2dma)(4-pic)2](PF6)2 (8) along with the measured non-bonded distances are shown in Figure
4.12. In all the cases, the non-bonded distances between the endo-CH and the H2/6 protons in the
SO2R-out conformer are shorter by at least 0.1 Å than these distances in the SO2R-in conformer,
supporting the above conclusion that made through NMR data stating that the endo-CH protons in
the Bis2 conformer is relatively closer to the N-donor aromatic ring than the endo-CH protons of
the Bis1 conformer.

Figure 4.12. Overlap of the stick drawings of [Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6, green) and
[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2]2+ (8, purple) by superimposing the Pt, N1, and N2 atoms.
The non-bonded distances between the endo-CH and the H2/64-pic protons were measured by using
Mercury CSD 3.10.1 software. For clarity, some of the hydrogens, methyl groups and the SO2Tol
group of the sulfonamides are hidden.
For all the bis complexes/adducts, the chemical shifts of H4/4′ signals of Bis1 are relatively
upfield by ~0.2 ppm than the chemical shifts of the H4/4′ signals of Bis2 (Table 4.5). Whereas, the
chemical shifts of the H5/5′ signals are similar for both conformers. As an example, the H4/4′
shifts for Bis1 and Bis2 in [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7) is 7.21 and 7.37 ppm,
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respectively, while the H5/5′ shift for both conformers is 7.32 ppm. This observation suggests that
the H4/4′ protons might be affected differently by the anisotropic aromatic rings of the
monodentate N-donors in each conformer resulting in different shifts as mentioned above; in the
Bis1 conformer, the N-donor aromatic ring anisotropy experienced by the H4/4′ protons could be
higher relative to the anisotropic effect experienced by the H4/4′ protons in the Bis2 conformer.
All the molecular structures containing SO2R-in conformation (3, 7, 8, and 10), the carrier-ligand
is distorted when compared to the molecular structures of the SO2R-out conformation (5 and 6).
In the former complexes, one of the imidazolyl rings (dihedral angle ~55°) is significantly more
canted than the other ring (72-85°), whereas in 5 and 6, the molecular structures are relatively more
symmetrical and both imidazolyl rings have similar dihedral angles (67-75°, Table 4.3). Because
of the low dihedral angle, the H4/4′ protons of the highly canted imidazolyl ring in each of 7, 8
and 10 complexes are closer to the nearby bound N-donor group (H4/4′ −N4-pic/3,5-lut non-bonded
distance ~3.1 Å) than the H4/4′ protons in the less canted imidazolyl ring in the same complex
(H4/4′ −N4-pic/3,5-lut non-bonded distance ~3.5 Å). Therefore, we suggest that due to the distorted
carrier-ligand in Bis1 (SO2R-in), the H4/4′ protons could be projecting towards the N-donor
aromatic rings, thus the H4/4′ signals of Bis1 could have upfield chemical shifts compared to the
H4/4′ signals of Bis2 (SO2R-out).
The conformational interchanging processes are greatly affected by temperature. Thus, to
further understand the processes involved in the conformer interchange in [Pt(N(SO2R)1,1'Me2dma)(N-donor)2]2+-type complexes, we collected NMR data at different temperatures by
utilizing a solution of [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7) in DMF-d7 (freezing point 60 °C). At RT, the two methylene doublets observed for Bis2 are connected through NOE crosspeaks (Figure C.8), showing that the endo- and exo-CH protons of Bis2 do not interchange. Even
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at high T such as 50 °C and low T such as -13 °C, these peaks remain sharp doublets (Figure C.9),
showing there are no dynamic processes involved within the Bis2 conformer (in contrast, NMR
data discussed below suggest that there is another dynamic process involved within Bis1 other
than the Bis1-Bis2 interchange). Each of the methylene doublets of Bis2 has EXSY peaks with the
broad methylene peak of Bis1 at RT, indicating the Bis1 and Bis2 methylene protons interchange
with each other through a relatively fast process on the NMR time scale. However, in the ROESY
spectrum recorded at low temperature (-13 °C, Figure C.10), no EXSY peaks were observed
between the methylene signals of Bis1 and Bis2, indicating that at this T, the interchange between
Bis1 and Bis2 is relatively very slow or does not occur.
The broadness of the methylene signal of Bis1 conformer [Pt(N(SO2Me)1,1'-Me2dma)(4pic)2](PF6)2 (7) in DMF-d7 at RT (5.33 ppm) suggests that all four methylene signals of Bis1 either
have similar chemical shifts or they interchange with each other very rapidly on the NMR time
scale. At high T such as 50 °C, we observed that the methylene signal for Bis1 become sharper
than the peak at RT (Supporting Information). However, in the 1H NMR spectra recorded at low
T (0 and -13 °C), the Bis1 methylene signal eventually resolve in to two signals (at -13 °C, Bis1
methylene protons produce two broad peaks at 5.04 and 5.62 ppm, Supporting Information). The
ROESY spectrum of this solution at -13 °C shows EXSY cross-peaks between these two peaks.
All these data indicate that within the Bis1 conformer, another rapid methylene proton interchange
process takes place. This interchange is a faster-dynamic process relative to the Bis1-Bis2
conversion process at RT, but this process slows down at low T to produce two peaks connected
through EXSY peaks (Supporting Information). The distortion of the carrier-ligand in SO2R-in
conformer shown in 7, 8, and 10 suggests that this fast interchange process within the Bis1
conformer could be a result of the inversion of the sulfonamide group.
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As discussed in the structural section, the central sulfonamide N is not bound, hence the
imidazolyl groups have freedom to rotate around the Pt−N bonds and the sulfonamide group has
some degree of freedom to invert at the N(sulfonamide) atom. Therefore, it is conceivable that the
observation of two different conformers for the [Pt(N(SO2R)1,1'-Me2dma)(DMAP)2]2+ adduct is a
result of a combination of the rotation of the imidazolyl rings and the inversion at N of the central
sulfonamide group.
Formation of the [Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]2+-type complexes through the
reaction of 5 and 6 with simple N-donors indicates that the Pt(N(SO2R)1,1'-Me2dma)Cl2
complexes are capable of acting as bifunctional platinum agents to form bis adducts with N-donors,
an important functionality relevant to biological applications because platinum anticancer agents
form adducts with guanine bases in DNA. As a preliminary step of evaluating the reactivity of the
Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes towards biological molecules, we treated 5 and 6 with two
different guanine derivatives, 9-MeG and Guo.
Reactions of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5) with G (G = 9-MeG and Guo). A 1H
NMR spectra of the reaction mixture of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5, 5 mM) and 2.5 molar
equiv of 9-MeG in DMSO-d6 lead to growth of a new set of signals with time until the reaction
was completed at 19 h (Figure 4.13). The new signals remained unchanged even after 14 d,
indicating that the adduct formed is stable.
In the 1H NMR spectrum of the adduct solution has a new broad H8 singlet at 8.60 ppm
characteristic of Pt(II)-bound 9-MeG40 because it is shifted downfield from the free H8 signal at
7.62 ppm (Table 4.6). Also, a new NH peak (11.35 ppm), which is shifted downfield from the free
NH signal by 0.8 ppm, is observed. A new NH2 peak detected at 7.01 ppm is downfield shifted by
0.54 ppm from the free NH2 signal. In addition to these peaks, four sharp doublets can be seen in
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the aromatic region; these should be signals of the carrier-ligand protons of the new G adduct
because they are the only other aromatic protons in the formed adduct (Figure 4.13). The
integration values of the four doublets and the bound H8 signal are roughly the same, which
indicates that the reaction produced a mono G adduct, [Pt(N(SO2Me)1,1'-Me2dma)(9-MeG)Cl]+.

Figure 4.13. Line drawings of [Pt(N(SO2Me)1,1′-Me2dma)(9-MeG)Cl]+ and 9-MeG (top) and
selected region of the 1H NMR spectra (bottom, 25 °C, DMSO-d6, shifts in ppm) of the reaction
mixture forming the adduct recorded 5 min, 1 h, 2 h, 4 h, 19 h, and 14 d after addition of 1.6 mg
of solid 5 in to a 25 mM solution of 9-MeG.
In order to conveniently assign the proton signals of the [Pt(N(SO2Me)1,1'-Me2dma)(9MeG)Cl]+ adduct, the 9-MeG and the imidazolyl ring with non-prime numbers are drawn on the
same side of the coordination plane, as shown in Figure 4.13. In a ROESY spectrum of the final
reaction mixture (Figure 4.14), an NOE cross-peak between the bound H8 signal and the most
downfield-shifted doublet (7.37 ppm) allows the signal to be assigned to the H4 proton (Table 4.7).
This H4 signal has an NOE cross-peak to the doublet at 7.21 ppm, allowing that signal to be
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assigned to H5. Two imidazolyl Me signals can be seen at 3.79 and 3.68 ppm (identified by
integration); the more upfield singlet at 3.68 ppm has an NOE cross-peak with the H5 signal and
thus can be assigned to 1-Me. The other aliphatic Me singlet at 3.79 ppm has an NOE cross-peak
with another aromatic doublet at 7.28 ppm, therefore each signal can be assigned to 1-Me' and H5'.
The remaining doublet is assigned to H4' (7.09 ppm), which is further supported by an NOE cross
peak between this peak and the H5' signal.
Table 4.6. Selected 1H NMR Data (ppm) for the G Ligand in [Pt(N(SO2R)1,1'-Me2dma)GCl]+
Adducts (ppm, DMSO-d6, 25 °C). Non-prime Numbering Signals are for the Protons of the
Imidazolyl Ring Closest to the Bound G (See Figure 4.10)
R

H8

NH2

NH

free

adduct

free

adduct

free

adduct

Me
Me

9-MeG
Guo

7.62
7.93

8.60
8.92, 8.90

6.47
6.49

7.01
7.01

10.56
10.66

11.35
11.39

Tol
Tol

9-MeG
Guo

7.61
7.90

8.59
8.91, 8.88

6.41
6.44

6.93
6.95

10.50
10.62

11.19
11.25

Observing only one H8 signal for the [Pt(N(SO2Me)1,1'-Me2dma)(9-MeG)Cl]+ adduct
indicates that the rotation of the guanine derivative is not highly impeded in the new adduct. As
discussed in our previous papers, the metal-bound-G molecules can rotate around the Pt−N7(G)
bond.22-23 If the in plane bulk of the carrier-ligand is high enough to restrict this rotation of the
bound G base on the NMR time scale, two or more H8 signals should be observed corresponding
to different rotamers of the adduct.22-23 However, the broadness of the H8 peak (instead of the
expected sharp peak for H8) of the [Pt(N(SO2Me)1,1'-Me2dma)(9-MeG)Cl]+ adduct suggests that
possibly the chemical shifts of the resulting rotamers perhaps have similar chemical shifts. The
adduct formation of the Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5) complex is significantly faster (∼19 h
to complete the reaction) than its analog compound, [Pt(N(Me)1,1'-Me2dma)Cl]Cl (the reaction
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completion time with 9-EtG is 10 d).22 The less steric hindrance created by the low canted aromatic
rings (dihedral angle ~75°) in the bifunctional coordination sphere of the new complex compared
to the monofunctional coordination sphere of the [Pt(N(Me)1,1'-Me2dma)Cl]Cl complex (dihedral
angle ~12°)22 might be the reason for the significantly different reaction times.

Figure 4.14. 1H-1H ROESY spectrum (selected region) of the [Pt(N(SO2Me)1,1′-Me2dma)(9MeG)Cl]+ adduct (25 °C, DMSO-d6, shifts in ppm).
Similar results were obtained when a 12.5 mM solution of Guo (2.5 molar equiv) in
DMSO-d6 was treated with 1.6 mg of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5, 5 mM). An 1H NMR
spectrum taken 10 min after the mixing showed signals of 5m (Figure 4.15). In a spectrum recorded
about 5 h after mixing showed clearly detectable peaks for the new adduct, [Pt(N(SO2Me)1,1'Me2dma)(Guo)Cl]+ (in addition to 5m peaks). The reaction was completed during the first 24 h
period as indicated by the ratio between the adduct peaks and the 5m peaks being constant (4:1,
calculated based on the integrations of carrier-ligand aromatic protons). The proton signals of the
[Pt(N(SO2Me)1,1'-Me2dma)(Guo)Cl]+ adduct were assigned in a similar way as for the 9-MeG
adduct, by using a ROESY spectrum of the reaction mixture (Tables 4.6 and 4.7 and Supporting
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Information). Among the four doublets corresponding to the imidazolyl aromatic protons, the two
peaks of H4 (7.40 ppm) and H5 (7.24 ppm) are broad, which may be because of quadrupolar N
atoms in the nearby guanine base. In contrast, the H4' (7.08 ppm) and H5' (7.30 ppm) peaks
corresponding to the carrier ligand side close to the bound chloride ion were sharp doublets. In
contrast to the broad one H8 peak observed for the 9-MeG adduct ([Pt(N(SO2Me)1,1'-Me2dma)(9MeG)Cl]+), the Guo adduct of 5 shows two closely associated signals at 8.92 and 8.90 ppm as the
adduct now contain a chiral center (Figure 4.12 and Table 4.6). In order to investigate if the
reaction would consume all of the complex (5 or 5m) molecules with the presence of a high
concentration of G, another experiment was performed by mixing Guo (100 mM) and 5 (10 mM)
in a 10:1 ratio (in DMSO-d6). The reaction was completed during the first 24 h and the integration
shows the same ratio of adduct:5m = ~4:1 as of the reaction mentioned above with a reaction
mixture of 2.5:1 (12.5 mM Guo and 5 mM 5).
Table 4.7. Selected 1H NMR Data (ppm) for the N(SO2R)1,1'-Me2dma Carrier Ligands in
[Pt(N(SO2R)1,1'-Me2dma)GCl]+ and in Pt(N(SO2R)1,1'-Me2dma)Cl2 (ppm, DMSO-d6, 25 °C).
Non-prime Numbering Signals are for the Protons of the Imidazolyl Ring Closest to the Bound G
(See Figure 4.10)
H4/4'
R

H4

Me
Me
Me

Cla
9-MeG
Clb

7.37

Me

Guo

7.40

H5/5'
H4'

H5

7.10

H5'

1/1′-Me
1-Me
1′-Me

SO2Me

3.72
3.79

3.28
3.31c
3.28

3.79

3.31c

7.20
7.09

7.21

7.10

7.28

3.68

7.19
7.08

7.25

3.72
7.30

3.68

Tol
Cla
7.10
7.21
3.79
Tol 9-MeG
7.38
7.10
7.23
7.31
3.75
3.88
b
Tol
Cl
7.09
7.20
3.79
Tol
Guo
7.41
7.10
7.27
7.32
3.64
3.76
a
b
Signals are recorded for a solution with excess of 9-MeG. Signals are recorded for a solution
with excess of Guo. aSignal is masked by a free G signal.
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The results for the reactions of Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5) with 9-MeG and Guo
reveal a contrastingly high reactivity compared to its dpa analog, Pt(N(SO2Me)3,3',5,5'Me4dpa)Cl2.16 The Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 complex, does not show any prominent
reaction with either 9-MeG or Guo.16 Instead, the complex get attacked by the solvent (DMSO) to
produce a monosolvolysis product and eventually 40% of the chelate ligand get dissociated. The
relative high robustness of 5 than of its analogous dpa complexes, Pt(N(SO2R)3,3',5,5'Me4dpa)Cl2,16 could be due to the less steric hindrance in the coordination sphere due to the small
size and the high basicity of the imidazolyl rings relative to the pyridyl rings.

Figure 4.15. Selected region of the 1H NMR spectra (bottom, 25 °C, DMSO-d6, shifts in ppm) of
the reaction mixture forming the [Pt(N(SO2Me)1,1′-Me2dma)(Guo)Cl]+ adduct recorded 10 min,
1 h, 5 h, 24 h, and 8 d after addition of 1.6 mg of solid 5 in to a 25 mM solution of Guo.
Reactions of Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6) with G (G = 9-MeG and Guo). As
observed for Pt(N(SO2Me)1,1'-Me2dma)Cl2 (5), the Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6, 5 mM)
complex also produces mono G adducts, [Pt(N(SO2Tol)1,1'-Me2dma)GCl]+, when treated with 2.5
molar equiv of G in DMSO-d6 (Supporting Information). The adduct yields and the reaction
completion times of the formation of each G adduct (G = 9-MeG and Guo) of 6 is similar to the
corresponding adduct formed with 5; the reactions between 6 and 9-MeG and Guo were finished
by ~19 h (100% yield) and ~24 h (80% yield), respectively. Furthermore, the chemical shifts of
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the carrier ligand and the G in each [Pt(N(SO2Tol)1,1'-Me2dma)GCl]+ mono adduct is similar to
its corresponding [Pt(N(SO2Me)1,1'-Me2dma)GCl]+ adduct (Tables 4.6 and 4.7), indicating that
the effect of the dangling R group on the chemical properties of the G adducts is minimal.
4.4 Conclusions
The N(SO2R)Mendpa ligands investigated here bind tridentately to the fac-[Re(I)(CO)3]+
core in the [Re(CO)3(N(Even though the N(R)1,1′-Me2dma type ligands (R = H or Me) bind
tridentately to Pt(II), the N(SO2R)1,1'-Me2dma ligands show bidentate coordination. In contrast,
N(SO2R)1,1'-Me2dma ligands coordinate tridentately to fac-[Re(CO)3]+ core. The different
binding modes exhibited by the N(SO2R)1,1'-Me2dma ligands with Pt(II) and Re(I) can be
attributed to the steric factors of the terminal imidazolyl rings and the electronic factors of the
central sulfonamide donor. Regardless of the different binding modes, both Pt(N(SO2R)1,1'Me2dma)Cl2 and [Re(CO)3(N(SO2R)1,1'-Me2dma)]ClO4 complexes are robust and do not show
any ligand dissociation in solution (DMSO-d6), indicating that the sulfonamide-incorporated
imidazolyl ligands, N(SO2R)1,1'-Me2dma, are better N-donor ligands than their dpa analogs,
N(SO2R)3,3',5,5'-Me4dpa. Chloride ligands of the Pt(N(SO2R)1,1'-Me2dma)Cl2 complexes were
easily replaced by simple N-donor ligands such as DMAP, 4-picoline, and 3,5-lutidine to produce
bis adducts. Furthermore, Pt(N(SO2R)1,1'-Me2dma)Cl2 react with G to form stable mono adducts,
[Pt(N(SO2R)1,1'-Me2dma)(G)Cl]+ (G = 9-MeG and Guo) in DMSO-d6, indicating that the new
imidazolyl based complexes are robust and reactive enough to employ in further studies to evaluate
if they possess any actual anticancer properties. Furthermore, NMR spectral data for the
Pt(N(SO2R)1,1'-Me2dma)Cl2

and

[Pt(N(SO2R)1,1'-Me2dma)(N-donor)2]2+-type

complexes

provide evidence for dynamic motion involving the 8-membered chelate ring. From the X-ray
structural results it is reasonable to conclude that the dynamic motion involves the rotation of the
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imidazolyl rings around the Pt–N bond and the inversion of the SO2R group at the sulfonamide N
atom leading to SO2R-in and SO2R-out conformations evident in solid-state structures.
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CHAPTER 5. CONCLUSIONS
This dissertation research contributes to the understanding of fundamental chemistry of
Pt(II) and Re(I) complexes of linear tridentate ligands terminated with aromatic N-donor groups;
this chemistry is relevant to biological/biomedical applications. A series of new ligands terminated
with either two pyridyl rings or two imidazolyl rings were utilized in preparing the new Pt(II) and
Re(I) complexes. Furthermore, the basic ligand framework of the tridentate ligands terminated by
aromatic rings was utilized to explore new bioconjugation possibilities with a N−S linker by
making the central nitrogen atom part of a tertiary sulfonamide group.
The [Pt(N(R)1,1′-Me2dma)Cl]Cl complexes were used to prepare several Pt(N(R)1,1′Me2dma)G mono adducts (G = unlinked guanine or hypoxanthine derivatives), which were
analyzed by using NMR spectroscopy to evaluate the chemical properties of the adducts relevant
to anticancer activity. The observation of two sharp G H8 NMR signals (corresponding to a
syn/anti rotamer mixture) indicates that these carrier-ligands are bulky enough to impede the free
rotation of the bound G molecules. Anticancer-active monofunctional platinum(II) complexes
have bulky carrier-ligands that cause DNA adducts to be distorted. Therefore, the [Pt(N(R)1,1′Me2dma)Cl]Cl complexes could be a good starting point to further analyze the relationship
between the ligand steric bulk and the anticancer properties of the monofunctional Pt(II)
complexes.
The N(SO2R)1,1′-Me2dma and N(SO2R)Mendpa ligands were utilized to develop a new
conjugation approach through a N−S link. Such new linking strategies are useful in introducing
biological properties (such as enhanced targeting ability, fluorescence, and high anticancer
activity) to metal complexes. The new N(SO2R)1,1′-Me2dma and N(SO2R)Mendpa ligand
frameworks demonstrate the derivatization flexibility of the central N−S linker and form
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isomerically pure highly robust fac-Re[(CO)3L]+ type complexes. These new complexes provide
useful insights in the development of 99mTc and 187Re radiopharmaceuticals.
The N(SO2R)1,1′-Me2dma and N(SO2R)Mendpa ligands were also utilized to investigate
whether the normally highly favorable Pt−N bond could also be formed by a sulfonamide N-donor
present in a tridentate ligand terminated by aromatic rings. This study shows that the sulfonamide
N atom in the N(SO2R)1,1′-Me2dma and N(SO2R)Mendpa ligands does not coordinate to the Pt(II)
center; as a consequence the ligands usually form Pt(N(SO2R)1,1′-Me2dma)Cl2 or
Pt(N(SO2R)Mendpa)Cl2 complexes with a bidentate coordination mode and an unusually large 8membered chelate ring; these complexes are the very first examples of Pt(II) complexes of
sulfonamide-incorporated linear ligands having 8-membered chelate rings. Both Pt(N(SO2R)1,1′Me2dma)Cl2 and Pt(N(SO2R)Mendpa)Cl2 type complexes exhibit interesting and unusual chemical
properties that are relevant to understanding the fundamental chemistry of this new class of Pt(II)
compounds.
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APPENDIX A. SUPPLEMENTARY MATERIAL FOR CHAPTER 2

Figure A.1. Tilting of the imidazolyl rings in the [Pt(N(R)1,1′-Me2dma)Cl]BF4 cations (overlay of
3b (R = H, pink) and 4b (R = Me, green) by superimposing the Pt, N2, and N3 atoms (left) and Pt,
N2, and N1 atoms (right) viewed along the coordination plane. In order to display the tilting
clearly, only parts of one chelate ring are shown in each half of the figure, and the N-Me group on
each imidazolyl ring is hidden. The figure shows that the methylene groups are farther on the other
side of the coordination plane from the NH or NMe group in the R = Me cation.

Figure A.2. Overlay of the [Pt(N(R)1,1′-Me2dma)Cl]BF4 cations, 3b (R = H, pink) and 4b (R =
Me, green) by superimposing the Pt, Cl, N1, N2, and N3 atoms, viewed from the top (top) and
along the coordination plane (bottom), where the endo-CH and the exo-CH protons are designated.
For clarity, the N-Me groups of the imidazolyl rings are hidden in the bottom structure.
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Figure A.3. Models of the anti (left) and syn (right) rotamers of the Pt(N(H)1,1′-Me2dma)(3'-GMP)
adduct based on the molecular structure of 5 as described in the main text. The ribose and
phosphate groups are hidden in order to display the models clearly.
Structural Features of the 3′-GMPH Ligand. Bond lengths and angles for the guanine
rings are in the normal range found for nucleotides, e.g., 5′-GMP70-71 and 3'-GMP.64 The nucleotide
conformation in 5 is anti, i.e., antiperiplanar (the C12─N6─C1'─O2 torsion angle around the
N6─C1' glycosidic bond is ‒164.9°).178 The 5'-GMP has the anti conformation in all of the
structurally characterized bis adducts of 5′-GMP69-72 referred to in the main text discussion. The
pucker of the ribose sugar group in 5 is C2'-endo (S pucker), as indicated by the 0.157 Å
displacement in the C5' direction of the C2' atom from the plane defined by the C1', C4' and O2
atoms and by the pseudo-rotation phase angle P ~177°.179 The ribose S puckering is retained in
solution, as indicated by the H1' and H2' coupling constant of 4.8 Hz.180-181 Most of the platinum
G adducts described in the literature have ribose groups with similar S puckering.66,70,181 Two of
the terminal P─O bonds in 5 have lengths (P─O5, 1.492(9) Å, and P─O7, 1.471(8) Å) that are
shorter than the P─O6 bond (1.574(9) Å), which is comparable in length to the P─OH bonds
(1.536(1)–1.598(5) Å) of the bis complexes of 5′-GMP referenced above.69-72 Thus, O6 in 5 is
protonated, although an H atom at O6 is not visible in the electron density map.
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Figure A.4. 1H-1H ROESY spectrum (selected region) of Pt(N(H)1,1′-Me2dma)Cl]Cl (3a) (25 °C,
D2O, pH 6, shifts in ppm).

Figure A.5. 1H-13C HSQC spectrum (aromatic region) of the [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a)
complex (25 °C, D2O, pH 6, shifts in ppm).
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NMR Assignments for [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a). As discussed in the main
text, 4a has downfield 1H NMR signals for the H4/4' and H5/5' aromatic protons. In the ROESY
spectrum in D2O for 4a (Figure A.6), a strong NOE cross-peak from the 1/1′-Me signal at 3.78
ppm assigns the most downfield signal (7.19 ppm) to H5/5'. The other aromatic peak (7.05 ppm)
can thus be assigned to H4/4', an assignment supported by the NOE cross-peak to the H5/5' signal
and by the absence of any other cross-peak. By the reasoning used in the main text, the upfield and
downfield methylene signals of 4a were assigned to the exo-CH and endo-CH signals, respectively.
Assignments of the

13

C NMR signals for 4a were made through an HSQC experiment (Figure

A.7). 13C NMR signals for the C4/4', C5/5', and C1/1' were assigned with the aid of cross-peaks
(in ppm) involving the H4/4' (7.05−124.3), H5/5' (7.20−122.6), Me-1/1' (3.78−34.7) and N-Me
(3.14−52.73) signals, respectively. Cross-peaks from the endo-CH and exo-CH signals assign the
13

C NMR signal at 61.95 ppm to C6/6'. The signal at 152.87 ppm, the only 13C NMR signal with

no HSQC cross-peak, is assigned to C2/2'.

Figure A.6. 1H-1H ROESY spectrum (selected region) of Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a) (25
°C, D2O, pH 6, shifts in ppm).
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Figure A.7. Selected region of a 1H-13C HSQC spectrum of [Pt(N(Me)1,1′-Me2dma)Cl]Cl (4a) (25
°C, D2O, pH 6, shifts in ppm).

Figure A.8. 1H NMR spectra of a 10 mM solution (600 µL) of [Pt(N(H)1,1′-Me2dma)Cl]Cl (3a)
(25 °C, D2O, shifts in ppm) at pH 7 before (bottom), and after adding 10 µL of concentrated HCl
(final [H+] = 0.2 M) at 15 min, 72 h and 7 d.
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Figure A.9. Aromatic and H1′ region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]+ (10
mM, bottom) and of the reaction mixture with 5'-GTP (1:2.5 molar ratio, 25 C, D2O, pH 4.0,
shifts in ppm). Peaks labeled as * are from 5′-GDP present as an impurity.

Figure A.10. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]+ (10
mM, bottom) and of the reaction mixture with 3′-GMP (1:2.5 molar ratio, 25 C, D2O, pH 4.0,
shifts in ppm).
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Figure A.11. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]+ (10
mM, bottom) and of the reaction mixture with Ino (1:2.5 molar ratio, 25 C, D2O, pH 4.0, shifts in
ppm).

Figure A.12. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]+ (10
mM, bottom) and of the reaction mixture with 1-MeGuo (1:2.5 molar ratio, 25 C, D2O, pH 4.0,
shifts in ppm).
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Figure A.13. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(H)1,1′-Me2dma)Cl]+ (10
mM, bottom) and of the reaction mixture with 9-EtG (1:2.5 molar ratio, 25 C, D2O, pH 4.0, shifts
in ppm). Note that 9-EtG is only partially soluble in D2O.

Figure A.14. Aromatic and H1' region of the 1H NMR spectra (25 °C, D2O, pH 4) of [Pt(N(Me)1,1′Me2dma)Cl]+(10 mM, bottom) and of the reaction mixture forming Pt(N(Me)1,1′-Me2dma)(5'GMP) 15 min, 12 h, 97 h, 181 h and 216 h after adding 2.5 molar equiv of 5'-GMP (shifts in ppm).
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Figure A.15. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(Me)1,1′-Me2dma)Cl]+ (10
mM, bottom) and of the reaction mixture with 5'-GTP (1:2.5 molar ratio, 25 C, D2O, pH 4.0, shifts
in ppm). Peaks labeled as * are from 5′-GDP present as an impurity.

Figure A.16. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(Me)1,1′-Me2dma)Cl]+ (10
mM, bottom) and of the reaction mixture with 3'-GMP (1:2.5 molar ratio, 25 C, D2O, pH 4.0,
shifts in ppm).
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Figure A.17. Aromatic and H1' region of the 1H NMR spectra of [Pt(N(Me)1,1′-Me2dma)Cl]+ (10
mM, bottom) and of the reaction mixture with 5'-IMP (1:2.5 molar ratio, 25 C, D2O, pH 4.0, shifts
in ppm).

Figure A.18. 1,1′-Me-to-H5/5′ NOE cross-peak (traced in green) in the 1H-1H ROESY spectrum
of the Pt(N(H)1,1′-Me2dma)(5'-GMP) adduct (25 °C, D2O, pH 4, shifts in ppm).
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Figure A.19. 1H-13C HSQC spectrum (aromatic region) of the Pt(N(H)1,1′-Me2dma)(5'-GMP)
adduct (25 °C, D2O, pH 4, shifts in ppm).

Figure A.20. 1H-13C HSQC spectrum (selected region) of the Pt(N(H)1,1′-Me2dma)(5'-GMP)
adduct (25 °C, D2O, pH 4, shifts in ppm).

157

Figure A.21. A selected region of the 1H-1H ROESY spectrum of the Pt(N(Me)1,1′-Me2dma)(5'GMP) adduct (25 °C, D2O, pH 4, shifts in ppm).
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Table A.1. 1H NMR Shifts (ppm) for the N(H)1,1'-Me2dma Carrier Ligands in Pt(N(H)1,1'Me2dma)G Adducts and in [Pt(N(H)1,1'-Me2dma)Cl]Cl in 65:35 D2O:DMSO-d6 (pH 4.0) at 25
°C. (Data5 for [Pt(N(H)dpa)(Cl)]Cl and Pt(N(H)dpa)G Are Included for Comparison.)
Complex

H4/4' or H6/6'
syn

Me-1/1'

N(Me)

7.02

3.56

-

anti

[Pt(N(H)1,1'-Me2dma)Cl]Cla

6.80

Pt(N(H)1,1'-Me2dma)(5'-GMP)a

6.41, 6.39

6.44

6.96b

3.57

-

Pt(N(H)1,1'-Me2dma)(5'-GTP)a

6.39, 6.37

6.42

6.97b

3.57

-

7.34

-

-

[Pt(N(H)dpa)(Cl)]Cl

a

H5/5'

8.61

Pt(N(H)dpa)(5'-GMP)

7.51, 7.44

7.57

7.21

-

-

Pt(N(H)dpa)(5'-GTP)

7.49, 7.43

7.57

7.23

-

-

endo and exo-H6/6' are masked by the solvent peak. bsyn and anti signals are overlapped.

Table A.2. Selected 1H NMR Shifts (ppm) for G in Pt(N(H)1,1′-Me2dma)G Adducts 65:35
D2O:DMSO-d6 (pH 4.0) at 25 °C. (Data for Pt(N(H)dpa)G5 Are Included for Comparison.)
Complex

H8
free

H8
syn

H8
anti

H1' free

H1'
syn

H1'
anti

syn:anti
ratio

Δδ

Pt(N(H)1,1′-Me2dma)(5'-GMP)

7.95

8.57

8.86

5.71

5.85

5.89

1.08:1

0.29

Pt(N(H)1,1′-Me2dma)(5'-GTP)

7.98

8.61

8.91

5.71

5.85

5.90

0.95:1

0.30

Pt(N(H)dpa)(5'-GMP)

7.96

8.72

9.08

5.71

5.91

5.98

1.14:1

0.36

Pt(N(H)dpa)(5'-GTP)

7.97

8.79

9.21

5.70

5.91

5.98

0.82:1

0.42
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Figure B.1. Relationship between the average Pt−N−aromatic ring centroid angle and the chelate
ring size of bifunctional Pt(II) complexes of linear ligands terminated by pyridyl or imidazolyl
rings (with the remaining coordination sites occupied by halide). Plot is based on reported
molecular structures (Cambridge Crystallographic Data Centre, ConQuest 1.19); of the 108
structures available for complexes with a 5-membered chelate ring, data from 26 randomly
selected structures were used to prepare the plot. Data for bifunctional Pt(II) complexes of
monodentately bound pyridyl or imidazolyl rings are also included for comparison.

Figure B.2. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Me)3,3′,5,5′-Me4dpa)Cl2 (5)
(25 °C, 10 mM, DMSO-d6, shifts in ppm). which is diminished when the solvent peak is
suppressed.
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Figure B.3. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Tol)3,3′,5,5′-Me4dpa)Cl2 (6)
(25 °C, 10 mM, DMSO-d6, shifts in ppm).

Figure B.4. Stack plot of 1H NMR spectra (selected region) of Pt(N(SO2Tol)3,3′,5,5′-Me4dpa)Cl2
(6) taken at different temperatures (10 mM, DMSO-d6, shifts in ppm).
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Figure B.5. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Tol)3,3′,5,5′-Me4dpa)Cl2 (6)
(75 °C, 10 mM, DMSO-d6, shifts in ppm). *Solvolysis peaks.

Figure B.6. 1H-1H ROESY spectrum (selected region) of [trans-Pt(DMSO)Cl2]2(N(SO2Me)6,6′Me2dpa) (7) (25 °C, 10 mM, DMSO-d6, shifts in ppm).
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Figure B.7. 1H-1H ROESY spectrum (selected region) of [trans-Pt(DMSO)Cl2]2(N(SO2Tol)6,6′Me2dpa) (8) (25 °C, 10 mM, DMSO-d6, shifts in ppm).

Figure B.8. 1H-1H ROESY spectrum (selected region) of [trans-Pt(DMSO)Cl2](N(SO2Tol)6,6′Me2dpa) (8a) (25 °C, 10 mM, DMSO-d6, shifts in ppm).
164

Figure B.9. 1H-1H ROESY spectrum (selected region) of fac-[Re(CO)3(N(SO2Me)3,3',5,5'Me4dpa)]PF6 (9) (25 C, 10 mM, DMSO-d6, shifts in ppm).

Figure B.10. 1H-1H ROESY spectrum (selected region) of fac-[Re(CO)3(N(SO2Tol)6,6'Me2dpa)]PF6 (12) (25 C, 10 mM, DMSO-d6, shifts in ppm). The green line indicates the NOE
cross-peak between the H3/5 signal and the p-tolyl methyl signal, which is diminished when the
solvent peak is suppressed.
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Figure B.11. Selected region of 1H NMR spectra in DMSO-d6 at 25 °C (shifts in ppm) of (a)
[Re(CO)3(N(SO2Me)6,6'-Me2dpa)]PF6 (11) and (b) Re(CO)3(N(SO2Tol)6,6'-Me2dpa)]PF6 (12).
1H

NMR Assignments of Methylene Signals. In the ROESY Spectrum of 5 (Figure B.2),

the 3/3'-Me signal has a very intense NOE cross-peak with the more upfield methylene doublet
(5.37 ppm). The cross-peak allows us to assign the doublet to the exo-CH, owing to the spatial
proximity of the exo-CH protons to the 3/3'-Me group (the non-bonded distances range from
2.22−2.31 Å). Therefore, the more downfield doublet (5.99 ppm) can confidently be assigned to
the endo-CH (the non-bonded distances between the endo-CH and the 3/3'-Me groups range from
3.66−3.71 Å). This conclusion is further supported by a relatively stronger exo-CH to SO2Me NOE
cross-peak compared to the endo-CH to SO2Me NOE cross-peak. In the molecular structure, the
non-bonded distances between this methyl group and the exo-CH (2.59−2.62 Å) are smaller than
the distances to the endo-CH (2.78−2.86 Å). This reasoning applies also to fac[Re(CO)3(N(SO2R)Mendpa)]PF6 complexes (9−12), and the ROESY spectra for 9 and 12 are
shown in Figures S9 and S10.
The ROESY spectrum of 6 taken at 25 °C (Figure B.3) has strong NOE cross-peaks
between the methylene AB signals and the 3/3'-Me and H2/6 protons. However, it is difficult to
assign the AB signals to endo- or exo-CH protons because the two AB signals have very similar
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shifts (separated by 0.08 ppm). Therefore, to assign the methylene signals of 6, the temperature
dependence of the shift of the methylene signals was investigated (Figure B.4). With increasing
temperature, the more downfield AB signal (5.55 ppm at 25 °C) moved upfield and the other signal
moved downfield (the two signals crossed between 40-50 °C). In the ROESY spectrum of 6 at 75
°C (Figure B.5), the 3/3'-Me signal has an intense NOE cross-peak with the more upfield
methylene signal (5.50 ppm), a finding allowing assignment of the 5.50 ppm signal to the exo-CH.
Therefore, the more downfield signal (5.60 ppm) can confidently be assigned to the endo-CH. The
more upfield AB signal at 75 °C and the more downfield AB signal at 25 °C can be assigned to
the exo-CH. Similarly, the more upfield AB signal at 25 °C can be assigned to the endo-CH.

Figure B.12. Selected region of 1H NMR spectra showing the reduction of 5sol peaks in a 1-dayold solution of Pt(N(SO2Me)3,3′,5,5′-Me4dpa)Cl2 (5) in DMSO-d6 (10 mM, bottom spectrum)
when 10 mg (10 molar equiv) of solid [Et4N]Cl was added (Solution 2). Spectra recorded 5 min,
30 min, 2 h, 4 h, 12 h, and 24 h after adding [Et4N]Cl (25 °C, shifts in ppm).
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Figure B.13. Percent distribution of Pt(N(SO2Me)3,3',5,5'-Me4dpa)Cl2 (5, orange),
[Pt(N(SO2Me)3,3',5,5'-Me4dpa)(DMSO)Cl]+ (5sol, green), and free N(SO2Me)3,3',5,5'-Me4dpa (1,
blue) in Solution 2 [a mixture of [Et4N]Cl (10 mg, 10 molar equiv) added to a 1-day-old solution
of 5 (10 mM) in DMSO-d6] at 25 °C plotted versus time. Percent distribution values were
calculated by using integrations of H4/4' signals of each species.

Table B.1. Selected 1H NMR Chemical Shifts for N(SO2Me)3,3',5,5'-Me4dpa (1) and
N(SO2Tol)3,3',5,5'-Me4dpa (2) and for Their Pt(II) Complexes (ppm, DMSO-d6, 25 °C)
H6/6′

a

H4/4′

CH2

5/5′-Me

3/3′-Me

SO2Me

SO2Tol
H2/6

H3/5

Me

1

8.17

7.33

4.45

2.12

2.23

3.13

-

-

-

5

8.98

7.56

5.99, 5.37

2.23

2.37

3.35

-

-

-

5a

9.04

7.61

6.25, 5.50

2.29

2.48

3.46

-

-

-

2

7.94

7.21

4.41

2.13

2.16

-

7.62

7.32

2.39

6

8.9

7.56

5.55, 5.47

2.21

2.45

-

8.03

7.60

2.50b

6a

8.97

7.63

5.77, 5.66

2.28

2.59

-

8.12

7.65

2.52

Shifts in DMF-d7, reference peak at 8.03 ppm. bSignal is masked by the solvent peak (DMSO-d6).
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Figure C.1. 1H-1H ROESY spectrum (selected region) of fac-[Re(CO)3(N(SO2Me)1,1'Me2dma)]ClO4 (3) (25 C, 10 mM, DMSO-d6, shifts in ppm).

Figure C.2. 1H-1H ROESY spectrum (selected region) of Pt(N(SO2Tol)1,1′-Me2dma)Cl2 (6) (25
°C, 10 mM, DMF-d7, shifts in ppm).
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Figure C.3. Selected region of 1H NMR spectra showing the formation of mono (red) and bis
adducts (Bis1-purple and Bis2-green) of 6 with DMAP at various time points after 1.9 mg of
Pt(N(SO2Tol)1,1′-Me2dma)Cl2 (6, blue) was dissolved in a 20 mM solution of DMAP in DMSOd6 (25 °C, shifts in ppm).

Figure C.4. 1H-1H ROESY spectrum (selected region) of [Pt(N(SO2Me)1,1'-Me2dma)(3,5lut)2](PF6)2 (9) (25 °C, 10 mM, DMSO-d6, shifts in ppm). *SO2Me group of Bis2 is suppressed
along with the HOD peak.
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Figure C.5. 1H NMR spectra (selected region) of [Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2](PF6)2 (8)
(25 °C, 10 mM, DMSO-d6, shifts in ppm).

Figure C.6. 1H-1H ROESY spectrum (selected region) of [Pt(N(SO2Tol)1,1'-Me2dma)(3,5lut)2](PF6)2 (10) (25 °C, 10 mM, DMSO-d6, shifts in ppm).
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Figure C.7. Overlap of the stick drawings of [Pt(N(SO2Tol)1,1'-Me2dma)Cl2 (6, green) and
[Pt(N(SO2Tol)1,1'-Me2dma)(4-pic)2]2+ (8, purple) by superimposing the Pt, N1, and N2 atoms.
The non-bonded distances (Å) between the H2/6 protons of the Tol group and the H2/64-pic protons
were measured by using Mercury CSD 3.10.1 software. For clarity, some of the hydrogen atoms,
oxygen atoms, and methyl groups are hidden.

Figure C.8. 1H-1H ROESY spectrum (selected region) of [Pt(N(SO2Me)1,1'-Me2dma)(4pic)2](PF6)2 (7) (25 °C, 10 mM, DMF-d6, shifts in ppm).
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Figure C.9. 1H NMR spectrum (selected region) of [Pt(N(SO2Me)1,1'-Me2dma)(4-pic)2](PF6)2 (7,
10 mM, DMF-d6, shifts in ppm) recorded at different temperatures, 50, 25, 0, and -13 °C.

Figure C.10. 1H-1H ROESY spectrum (selected region) of [Pt(N(SO2Me)1,1'-Me2dma)(4pic)2](PF6)2 (7) (-13 °C, 10 mM, DMF-d6, shifts in ppm).
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Figure C.11. 1H-1H ROESY spectrum (selected region) of the [Pt(N(SO2Me)1,1′Me2dma)(Guo)Cl]+ adduct (25 °C, DMSO-d6, shifts in ppm).

Figure C.12. Selected region of the 1H NMR spectra of the reaction mixture forming
[Pt(N(SO2Tol)1,1′-Me2dma)(9-MeG)Cl]+ adduct recorded 5 min, 1 h, 2 h, 19 h, 24 h, and 8 d after
addition of 1.9 mg of solid 6 in to a 25 mM solution of 9-MeG (25 °C, DMSO-d6, shifts in ppm).
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Figure C.13. Selected region of the 1H NMR spectra of the reaction mixture forming
[Pt(N(SO2Tol)1,1′-Me2dma)(Guo)Cl]+ adduct recorded 5 min, 1 h, 12 h, and 24 h after addition of
1.9 mg of solid 6 in to a 25 mM solution of Guo (25 °C, DMSO-d6, shifts in ppm).

175

APPENDIX D. PERMISSION

176

VITA
Kokila Ranasinghe, eldest daughter of Ajith and Wasantha Ranasinghe, was born in 1987
in Colombo, Sri Lanka. Came from a modest family, she utilized the perks of the government’s
free education to become the first science graduate in her extended family. She received her school
education from Anula Vidyalaya, Nugegoda. Then she entered the University of Sri
Jayewardanepura in 2008 and graduated in 2012 with a Bachelor of Science degree majoring in
Chemistry. She was one of the first undergraduate students of Dr. Theshini Perera, who inspired
Kokila to pursue a career in science.
She entered the doctoral program of chemistry at Louisiana State University and joined the
laboratory of Prof. Luigi G. Marzilli in May 2014 as the last graduate student of the group. Kokila
was the recipient of the Mary Jo Pribble graduate student award for excellence in inorganic
chemistry awarded by the Department of Chemistry, Louisiana State University in 2018. She is a
candidate for the degree of Doctor of Philosophy in the Summer Commencement of 2018. Upon
graduation, she plans to become a teacher to motivate young sri lankans to pursue and excel in
science.

177

